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Chapter 1 
GENERAL INTRODUCTION 
ARTICULAR CARTILAGE 
Articular cartilage is an avascular, paucicellular tissue, mainly consisting of 
extracellular matrix. The composition of this matrix is maintained and adjusted 
by the cartilage cell, the chondrocyte. The matrix consists of a meshwork of 
collagen fibrils (mainly type II, with small amounts of types V,VI,IX, and XI) 
and proteoglycans. Proteoglycans consist of a core protein with negatively 
charged glycosaminoglycan (GAG) chains. The major proteoglycan found in 
articular cartilage is aggrecan, a high molecular weight aggregating proteogly­
can. Characteristic of cartilage are large aggregates, consisting of many («20-
50) aggrecan monomers complexed specifically to hyaluronan through the 
hyaluronan binding region of the core protein. This interaction is further 
stabilized by attachment of a link protein (fig 1). In addition to aggrecan, 
cartilage contains several nonaggregating small proteoglycans, the molar 
concentration of which is in the same order of magnitude as that of the large 
\ G2 Keratan sulphate 
protein 1 II! i l l Fil ι mil · ЧІІІ' 
ι Chondroitin sulphate 
Hyaluronan ", 
Figure 1. Schematic representation of aggrecan monomer (lefl) and of the multi-
molecular aggregates (right) comprising many of these proteoglycan monomers, 
non-covalently bound to hyaluronan. (G1-G3 = globular domains of core 
protein) 
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proteoglycan (1). The most well-known small proteoglycans are decorni (36.5 
kD, 1 GAG chain), which binds to the collagen fibrils, and biglycan (38kD, 1 
or 2 GAG chains), which is localized preferentially in the pericellular space of 
the chondrocyte. While the collagen fibrils provide tensile stiffness and strength 
to the tissue (2,3), proteoglycans are predominantly responsible for the hydrata-
tion, swelling pressure, and compressive properties of cartilage (4). Proteo-
glycan synthesis can be determined by measurement of incorporation of 35S-labe-
led sulfate in these highly sulfated molecules (5). Proteoglycan content of carti-
lage can be determined with colorimetrie methods (6) based on specific binding 
of dye to the GAG chains, with their typical strong negative charge. 
DESTRUCTION OF ARTICULAR CARTILAGE IN RHEUMATOID AR-
THRITIS 
Rheumatoid arthritis (RA) is a systemic illness with chronic, symmetric polyar-
thritis as its most important clinical feature. Its aetiology is still unknown. 
Rheumatoid joint inflammation is characterized by a chronic synovitis and a 
synovial exudate consisting mainly of polymorphonuclear leukocytes and for a 
smaller part of mononuclear leukocytes. Most probably, factors released by 
inflammatory cells, synovial lining cells and chondrocytes are resposible for loss 
of proteoglycans, denaturation of collagen, and chondrocyte necrosis as seen in 
rheumatoid cartilage. Longstanding arthritis leads to loss of articular cartilage 
(joint space narrowing) and bone erosion. 
MECHANISM OF ARTICULAR CARTILAGE DESTRUCTION 
The loss of joint function associated with chronic arthritis, e.g. rheumatoid 
arthritis, is at least in part due to erosion of the articular cartilage surface. 
Specific therapeutic interference may be possible if we know the general mecha-
nisms that underly cartilage destruction during arthritis. Different aspects of this 
destruction can be distinguished. Proteoglycans present in the articular cartilage 
matrix are degraded by mechanisms as yet unknown and released into the 
synovial fluid. Apart from this, the synthesis of new proteoglycans by the 
chondrocyte is strongly inhibited, contributing to matrix depletion. In addition, 
chondrocyte death has to be discerned. Since the latter type of damage, unlike 
the stimulation of degradation and the inhibition of synthesis of proteoglycans, 
is irreversible, it may be an important factor in joint destruction. Unknown 
cytotoxic factors could be responsible for chondrocyte death, but there is also 
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suggestive evidence that it could also be a reaction to longterm and severe 
matrix depletion and inhibition of chondrocyte metabolism (7). 
In the inflamed joint several soluble factors are present which have the 
capacity to cause cartilage destruction in vitro. These factors include: oxygen 
metabolites, proteases, and a still growing list of cytokines. They may be 
released by cells from various compartments of the joint: inflammatory cells 
infiltrating the synovial membrane, synoviocytes, inflammatory cells in synovial 
exudate in the joint space, cells of the so-called pannus tissue overgrowing the 
cartilage from the edges, and, last but not least, the chondrocytes of the 
cartilage itself. Figure 2 illustrates the release of destructive mediators in the 
different compartments of the inflamed joint. 
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Figure 2. Release of destructive mediators in the different compartments of the 
inflamed joint. Destructive factors of inflammatory cells (predominantly PMNs) 
in synovial fluid and of synovial fibroblasts, lining cells and macrophages can 
reach articular cartilage only via the joint cavity. Products of pannus tissue and 
of articular chondrocytes can escape control by factors present in synovial fluid. 
Oxygen metabolites are released in vast amounts by activated phagocytic 
inflammatory cells, like the polymorphonuclear neutrophil (PMN), which is the 
dominant inflammatory cell in the joint space in the acute phase of all murine 
arthritis models. In vitro exposure of articular cartilage to enzymatically 
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generated fluxes of oxygen species resulted in severe inhibition of chondrocyte 
proteoglycan synthesis (8,9). Oxygen species degrade proteoglycan aggregates 
in vitro (10), but proteoglycan degradation may also be induced indirectly, by 
inactivation of inhibitors of the enzyme elastase by reactive oxygen species (11). 
The literature provides little evidence, however, for an in vivo role of oxygen 
metabolites in articular cartilage destruction, probably due to limited access to 
the cells of the tissue and the presence of endogenous scavenging enzymes and 
other antioxidants. Treatment with scavengers had no effect on cartilage 
damage in antigen-induced arthritis (12). In only one study treatment of LPS-
induced arthritis with superoxide dismutase was reported to prevent proteo­
glycan loss (13). In line with most studies in animal models, antioxidant 
therapy in RA and osteoarthritis (OA) patients had no effect on cartilage de­
struction (14). 
Apart from generation of oxygen species, activation of phagocytic in­
flammatory cells such as granulocytes or macrophages also results in the release 
of lysosomal enzymes. Neutral protease released from granulocytes like elastase 
and cathepsin G are highly cationic and are therefore expected to penetrate the 
negatively charged cartilage matrix. Leukocyte elastase is capable in vitro to 
induce both proteoglycan degradation and suppression of chondrocyte proteogly­
can synthesis (15,16). However, the in vivo role of this enzyme, and other 
proteases in general, has always been questioned in view of the large amounts 
of enzyme inhibitors present in the inflamed joint. To evaluate the in vivo role 
of elastase, arthritis was compared in normal C57black/6 mice and the beige 
(Chediak-Higashi) mutant, which is known to be deficient for PMN elastase and 
cathepsin G. From these experiments performed in three arthritis models no evi­
dence for PMN protease dependence of cartilage destruction was derived (17-
20). Additive evidence against an in vivo role for PMN products in inhibition of 
proteoglycan synthesis and in stimulation of proteoglycan degradation during 
arthritis is provided by recent studies using neutropenic mice. Inhibition of 
proteoglycan synthesis was PMN independent in antigen-induced arthritis (AIA) 
and immune complex arthritis (ICA) (21). Proteoglycan degradation appeared to 
be highly PMN dependent in the passively induced ICA and not in the Τ cell 
driven AIA (20,22). However, ICA in beige mice shows full destruction, 
arguing against a role of PMN elastase. The PMN dependence found in ICA 
could be indirect; probably the PMN initiates or amplifies inflammation in the 
synovial tissue, with subsequent activation of macrophages and fibroblasts. 
All these data indicate that PMN products such as oxygen metabolites 
and lysosomal enzymes have no direct role in cartilage destruction during 
arthritis. It must be concluded that under normal conditions enzymes released 
from activated PMNs will be captured by inhibitors such as alpha· 1 PI and 
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alpha-2 macroglobulin. Escape from these large and anionic inhibitors is only 
possible if PMNs are in direct contact with the cartilage surface, as has been 
shown in vitro (16). Sticking of PMNs in vivo was found in severe cases of 
murine collagen induced arthritis. Moreover, in pannus tissue direct contact of 
PMNs with cartilage might occur. It can not be excluded that under such 
circumstances PMN enzymes play a major role in cartilage destruction. 
At the moment there is much attention for cartilage degradation caused 
by metalloproteases released by synovial cells and the chondrocyte itself, in 
reaction to cytokines produced in the nearby inflammation. Proteases produced 
by synovial cells just like those produced by PMNs are likely to be captured by 
inhibitors present in synovial fluid. Escape from these inhibitors could be 
possible if synoviocytes are present in pannus, but this is certainly not the main 
mechanism of cartilage destruction, because cartilage damage during arthritis is 
also present in cartilage areas distant from pannus overgrowth (23). Therefore, 
it is likely that breakdown of matrix components by the activated chondrocyte is 
an important determinant. Enzymes released in the matrix include the neutral 
metalloproteinase stromelysin, acid metalloproteinase, collagenase, and gelati-
nase (24). Stromelysin and acid metalloproteinase have the capacity to degrade 
proteoglycans (25-27), collagenase cleaves the native triple helical region of 
collagen, and gelatinase degrades the collagen fragments and denatured alpha 
chains of collagen (28-30). Proteases are secreted from the cells in a latent 
form, are activated extracellularly, and are inhibited by a tissue inhibitor of 
metalloproteinase (TIMP) (31-33). They have been found to be active in normal 
articular cartilage (34), and elevated metalloproteinase activities have been 
detected in synovial fluids of RA (35) and osteoarthritis (33,36) patients, and in 
cartilage and synovium in the presence of the cytokine interleukin-1 (IL-1) (37-
40). 
CYTOKINES 
Cytokines in RA synovial fluids. 
The discovery of cytokines and their role in normal and abnormal physiology 
has been subject of intense research. Numerous reports suggest that cytokines 
mediate cell-cell interactions that result in the release of enzymes capable of 
extensive tissue damage. Production and degradation of cartilage matrix by the 
chondrocyte are shown to be under direct control. To date we know that in RA 
synovial fluid cytokines like IL-1 (41-43), interleukin-6 flL-6) (44,45), interleu-
kin-8 (IL-8) (46,47), granulocyte macrophage colony stimulating factor (GM-
CSF) (48), tumour necrosis factor alpha (TNF-a) (45,49), and leukemia inhibi-
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tory factor (LIF) (50) are detectable in abundance, whilst the Τ cell cytokines 
IL-2, IL-4, interferon-γ, and lymphotoxin are virtually undetectable (51,52). 
Moreover, synovium of RA patients has been shown to produce growth factors, 
i.e. cytokines that were initially identified because of their effects on cell 
proliferation. These cytokines are: transforming growth factor beta (TGF-ß), 
basic fibroblast growth factor (bFGF) and platelet derived growth factor 
(PDGF) (53-56). Another important growth factor, not confined to inflam-
mation, is insulin-like growth factor-1 (IGF-1). It has been shown to be the 
main stimulator of cartilage extracellular matrix synthesis present in synovial 
fluids (57,58). This growth factor also protects against cartilage degradation 
(59). 
Over the past few years it has become clear that interpretation of 
cytokine detection studies is dependent upon the assays used, and an awareness 
of the many factors that interfere. Technical problems of cytokine detection in 
synovial fluids and plasma are the lack of cytokine specificity of bioassays, and 
epitope masking by non-specific serum proteins in immunoassays. Moreover, 
immunoassays are limited in that they give little information regarding levels of 
biologically active protein. Large discrepancies have been found in bioactive 
and immunoreactive levels of cytokines in synovial fluids and plasma of arthritic 
patients. This has been described both for IL-1 (45) and TNFa (60). Such 
discrepancies have been shown to be due, at least in part, to the presence of 
specific inhibitors which themselves are critical components of cytokine regula-
tory networks. Thus, the balance between cytokines and levels of their respec-
tive inhibitors will determine bioactivity. In the case of IL-1 these inhibitors 
include the IL-1 receptor antagonist (IL-lra), shed IL-1 receptor, anti-IL-la 
antibodies, but also TGF-ß, which suppresses IL-1 effects in many systems. All 
these inhibitors have been found in the inflammatory field. Figure 3 illustrates 
control of destructive factors in the arthritic joint by natural inhibitors. Sugges-
tive evidence exists for a relation between synovial fluid IL-1 and IL-lra con-
centration levels and the time of recovery from an episode of Lyme arthritis 
(61). Soluble receptors have now been described for many cytokines including 
IL-1, IL-2, IL-4, IL-5, IL-6, IL-7, TNF, LIF, CSF-1, and interferon-7 (62,63) 
and are known to represent truncated forms of membrane receptors lacking 
transmembrane and intracytoplasmic domains. When the relevant immunoassays 
for these molecules become available, it may be possible to determine whether 
over-expression of cytokines in chronic inflammatory states is related to inherent 
abnormalities in the production of the relevant inhibitors. 
Apart from the technical hurdles of cytokine measurements, also diffi-
culty in interpretation of the results has arisen. The presence of a cytokine at 
high levels does not necessarily indicate a pathogenic role; possibly it is a 
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Figure 3. Natural protection against proteoglycan depletion in articular 
cartilage by factors present in synovial fluid and cartilage during joint inflam­
mation. 
secondary effect. Studies using neutralizing antibodies, or injection of cytokine 
into normal joints could yield more insight in this matter. 
Role of IL-1 in cartilage destruction during arthritis 
Of all the factors in RA synovial fluids (RASF) only the monocyte products IL-
1 and TNF-a have been shown to stimulate production of collagenase and other 
neutral proteases by synovial fibroblasts and chondrocytes, and to suppress 
chondrocyte proteoglycan synthesis. Both IL-1 and TNFa are present in high 
levels in RASF and both cytokines have profound catabolic effects on living 
cartilage expiants derived from different species (64-67). There is no doubt that 
in terms of cartilage destruction IL-1 is by far the more potent cytokine compa­
red to TNFa (64,68). In vitro the cartilage degradative action of RA synovial 
culture medium was inhibited up to 80% by antibody to IL-1 (69). In another 
study (70) proteoglycan loss induced by RASF was reversed by anti-IL-1 antibo­
dies for 3 out of 4 fluids. Although IL-1 seems to be a more potent inducer of 
cartilage damage, TNFa could still play an important role, because of the 
proinflammatory effects it shares with IL-1 (71). Interestingly, transgenic mice 
overexpressing TNF-a develop chronic polyarthritis (72). 
The effects of murine recombinant IL-1 on chondrocyte metabolism in 
anatomically intact homologous articular cartilage, the murine patella, have been 
studied extensively in our lab (66). This and other (64,65,67) in vitro studies 
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have shown that both inhibition of chondrocyte proteoglycan synthesis and 
enhanced chondrocyte proteoglycan degradation, mediated by metalloproteinases 
(37,40), contribute to IL-1 induced cartilage matrix depletion. Intra-articular 
injections of IL-1 (73,74) resulted in marked depletion of the cartilage matrix 
and influx of inflammatory cells, predominantly neutrophils, a picture similar to 
that seen in early experimental arthritis. Intra-articular injection of IL-1 has also 
been shown to induce the endogenous expression of stromelysin mRNA and 
protein in both synovium and cartilage (38). Conclusive evidence for a similar 
direct role of TNFa in vivo is lacking. 
Direct evidence for IL-1 involvement as a key mediator of arthritis is 
provided by studies using specific IL-1 inhibitors. The use of a soluble IL-1 
receptor in chronic studies may be limited because of its short half life (2h) 
(75). Also IL-lra is not a likely candidate for in vivo interference. Besides its 
short half life , and poor penetration into the cartilage, it has limited affinity for 
the type I IL-1 receptor on chondrocytes. Due to the surplus of IL-1 receptors 
on cells compared to the number required to mediate biological activity, a 100-
500-fold excess of IL-lra is required to inhibit 50% of IL-1-induced responses 
(76). Treatment with anti-IL-1 antibodies in the acute induction phase of antigen 
induced arthritis could significantly suppress inflammation, but had a cartilage 
protecting effect that exceeded its antiinflammatory effect (77). 
INTERPLAY OF CYTOKINES 
In the in vivo situation the chondrocyte is under control of a set of cytokines 
and growth factors. The net effect of this environment is not merely the sum of 
the effects of isolated mediators. One factor can modulate effects of another 
factor via stimulation or suppression of the production of the other factor or its 
inhibitors. Also regulation at the level of receptor expression is a common 
mechanism; stimulation of chondrocyte IL-1 receptor expression was reported 
for PDGF and bFGF (78-80), while TGF-ß down-regulated IL-1 receptor 
expression (81,82). This regulation at the IL-1 receptor levels was parallelled by 
regulation of IL-1-induced collagenase/stromelysin production (83-85), while 
these growth factors, when added alone, did not induce any enzyme synthesis. 
To complicate this story even further, TGF-ß modulates also production of 
PDGF and the PDGF receptor (86,87), and of the important anabolic factor for 
cartilage, IGF-1 (88) and the IGF-1-binding protein (89). Obviously, the inter-
pretation of biologic effects is complicated by remarkable synergism and antago-
nism observed with combinations of cytokines and growth factors. 
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:ounteraction of IL-1 effects by TGF-ß 
lecause of the pivotal role of IL-1 in experimental arthritis, and presumably 
Jso in RA, in vivo suppression of its effects could ameliorate joint disease, 
leverai groups (90-93,77,20) already tried to protect articular cartilage during 
experimental arthritis by IL-Ira or anti-IL-1 antibodies, with variable success. 
Uso suppression of IL-1 effects by TGF-ß could be of much importance in 
irotecting articular cartilage during experimental arthritis and RA. The TGF-ßs 
ire multifunctional cytokines and consist a family of five isoforms (designated 
rGF-ßl to TGF-B5) and are members of a superfamily of regulatory molecules, 
vhich includes activins, inhibins, and bone morphogenetic proteins. Recently, 
everal groups have injected TGF-ß or anti-TGF-ß antibodies before or during 
experimental arthritis, in an attempt to ameliorate joint disease, and to elucidate 
he function of TGF-ß in the joint. Systemic TGF-ß injections appeared to 
lecrease inflammation (94,95), probably as a result of the strong suppressive ef-
ects of TGF-ß on different components of the immune system (reviewed in 
»6,97). In contrast, intra-articular injections of TGF-ß or anti-TGF-ß antibodies 
98,99) indicated that TGF-ß aggravates arthritis. This might be related to the 
trong attraction of inflammatory cells induced by TGF-ß (100-102), which, 
¡specially in the induction phase, could promote arthritis. Probably in a later 
tage TGF-ß ameliorates arthritis via suppression of immune functions. 
In the normal joint TGF-/3 is produced in an inactive form and during 
irthritis this latent TGF-0 becomes activated by as yet unknown activation 
nechanisms. As a consequence, in the joint it is active in circumstances where 
Jso high levels of IL-1 are present. Biologic responses to IL-1 present in RA 
ynovial fluids have been shown to be partially suppressed by endogenous TGF-
Ì (103,104). TGF-0 was also produced in synovium during experimental ar-
hritis in rats (105). 
If, after administration of both IL-1 and TGF-ß to a normal joint, TGF-
l appears to protect articular cartilage against the deleterious effects of IL-1, 
'arious mechanism could be involved. As mentioned before, TGF-ß can 
uppress IL-1 effects by interfering with IL-1 signalling. It has been reported to 
uppress IL-1 receptor expression on chondrocytes (81,82) and to stimulate IL-
ra synthesis (106,107). Besides these indirect effects TGF-ß can counteract IL-
with its own effects on extracellular matrix metabolism. It has been reported 
о stimulate chondrocyte synthesis of the important extracellular matrix com-
lonents proteoglycan (108-110) and collagen (110). It also inhibited matrix 
legradation by suppression of metalloprotease synthesis (111,112) and stimula-
ion of the synthesis of protease inhibitors by connective tissue cells (111-113). 
Ul these effects of TGF-/3 are opposite to the effects of IL-1 (figure 4). Accor-
ling to the spirit of this chapter it has to be mentioned that modulation of 
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production and/or signalling of other growth factors or cytokines could also 
interfere with IL-1 effects on articular cartilage. 
IL-1 
proteoglycan J 
collagen | 
protease f 
protease inhibitor j 
Figure 4. Opposite effects of IL-1 and TGF-fi on synthetic fiinctions of the 
chondrocyte. 
ARTHRITIS AT OLDER AGE 
Because of its chronicity, RA is a major problem in the elderly: 1.5% of the 
men and 4.7% of the women in the Netherlands above the age of 65 are 
suffering from RA. Recent prospective followup studies of early RA patients 
showed a more severe course at older age О 60 years). Both a higher disease 
activity and a tendency towards more radiographic damage were found in older 
onset RA (114-115). 
The cartilage destructive effect of arthritis is dependent on the clearance 
of the inflammation provoking agent by the immune system, the production of 
destructive factors and their inhibitors during acute arthritis, the succeeding 
downregulation of arthritis, the structure of the articular cartilage matrix, and 
the restorative capacity of the chondrocytes. All these parameters change during 
aging. With increasing age, the responses of the T-immune system show a 
decline in absolute terms as well as in specificity of the responses (reviewed in 
116,117). This degeneracy of the T-cell repertoire of old individuals is related 
to the involution of the thymus, where T-cells mature, during aging. The 
immune responses of the B-cell system also show an impairment with age. This 
latter deterioration with age could not be ascribed to intrinsic factors in the B-
TGF-b 
proteoglycan f 
collagen f 
protease i 
protease Inhibitor f 
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cell system and seems to be caused by age-related changes in the T-cell system. 
Aging causes a decline in synthesis (118,119) and receptor expression (120,121) 
of the T- and B-cell growth factor IL-2, and impaired Τ cell responsiveness to 
IL-2 (122,123). In addition to these lymphocyte defects, also antigen-presentati­
on by the macrophage is impaired in later life (124,125). 
With increasing age also the composition of articular cartilage changes 
considerably. The content of glycosaminoglycans, per μg dry weight, seems to 
be rather constant (126). The water content, however, decreases with age (127). 
Aggrecan exhibits an age-related decrease in size, reflecting changes in the 
synthesis of the GAG chains, but also extracellular degradation by proteases 
(128). Hyaluronic acid content increases, but hyaluronic acid chain size decrea­
ses with age (129). The relative proportion of chondroitin sulfate in proteogly­
can monomers decreases, while that of keratan sulfate increases with increasing 
age (130). Also extractability of proteoglycans is decreased in later life (131). 
Furthermore, the ratio of chondroitin-6-sulfate over chondroitin-4-sulfate 
increases with aging (132). Together with increased cross-linking of the collagen 
fibrils (133), these changes in composition of articular cartilage alter its resis­
tance to mechanical forces, possibly leading to lesions. It is unknown whether 
there is a relation between these age-dependent changes and development of 
arthritis or the amount of cartilage destruction caused by arthritis. Exposure of 
immunogenic epitopes in cartilage lesions and altered diffusion of nutrients and 
cytokines could be the result of these age-related changes in articular cartilage. 
Possibly, these changes promote the development of arthritis and/or increase the 
resulting cartilage destruction. 
AIM AND STRUCTURE OF THIS STUDY 
The observation of a more severe course of older onset RA (ref) has been the 
starting-point of our studies. The aim of the present study was to gain insight 
into the factors determining enhanced vulnerability of old joints. In chapter 2 
the characteristics of experimental arthritis were examined in mice of different 
ages. 
In addition to measurements of the total cascade of reactions caused by 
joint inflammation, also the effects of a single mediator were studied. In chapter 
3 the proteoglycan depleting effects of IL-1, by now considered a key mediator 
in the process of cartilage destruction during arthritis, were determined in vitro 
and in vivo. We studied the effects of IL-1 in young adult and old animals, 
because information about the influence of age on IL-1 effects on the articular 
chondrocyte in vitro was scanty and studies of age-related differences in 
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responses after in vivo administration were lacking. 
Recovery of articular cartilage proteoglycan synthesis after suppression 
induced by IL-1 exposure in vivo appeared to be retarded in old mice. In 
chapter 4 the hypothesis was tested that age-related changes in availability of, 
and chondrocyte reactivity to the anabolic factor IGF-I play a role in the 
retarded restoration of matrix integrity found in old cartilage. 
In chapter 5 the effects of TGF-ß, another anabolic factor reported to 
stimulate proteoglycan synthesis and to inhibit proteoglycan degradation in vitro 
were studied. Murine patellae were incubated with combinations of TGF-ß 1, IL-
1, and IGF-I and the result of their interplay on proteoglycan metabolism was 
determined. Moreover, for the first time TGF-ß 1 effects on articular cartilage 
were studied in the more complex in vivo situation, shortly after a single intra-
articular injection. 
In chapter 6 the effects of TGF-ß 1 injections on articular cartilage, 
synovium and periosteum were examined, to assess whether this mediator can 
mimic features of joint pathology found in experimental joint disease. These 
effects were compared in mice of different ages. 
In chapter 7 in vivo modulation by TGF-ß 1 of IL-1 effects was investi-
gated after prolonged exposure. Histology and articular cartilage proteoglycan 
synthesis and content was studied after triple intra-articular injections of both 
mediators. In addition, age-dependency of TGF-ß/IL-1 interplay was studied. 
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AGE- AND SEX-RELATED DIFFERENCES IN ANTIGEN-INDUCED 
ARTHRITIS IN C57BI/10 MICE 
Henk M. van Beuningen, Wim В. van den Berg, Joost Schalkwijk, Onno J. 
Arntz and Levinus B.A. van de Putte. 
(Arthritis and Rheumatism 32:789-794,1989) 
ABSTRACT 
The influence of both age and sex on antigen-induced arthritis in C57B1/10 
mice was studied. Methylated bovine serum albumin was used to induce 
arthritis in young adult (3 months) and old (18 months) male and female 
mice. Arthritis became chronic and led to severe joint damage more often in 
18-month-old female mice, compared with both young adult female mice 
and with male mice of both ages. Τ cell immunity and levels of antibodies 
against methylated bovine serum albumin were comparable in all groups. 
Antigen retention in the joint was greater in old compared with young adult 
mice of both sexes, and could therefore not entirely explain the increased 
prevalence of persistent arthritis in old females. Our data suggest that 
female hormones, in combination with age, are important factors in the 
chronicity and destructive character of this type of arthritis. 
INTRODUCTION 
Rheumatoid arthritis is a disease more common in women than in men, and 
onset of the disease occurs most often between the ages of 20 and 60 years. 
Studies using a number of experimental arthritis models have revealed diverse 
effects of sex hormones on the course of the arthritis. Allen et al (1) showed 
that the severity of chronic polyarthritis induced with streptococcal cell wall 
fragments was enhanced by female sex hormones. On the other hand, other 
investigators have found that female sex hormones suppressed adjuvant arthritis 
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(2) and clearly reduced the incidence and severity of collagen-induced arthritis 
(3). Most studies on the spontaneous rheumatoid arthritis-like lesions in MRL-
mç-lpr/lpr mice have used female animals (4), but a report clearly showing sex-
related differences in these lesions is lacking. Mikecz et al, in a recent study of 
mice with experimental chronic erosive arthritis with features of spondylitis, 
again noted a greater prevalence of the arthritis in females (5). In the present 
study, we investigated the influence of both sex and age on the course of murine 
antigen-induced arthritis. Incidence and severity of the arthritis were examined 
in male and female mice at the ages of 3 months (young adult) or 18 months 
(old). Although a similar tendency was seen in young mice, sex-related differen-
ces were far more striking in old animals. 
MATERIALS AND METHODS 
Animab. C57B1/10 mice aged 3 months or 18 months at the induction of arthritis were 
used for study. They were bred at our Central Animal Laboratory and were fed a standard diet 
and tap water ad libitum. The mice were specified pathogen free, and none of the animals 
selected for study showed evidence of tumors, abscesses, or limb fixation. The mice were 
immunized as previously described (6). Arthritis was induced by injecting 60 /ig methylated 
bovine serum albumin (mBSA) in б μΐ saline into the right knee joint. 
Determination of cellular and humoral immunity. Cellular immune responses against 
mBSA were tested in additional groups of mice by skin testing as previously described (7). Arthus 
reaction was determined after 3 hours, and delayed-type hypersensitivity after 24 hours. Humoral 
immunity was measured using an enzyme-linked immunosorbent assay (7). 
"'"Technetium measurement. Joint inflammation was determined by measurement of 
" T c pertechnetate uptake in the knee joints, as previously described (8). 
Histologic grading of inflammation and joint destruction. At days 3, 7, 14, and 28, 
groups of mice were killed, and the knee joints were dissected and processed for histologic gra­
ding (6). Cellular infiltration and exudation, bone apposition (osteophyte formation), and 
chrondrocyte death were scored semiquantitatively on 5-7 frontal semiserial sections of the knee 
joint. These parameters were scored on a 4-point scale (0-3). The left knee of each animal was 
used as a control. 
Antigen clearance. Sixty micrograms of l25I-labeled mBSA (6 μΐ) was injected into the 
right knee joint of immunized animals. At days 2, 4, 7, and 14, 125I radioactivity in the arthritic 
joints was measured by external gamma counting, as described for " T c uptake measurements 
(8). 
Estradiol measurents. Estradiol concentrations were estimated by radioimmunoassay 
using diethylether extraction and paper chromatography in a Bush A system (petroleum-ether 
[boiling point 80-110eC]:methanol:water, 9:7:4 by volume). 
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RESULTS 
Joint inflammation. Edema formation was measured by T c uptake at 
days 3 and 7 after the induction of arthritis (Table 1). Both age and sex were 
determinants of the severity of the inflammation. In the female group, the 
highest values were found in old mice, and this reached statistical significance at 
day 7. A similar trend with regard to age differences was noted in male mice. 
Moreover, the severity of arthritis was generally greater in females than in 
males in both age groups, although this difference was not always statistically 
significant. 
Table 1. Joint edema as measured by ""technetium uptake in mice with 
antigen-induced arthritis 
Ratio of ""Tc uptake* 
Sex, timepoint Young adult (n) Old (n) 
Female, day 3 2.13 ± 0.39 (10) 2.32 ± 0.32 (20) 
Male, day 3 1.86 ± 0.30 (10) 1.74 ± 0.26 (10)t 
Female, day 7 1.63 ± 0.36 (15) 1.96 + 0.43 (30)$ 
Male, day 7 1.40 ± 0.24 (15)t 1.78 ± 0.37 (15)§ 
* Expressed as the mean ± SD ratio of " T c uptake in inflamed knees versus untreated 
contralateral knees. 1.0 = no edema. 
t Ρ < 0.002 versus old females, by Mann-Whitney U test. 
t Ρ < 0.05 versus young adult females, by Mann-Whitney U test. 
§ Ρ < 0.002 versus young adult males, by Mann-Whitney U test. 
In addition to " T c uptake measurents, joint inflammation was studied 
by histologic analysis. At days 3 and 7, massive infiltration was found in the 
knees of all groups of mice studied, and no significant differences in the amount 
and type of inflammatory cells (mainly granulocytes and monocytes) were 
noted. At later days (14 and 28), the inflammation waned in all groups, but 
significantly more infiltrate remained present in old female mice (Table 2). 
Cartilage destruction. Cartilage destruction was scored at days 14 and 
28 after the induction of arthritis. The difference between the age groups was 
pronounced in female mice, whereas this difference was less clear in male mice. 
In fact, as was the case with cellular infiltration, at day 28 joint destruction was 
minimal in males. Therefore, the study of age-related cartilage destruction was 
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Table 2. Chronicity of inflammation in mice with antigen-induced arthritis, 
according to sex and age 
Sex, timepoint 
Female, day 14 
Male, day 14 
Female, day 28 
Male, day 28 
No. of animals with persistent 
inflammation/total no. tested* 
Young adult 
12/39 
2/20 
3/41 
0/21 
Old 
28/44t 
5/19 
20/49Φ 
1/20 
•Inflammation was defined as a score of à 1 for infiltration of inflammatory cells (see Materials 
and Methods for scoring procedure). 
t Ρ < 0.01 versus young adult females, by chi-square test. 
% Ρ < 0.001 versus young adult females, by chi-square test. 
confined to female mice. At day 28, mean ± SD values for chondrocyte death 
in patellar cartilage of old and young adult female mice were 1.63 ± 1.36 and 
0.48 ± 0.74, respectively (P< 0.001, Mann-Whitney U test). 
Figure 1 shows the distribution of 3 degrees of chondro-cyte death in 
the 2 age groups. In both age groups this distribution was skewed. However, it 
is clear that both the incidence and the degree of chondrocyte death were higher 
in older mice at day 28. Interestingly, after day 14, chondrocyte death was 
progressive in older mice, whereas this phenomenon was not found in young 
adult animals. 
New bone formation. In addition to chondrocyte death, bone apposition 
(osteophyte formation) was another parameter that was strikingly different in the 
age groups. Bone apposition was far more impressive in old versus young 
animals (data not shown). In contrast to chondrocyte death, this parameter did 
not show a progressive change between days 14 and 28 in old mice. It is 
noteworthy that in young adult animals, there was a trend showing bone 
apposition to be even less at day 28 than at day 14, indicating potential rever­
sibility. 
Correlation between inflammation and destruction. Joint damage 
appeared to be closely correlated with residual inflammatory mass at the later 
timepoints studied. In old females, at day 28 after arthritis induction, the 
presence of a synovial infiltrate (grade ^ 1) was accompanied by severe (grade 
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CHONDROCYTE DEATH 
Figure 1. Distribution pattern of 3 degrees of chondrocyte death in young adult (open columns) 
and old (shaded columns) female mice at day 14 and day 28 after induction of arthritis. Histologic 
scores S i = little or no chondrocyte loss; scores of 1-2 = significant loss; scores S 2 = severe 
damage (see Materials and Methods for scoring procedure). At day 14, no significant age-related 
differences were noted. At day 28, the distribution of the 3 degrees of chondrocyte death differed 
significantly between the 2 age groups (P<0.001 by chi-square test). 
¿t2) depletion of chondrocytes in patellar cartilage in 19 out of 20 mice with 
the chronic type of arthritis. Also, severe bone apposition (grade ^2) was seen 
in 19 out of 20 of these arthritic mice. 
Immunity. We attempted to determine whether the observed differences 
in the course of inflammation correlated with differences in cellular or humoral 
immunity. Skin tests showed no significant differences between sexes or 
between age groups with regard to Arthus reactions or delayed-type hypersen-
sitivity responses. Additionally, no differences were found in anti-mBSA titers 
(results not shown). 
Clearance of antigen. We investigated the relationship between chronic 
inflammation in old animals and inadequate clearance of the antigen from the 
joint. In nonimmune mice, clearance of mBSA was initially similar in the 4 
categories of mice studied (data not shown). In the immune animals, the clea-
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days alter intra-articular injection 
Figure 2. Retention of 12SI-labeled methylated bovine serum albumin in the knee joints of a, 
female (n = 18) and b, male (n=6) C57B1/10 mice with antigen-induced arthritis. Solid lines 
represent young adult mice (age 3 months at induction of arthritis); broken lines represent old 
mice (age 18 months at induction of arthritis). Bars represent SEM. 
ranee of mBSA from the joints was much faster than in nonimmune animals in 
all age groups, confirming earlier observations that enhanced antigen clearance 
is due to immune clearance and inflammation (9) (Figure 2). Age-related diffe-
rences in antigen clearance were already evident in the early days of the study. 
Young adult mice, especially the males, cleared the antigen very quickly. In the 
18-month-old-mice, clearance was impaired both in males and females, as 
compared with young animals; however, no sex difference was noted in the old 
mice with respect to antigen clearance. 
Estradiol measurements. The mean ± SD estradiol concen-trations 
were comparable in sera of 5 old and 5 young adult female mice (0.072 ± 
0.013 and 0.082 ± 0.013 nmoles/liter, respectively). 
DISCUSSION 
In this study, we demonstrated that in 18-month-old female C57B1/10 mice, 
mBSA-induced arthritis more often became chronic and more often led to severe 
joint damage, as compared with young adults and with males of both ages. This 
suggests that both age and sex (i.e., sex hormones) determine susceptibility to 
chronic arthritis. This conclusion seems valid because old females still produce 
considerable amounts of sex hormones. 
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Antigen-induced arthritis in mice has been described ex-tensively (10). 
This type of experimental arthritis is Τ cell dependent (11), and chronic 
inflammation can be induced only by antigens that are retained by the joint 
tissues (7). Most likely it is because only small amounts of antigen leak out of 
the joint tissues that chronic arthritis is sustained for a long period of time. 
Based on this premise, the induction of antigen-specific local hyperreactivity is 
of utmost importance (12). Sex-related differences in the course and destructive 
effects of antigen-induced arthritis in mice have not been reported previously, 
probably because only young adults were studied. In fact, these sex-related 
differences appear to be most obvious in older mice. It is also clear that joint 
damage in mBSA-induced arthritis correlates with chronicity of inflammation. 
This substantiates our 1985 report indicating that the development of cartilage 
destruction depends upon both the severity of the initial inflammation and the 
chronicity of the mBSA-induced arthritis (13). 
In male mice, age-related differences in the chronicity and the destruc­
tive effects of mBSA-induced arthritis are much smaller than the differences in 
females. This observation seems to rule out the possibility that the age-related 
differences we found in females could have been caused by spontaneously 
occuring osteoarthritis in old mice, since this phenomenon is found predomi­
nantly in male mice (14). Moreover, we confirmed our observation by exami­
ning the untreated contralateral knees for osteoarthritic changes. Such changes 
were found only sporadically, and data obtained from these animals were then 
eliminated. Thus, the differences we found actually represent sex-linked 
differences in the course of mBSA-induced arthritis. 
The question now centers on why arthritis is more chro-nic, and 
therefore more destructive, in old females. Our measurements of cellular and 
humoral immunity did not show age- and sex-related changes, indicating that 
altered immunity against mBSA could not be responsible for the above-men­
tioned histologic observations. In fact, Vissinga and coworkers reported a 
decline in delayed-type hypersensitivity Τ cell function with age (15), suggesting 
that this highly Τ cell-dependent arthritis would, if anything, be less severe in 
older animals. On the other hand, defects in suppressor function have been 
described in older mice, especially in females. Therefore, it is tempting to 
speculate that part of the chronicity of disease in the antigen-induced arthritis 
model is related to development of autoimmunity to damaged cartilage, and that 
this response finds more expression in old females. This hypothesis is at present 
under investigation. 
As stated before, in addition to Τ cell immunity, the amount of antigen 
retained in the joint is a crucial factor in antigen-induced arthritis (7). So far, no 
evidence exists for defective antigen clearance from the circulation in older ani-
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mals. However, Holmes and colleagues (16) demonstrated that retention of 
antigen was enhanced in collagenous tissues of older mice, and this was 
probably related to changes in tissue composition. To our knowledge, sex-
related differences in antigen retention have never been described. 
In the present study we also observed a retarded clearance (enhanced 
retention) of l2iI-labeled mBSA from the joints of old animals. This phenomenon 
was found in both males and females and therefore could not completely explain 
the prevalence of persistent arthritis in old females. This implies that, in 
addition to enhanced antigen retention, sex hormones are a possible determining 
factor in the chronicity of disease in old females. 
In addition to the chronicity of the arthritis (13), the vulnerability of 
joint tissues will determine the ultimate extent of joint damage. In a previous 
study, we determined the effects of hydrogen peroxide and elastase, two potent 
polymorphonuclear leukocyte-derived mediators, on patellar cartilage of young 
and old mice. After short-term in vitro exposure, no differences in susceptiblity 
were noted (17). However, a reduced capacity of old cartilage to recover from 
oxidative stress was seen in vivo, and similar observations were recently made 
after exposure of the cartilage to interleukin-1 (unpublished observations). Sex-
related vulnerability was not determined in these studies. 
Sex-related differences in disease susceptibility have already been 
described in a number of other experimental arthritis models. Female animals 
have been shown to be more susceptible to proteoglycan-induced polyarthritis 
(S) and streptococcal cell wall arthritis (1). A number of models of spontaneous 
autoimmune disease also show increased disease progression in females, which 
can be down-regulated with androgen treatment (18). Because in humans the 
onset of joint diseases like rheumatoid arthritis usually occurs at middle age and 
has a preponderance in women, it seams reasonable, in selecting the most 
relevant experimental models for the study of these phenomena, to look for a 
model in which susceptibility to arthritis is increased at mid-life and in females. 
In this respect, the present observations in the antigen-induced arthritis model 
nicely fit these criteria. 
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IN VIVO EFFECTS OF INTERLEUKIN-1 ON ARTICULAR CARTILAGE 
Prolongation of Proteoglycan Metabolic Disturbances in Old Mice 
Henk M. van Beuningen, Orino J. Arntz and Wim В. van den Berg 
(Arthritis and Rheumatism 34:606-615, 1991) 
ABSTRACT 
We investigated the effects of intraarticular injections of interleukin-la (IL-
la) into the knee joints of young (3-month-old) and old (18-month-old) 
C57B1/10 mice. In this in vivo study, MS-sulfate incorporation and release 
were used to compare the effects of IL-1 on patellar cartilage proteoglycan 
metabolism. IL-1-induced stimulation of proteoglycan degradation was 
confined to the first 24 hours after injection in both young and old animals 
and was only slightly lower in old cartilage than in young. In old patellar 
cartilage, IL-1-induced suppression of proteoglycan synthesis appeared to be 
more prolonged. Also, the time needed to restore the cartilage matrix, 
characterized by proteoglycan synthesis above normal levels, was longer in 
old animals. Histologic analysis confirmed the retarded recovery in the 
cartilage of old mice. Autoradiography showed that the chondrocytes of the 
medial side of the femorotibial area were most vulnerable to IL-1-induced 
suppression of proteoglycan synthesis, especially the medial tibial plateau. 
As with the patellar cartilage, IL-1-induced suppression of proteoglycan 
synthesis in this area of articular cartilage was more prolonged in old 
animals. Our data indicate that the impact of IL-1 on articular cartilage is 
higher in old mice and that, consistent with certain loci found to be at risk 
in experimental osteoarthritis, there are sites at which IL-1 is more likely to 
act. 
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INTRODUCTION 
The 17-kd protein interleukin-1 (IL-1) has been the subject of numerous studies 
in the last decade. Those studies strongly suggest that IL-1 is an important 
mediator of connective tissue destruction in inflammatory joint disease. IL-1 has 
been shown to stimulate the production of prostaglandins and degradative 
enzymes in a variety of cell types, including fibroblasts, osteoclasts and chon­
drocytes (1-6). IL-1 has been detected in the synovial fluid of patients with joint 
inflammation (7-9), and IL-1-like activity has been produced in vitro by 
rheumatoid synovial cells (9-13). In articular cartilage, IL-1 induces the sup­
pression of chondrocyte proteoglycan synthesis and stimulation of proteoglycan 
degradation (14-17). 
It has recently been shown that IL-1 also induces marked cartilage destruction in 
vivo (18,19). Most studies describing the effects of IL-1 on cartilage have used 
cartilage obtained from young animals. Since rheumatoid arthritis and especially 
osteoarthritis occur predominantly in middle-aged and older people, it seems of 
utmost importance to study the in vivo effects of IL-1 on cartilage of different 
ages. To our knowledge, no such experiments have been carried out, and the 
results of only 1 in vitro study have been published (20). Here, we compare the 
in vivo effects of murine recombinant IL-1 on chondrocyte proteoglycan 
synthesis, proteoglycan degradation, and the succeeding restoration of articular 
cartilage matrix in young adult mice and old mice. The effects on young and old 
animals were always compared in parallel experiments. 
MATERIALS AND METHODS 
Animate. C57B1/10 mice, aged 3 months or 18 months, were used. Mice were bred, 
specified pathogen free, at our Central Animal Laboratory. The mice were fed a standard diet and 
tap water ad libitum. 
Interleukin-1. Murine recombinant IL-1 was kindly supplied by Dr. I.G. Ottemess 
(Pfizer Central Research, Groton CT). Biologic activity was determined using the lymphocyte-
activating factor (LAF) assay (17). A biologic activity of 1 unit was consistently found to cor­
respond to 10-40 pg. The IL-1 preparation was stored at -20°C, and it showed constant LAF 
activity over the period studied. 
Intraarticular injections. Recombinant IL-1 (300 units) was injected into the joint space 
of the right knee of the mice. The contralateral joint was injected with an equal volume (6μ1) of 
saline. 
Proteoglycan synthesis measurements. Proteoglycan synthesis was determined as 
described previously (21). Briefly, the patellae and a minimal amount of surrounding tissue were 
dissected. Six patellae were placed in 1 ml of incubation medium consisting of RPMI 1640 (Dutch 
modification) supplemented with 2mM L-glutaminc and 30 дСі of "S04. After labeling for 2 
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lours at 37'C in an atmosphere of 5% C02, the patellae were rinsed in saline and fixed 
svemight in 10% formalin. The next day, the patellae were decalcified in S % formic acid (4 
tiours), after which they could easily be punched out of the surrounding tissue. The patellae were 
dissolved in Luma Solve (Hicol, Oud-Beijerland, The Netherlands) at 60°C. The '5S content of 
each patella, which is a reliable measure of the proteoglycan production (22,23), was measured 
by liquid scintillation counting. 
IL-1 in cartilage culture. The in vitro effects of IL-1 (30 units/ml) on the patellar 
cartilage were determined after 48 hours of culture (at 37°C in 5% C02 in air). Six patellae were 
placed in 1 ml RPMI 1640 (Dutch modification) supplemented with 2mM L-glutamine, ImM 
pyruvate, 40 μ% of gentamycine, and 5% fetal calf serum (FCS) or 0,5 μg of recombinant human 
insulin-like growth factor-1 (IGF-1) per ml (Boehringer, Mannheim, FRG). IGF-1 was reconsti­
tuted with 0.1M acetic acid before use, and it was always used in the presence of 0.1% bovine 
serum albumin (Sigma, St. Louis, MO). For each animal studied, one patella was incubated in 
this medium alone and the other was incubated in this medium with IL-1 added. After 24 hours, 
the medium was changed. After 48 hours, the patellae were washed in phosphate buffered saline, 
ind labeled with MS-sulphate for 2 hours. 
Proteoglycan degradation measurements. To study in vivo degradation of patellar 
cartilage, proteoglycans were prelabeled with 35S-sulfate . Labeled sulfate was injected intraperi-
toneally 24 hours before the intraarticular injection of IL-1. Because proteoglycan synthesis in old 
animals is about half that of young adults, we injected double the amount of labeled sulfate into 
the old animals (fyCVgm body weight versus Αμα/gm body weight in young mice) so that 
enough radiolabel would be incorporated into the cartilage. At different times after IL-1 injection, 
the amount of MS-sulfate-labeled proteoglycans was determined. 
Radiolabeling of IL-1. About 25 μg IL-1 was radiolabeled with Ш І (Amersham, 
Buckinghamshire, UK) according to the method of Bolton and Hunter (24). Biologic activity was 
left intact by this iodination procedure. lodinated IL-1 was separated from free l25I by Sephadex 
G-25 fractionation. 
Measurement of retained IL-1. ,Ml-labeled IL-1 was injected into the right knee joint. At 
various times thereafter, the radioactivity of both knees was measured by external gamma 
counting. The value found in the right knee was corrected by subtracting that found in the left, 
untreated knee (background activity). The amount of labeled IL-1 retained was expressed as a 
percentage of the initial counts per minute, as measured immediately after injection of the 125I-
labeled IL-1. 
Histologic determination of IL-1 effects. To allow for histologic grading of the effects of 
IL-1, the knee joints were dissected and processed as described previously (25). Semiserial frontal 
sections were stained with Safranin-O or hematoxylin and eosin. Safranin-O stains glycosamino-
glycans; diminished staining would therefore represent cartilage degradation. Cartilage proteogly­
can depletion was graded using a 4-point scale, where 0 = no depletion and 3 = severe 
depletion. 
Autoradiography. Autoradiography was performed to detect potential variations in the 
IL-1 sensitivity of chondrocytes in various regions. 35S-sulfate was injected intraperitoneally as 
described above. The knee joints were dissected 2 hours after sulfate injection and prepared for 
histologic analysis as described above. After processing for histologic studies, 6-/im sections were 
prepared and mounted on gelatin-coated slides. These were dipped in K4 emulsion (Ilford, 
Basildon, Essex, UK) and exposed for 3-5 weeks. After this period the slides were developed and 
stained with hematoxylin and eosin. 
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proteoglycan synthesis (% of control) 
Time (days) after single IL-1 injection 
Figure 1. In vivo effects of age on interleukinl (IL-l)-induced suppression of proteoglycan 
synthesis, after a single intraarticular injection (300 units) in 3-month-old ( A) and 18-month-old 
( · ) C57B1/10 mice. Values determined according to 15S-sulfate incorporation into patellar 
cartilage (% of contralateral, uninjected knee). (Synthesis was not studied between days 6 and 12, 
but other experiments have shown that enhanced synthesis above normal occurs in both young and 
old mice at these times [data not shown].) * = significant difference in young versus old animals, 
by Wilcoxon's rank sum test; •» = significant difference in injected versus control patellae of old 
mice. Values are the mean and SD of 6 mice. 
RESULTS 
Inhibition of chondrocyte proteoglycan synthesis. The in vivo effects 
of IL-1 on chondrocyte proteoglycan synthesis in patellar cartilage were 
determined at different times after intraarticular injection of IL-1. In 4 com-
parative experiments, the effect of IL-1 was followed in mice of both age 
groups; a representative experiment is shown in Figure 1. We observed no 
influence of IL-1 on the contralateral patellae. Significant suppression of 
proteoglycan synthesis was noted as early as at 12 hours after the IL-1 injection 
(data not shown), indicating that the in vivo effect of IL-1 was accelerated 
compared with the suppression observed in vitro (17). Moreover, suppression of 
chondrocyte proteoglycan synthesis, as observed at 24 hours, always was 
slightly higher in old mice than in young mice. Synthesis returned to normal 
levels after day 3 in the young mice, while recovery was consistently retarded in 
the old animals. 
34 
Chapter 3 
Table 1. Influence of sex on IL-l-induced suppression of proteoglycan synthesis in patellar cartilage 
of C57B1/10 mice* 
Age/sex 
3 months 
Female 
Male 
18 months 
Female 
Male 
3 }S incorporation at 24 hours 
Control 
882 ± 152 
1,150 ± 117 
622 ± 163 
683 ± 72 
IL-l-treated 
270 ± 69 
367 ± 104 
197 ± 78 
202 ± 6 
% 
suppression 
69 
68 
68 
70 
" S incorporation at % hours 
Control 
952 ± 191 
1,187 ± 133 
507 ± 102 
675 ± 146 
IL-l-treated 
1,008 ± 362 
1,116 ± 315 
212 ± 130 
265 ± 148 
% 
suppression 
-6 
6 
58 
61 
* Interleukm-1 (IL-1) was injected, and the amount of 3 5S incorporated at 24 hours and % hours was 
assessed, as descnbed in Materials and Methods Values are the mean ± SD cpm of 6 mice. 
Enhanced proteoglycan synthesis (above normal) was evident at day 6 in young 
mice, whereas a similar phenomenon was noted in old mice, but always on later 
days. Enhanced synthesis was still significant in the injected patellae compared 
wih the contralateral patellae in the old mice at day 18. The most consistent 
finding was the retarded recovery of proteoglycan synthesis in the old animals. 
In addition to age-related effects, we studied the impact of IL-1 treat­
ment in male and female mice of both age groups. No significant differences 
were noted (Table 1). 
Interestingly, in standard cartilage cultures containing 5% FCS, IL-l-
induced suppression of proteoglycan synthesis was more pronounced in the 
cartilage of young adult animals (Table 2). This contrasts with the in vivo 
effects of IL-1, where old cartilage appeared to be most vulnerable. However, 
when culture conditions were optimized by addition of 0.5 μg of IGF-1 per ml, 
IL-1 caused comparable suppression in old and in young cartilage. Thus, the 
Table 2. IL-l-induced suppression of proteoglycan synthesis in cultures of patellar cartilage of 
C57B1/10 mice* 
Age 
3 months 
18 months 
3 5S incorporation in absence of IGF 
% 
Control IL-l-treated suppression 
669 ± 63 313 ± 65 53 
338 ± 46 224 ± 50 34 
33S incorporation in presence of IGF 
Control IL-l-treated 
1,039 ±111 423 ± 58 
658 ± 141 292 ± 28 
% 
suppression 
59 
56 
* Patellae were dissected and cultured with interleukin-l (IL-1) as descnbed in Materials and Methods. 
All cultures contained 5% fetal calf serum, and after 48 hours of incubation, cultures were pulsed for 
2 hours with ' 5 S 0 4 Values are the mean ± SD of 2 experiments in the absence of insulin-like growth 
factor-1 (IGF) (n = 12 patellae) and of 4 experiments in the presence of 0 5 Mg/ml of IGF (n = 24 
patellae). See Materials and Methods for details. 
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addition of IGF-1, the most important anabolic factor for cartilage present in 
serum and synovial fluid (26,27), leads to a condition that is more consistent 
with that in vivo. 
IL-1 retention. IL-1 was labeled according to the Bolton-Hunter 
method, and it was verified that the iodinated IL-1 retained its biologic activity. 
After injection into the knee joint, gamma radiation was measured externally. 
One hour after injection of the 125I-labeled IL-1, 30% of the initial cpm was 
present in animals of both age groups (Figure 2). At 6 hours, more than 90% of 
the radioactivity was cleared from the joints. No significant differences were 
noted between the young and old mice. 
time (h) after IL-1 injection 
Figure 2. Retention of mI-labeled interleukin-1 (IL-1) in the knee joints of 3-month-old ( A ) and 
18-month-old ( · ) C57B1/10 mice. Values are the mean of 6 mice. 
Degradation of proteoglycans. Cartilage was prelabeled in vivo by 
intraperitoneal injection of 35S-sulfate. After 24 hours, IL-1 (300 units) was 
injected into the right knee joint, and after another 24 hours the effects of IL-1 
on proteoglycan degradation were determined (Table 3). Basal degradation of 
patellar proteoglycans was clearly measurable in both young and old cartilage. 
There was a 15% increase in proteoglycan degradation in the first 24 hours after 
IL-1 injection in the young adult mice and only a 7% increase in the old animals 
(Table 3). Earlier studies have shown that IL-1-induced proteoglycan degrada-
tion after a single injection occurs only during the first 24 hours in young adult 
mice (17). This observation was confirmed and shown to also be the case in old 
animals. 
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Table 3. Effect of IL-1 on loss of newly synthesized proteoglycans 
in vivo in the patellar cartilage of C57B1/10 mice* 
Time % i
o s s 0 f
 35S-labeled 
after proteoglycans IL-1-induced 
IL-1 increase in 
Age injection Control IL-1-treated % loss 
3 months 24 hours 23.2 ± 23.2 38.1 ± 22.5 15.0 ± 12.3t 
3 months 48 hours 36.6 ± 19.4 50.7 ± 10.6 14.2 ± 11.6Φ 
18 months 24 hours 22.0 ± 19.8 29.0 ± 16.4 7.0 ± 16.1 
18 months 48 hours 30.1 ± 16.8 37.7 ± 19.3 7.6+10.5 
*
 3 5 S 0 4 was injected intraperitoneally 24 hours prior to intraarticular 
injection of interleukin-1 (IL-1). Loss of 35S-labeled proteoglycans is 
expressed as the percentage of 3 5 S 0 4 content at the time of IL-1 
injections. Values are the mean ± SD. 
t Ρ = 0.055 versus 18-month-old mice at the same time point (by 
Student's Mest) (4 experiments with 26 mice of each age group). 
Χ Ρ = 0.06 versus 18-month-old mice at the same time point (by 
Student's Mest) (3 experiments with 19 mice). 
Effects of repeated IL-1 injections on the cartilage matrix. After a 
single injection of IL-1, depletion of cartilage proteoglycans was not sufficient 
to be reliably scored on Safranin O-stained sections. When IL-1 was injected 
into the same knee-joint 3 times (with 2-day intervals between injections), more 
cellular infiltrate was seen and proteoglycan depletion of the cartilage matrix 
was evident, in the femoropatellar area. In general, changes in the cartilage 
matrix in the femorotibial area were less pronounced. Staining intensity in this 
cartilage is less homogeneous, even in untreated knees, and this feature hampers 
the reliability of age-related and focal differences seen in this part of the joint. 
The patella appears to be the best indicator area for determining cartilage 
destruction. This was also noted in our earlier studies of antigen-induced 
arthritis (28). Both young and old patellar cartilage were severely depleted 1 
day after the last injection. On day 5, significant restoration of the cartilage 
matrix was seen only in young mice (Figure 3 and Table 4). 
We also studied the effects of the 3 injections of IL-1 by measuring 
proteoglycan synthesis (Figure 4). At 24 hours after the last injection, IL-1-
induced suppression of chondrocyte proteoglycan synthesis was 40% in young 
adult mice and 70% in old mice. These values are comparable with those found 
at 24 hours after the single injection of IL-1. By day 3, the proteoglycan 
synthesis in the cartilage of young adult animals had exceeded the normal level, 
indicating an accelerated recovery compared with the findings after a single 
injection. Synthesis was still suppressed in old animals on day 3. As was the 
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Table 4. Depletion of proteoglycans in articular cartilage after 3 
intraarticular injections of IL-1 into C57B1/10 mice* 
Age 
3 months 
3 months 
18 months 
18 months 
Time after 
third IL-1 
injection 
1 day 
5 days 
1 day 
5 days 
Depletion of 
patellar cartilage 
1.58 ± 0.60t 
0.61 ± 0.90 
1.56 ± 0.66 
1.28 ± 1.02 
* Values are the mean ± SD loss of Safranin О staining in sections 
of joints, scored 0-3, where 0 = none and 3 = severe loss of staining. 
At each time point, 12 young and 16 old animals were used. 
t Ρ < 0.01 versus 3-month-old mice at 5 days (by Wilcoxon's rank 
test). All other differences were not statistically significant. 
Proteoglycan synthesis (% of control) 
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Figure 4. Proteoglycan synthesis in patellar cartilage of 3-month-old ( A ) and 18-month-old ( · ) 
C57BI/10 mice injected 3 times with interleukin-1 (IL-1). * = significant difference in young 
versus old animals, by wilcoxon's rank sum test; * = significant difference in injected versus 
control patellae of old mice. Values are the mean and SD of 6 mice. See Figure 1 for further 
details. 
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Figure 3. Safranin O-stained sections of patellar cartilage from 3-month-old and 18-month-old 
C57B1/10 mice injected 3 times with interleukin-1 (IL-1). A, One day after the last of 3 
injections, there was a significant infiltration of inflammatory cells in the synovium and a distinct 
loss of staining of the superficial layer, the metabolically active part of the cartilage. B, Five days 
after the last injection, the cartilage matrix in most of the young animals was almost completely 
restored. C, Five days after the last injection, severe depletion was still present in the patellar 
cartilage in old animals, but partial restoration of the cartilage matrix was often seen at this time 
point. Ρ = patella; F = femur. (Original magnification χ 95.) 
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case after a single injection, there was a delay in the restoration of proteoglycan 
synthesis in the cartilage of old animals. Both suppression and enhancement 
above normal levis of chondrocyte proteoglycan synthesis lasted longer in old 
animals. Synthetic activity was still significantly higher than control values on 
day 18 in old mice. 
Localization of IL-1 effects. Autoradiography on day 1 after the last of 
3 IL-1 injections (Figure 5) showed suppression of proteoglycan synthesis in the 
femoropatellar area in animals of both age groups. In the femorotibial area of 
young mice, suppression was most obvious in the medial tibial plateau, whereas 
in old animals suppression was seen in the entire area. 
Five days after the last IL-1 injection in young adult animals, most 
chondrocytes showed proteoglycan synthesis above normal levels, especially 
those of the patella and the medial tibia (Figure 6). In old mice at this time 
point, severe suppression could still be seen in the femorotibial area, especially 
in the medial tibia, and sometimes in the central portion of patellar cartilage. 
Chondrocytes adjacent to these lesions, probably non-weight-bearing areas, 
showed above-normal synthesis. The chondrocytes of the medial tibia of old 
animals, thus, appear to be most vulnerable to IL-1 induced suppression of 
proteoglycan synthesis. 
Chapter 3 
Figure 5. Autoradiographs (hematoxylin and eosin-stained 
sections) of articular cartilage from 3-month-old C57B1/10 mice 1 day after the last of 3 injections 
of interleukin-1 (IL-1). A, IL-1-induced suppression of proteoglycan synthesis is present in the 
whole femoropatellar ara. В, In the femorotibial area, suppression of proteoglycan synthesis is 
largely restricted to the medial tibia (T). C, Normal patella (P). D, Normal femorotibial area. F 
= femur. The joints of 18-month-old mice were grossly the same at this time. (Original magni­
fication χ 160.) 
41 
Chapter 3 
Figure 6. Autoradiographs (hematoxylin and eosin-stained sections) of articular cartilage from 3-
month-old and 18-month-old C57B1/10 mice 5 days after the last of 3 injections of interleukin-1 
(IL-1). A, Femoropatellar cartilage of young animal, showing stronger staining than in normal 
joints, reflecting the doubled proteoglycan synthesis. B, Femoropatellar cartilage of old animal, 
showing enhanced synthesis in this area. In some old animals, the central part of the patella (P) 
remained suppressed. C, Femorotibial area of young animal, showing complete restoration of 
proteoglycan synthesis, as well as enhancement of synthesis in the medial tibia (T). D, Femoroti­
bial area of old animal, showing little or no recovery of synthesis in this area. Severe suppression 
of synthesis is still present in the medial tibia. Note the high level of proteoglycan synthesis in 
cartilage adjacent to the weight-bearing area. F = femur. (Original magnification χ 160.) 
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DISCUSSION 
[η this study, we have shown that intraarticular injection of murine recombinant 
IL-1 enhanced proteoglycan breakdown and suppressed chondrocyte proteogly­
can synthesis in the patellar cartilage of both young and old mice to the same 
extent. In a comparative study, IL-1-induced breakdown of proteoglycans 
appeared to be somewhat less in old mice. However, recovery from IL-1-
induced inhibition of chondrocyte proteoglycan synthesis was clearly retarded in 
aid mice, and prolonged suppression was found at specific sites, in particular in 
the medial tibia. 
The effect of IL-1 on cartilage has mainly been studied in vitro, and 
virtually all investigations have been of cartilage from young animals. Since IL-
1 has been implicated as playing a role in such human diseases as rheumatoid 
arthritis and osteoarthritis, it makes sense to study the sensitivity of old cartilage 
to IL-1. There are only a few studies which actually compare the effects of IL-1 
on young and old cartilage. Age-related differences have been noted under 
conditions of longterm in vitro culture (20). Our in vitro studies indicated that 
the sensitivity to IL-1 may differ according to the culture conditions chosen. 
When 5% FCS was used, young cartilage appeared more vulnerable to IL-1-
induced suppression. However, after addition of physiologic amounts of 
recombinant human IGF-1, the most important anabolic factor for cartilage 
present in serum and synovial fluid (26,27), age-related differences were no 
longer seen. These studies provided evidence that IL-1 is active in old cartilage 
as well as young. In addition, such in vivo conditions as load-bearing and 
prolonged activation of synovium with continued production of other cytokines 
and growth factors may further contribute to differences in IL-1 sensitivity in 
vivo. For instance, IL-1 receptor expression can be potentiated by fibroblast 
growth factor and platelet-derived growth factor (29,30), and IL-1-induced 
proteoglycan degradation can be inhibited by transforming growth factor-/3 
(31,32) and enhanced by fibroblast growth factor (33). 
We and others (18,19) have recently shown that IL-1 induces marked 
cartilage destruction in young animals in vivo. We now report that the effects of 
IL-1 are at least similar or even worse in old animals. The latter finding is 
consistent with the recent observation that joint destruction is enhanced in 
antigen-induced arthritis in old mice (28). This could be caused by the more 
chronic character of the arthritis in older animals (28), but equally plausible 
would be an enhanced sensitivity of old cartilage to the destructive action of 
inflammatory mediators, including IL-1. Although the importance of IL-1 in this 
model has yet to be proven, evidence is now emerging that cartilage destruction 
can be suppressed by pretreatment with anti-IL-1 antisera (unpublished obser-
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vations). 
The most marked age-related difference noted in the present study was 
the retarded recovery of IL-1-inhibited chondrocytes in old animals. Unfor-
tunately, we were not able to explore this phenomenon in more detail ex vivo, 
since recovery was severely impaired under the culture conditions used. 
Potential factors influencing in vivo recovery are the degree and time course of 
inflammation and the clearance of IL-1. We first compared the degree of joint 
inflammation induced by IL-1 in old and young animals. In contrast to the 
findings from studies of other species (18,34) we saw only a very low number 
of infiltrating cells, mainly polymorphonuclear cells, in both young and old 
mice. This makes it highly unlikely that differences in the level of infiltrating 
cells are responsible for the age-related changes in the effects of IL-1. In 
addition, recent studies by Pettipher and colleagues (34) have provided evidence 
for a minor role of the inflammatory infíltrate in proteoglycan degradation. 
Those aythors have also shown that IL-1-induced proteoglycan loss from 
cartilage is unimpaired in neutropenic rabbits, and pronounced proteoglycan 
degradation is still observed in neutropenic animals with antigen-induced 
arthritis (35,36). This is also illustrated by our experiments using triple injec-
tions of IL-1. In contrast to the single injection, cellular infiltration after 3 IL-1 
injections was considerable, but IL-1 effects on proteoglycan synthesis and 
degradation were of the same order of magnitude as those seen after a single 
injection. 
Another possible explanation for the retarded recovery of proteoglycan 
synthesis in old animals could be a defective clearance of the suppression-
inducing cytokines from the joint. To exclude this possibility we measured the 
clearance of^I-labeled IL-1 from the knee. Radiolabeled IL-1 was rapidly 
cleared from the joint, consistent with findings of earlier studies in rabbits and 
mice (18,37). No age-related differences in IL-1 clearance were seen, but the 
possibility that IL-1 biologic activity is removed faster from the joints of young 
animals than from old animals cannot be excluded. Moreover, the production of 
II-1 (38) and other factors by II-1 activated synovium could be responsible for 
part of the effects of IL-1, especially in the recovery period. It is still to be 
determined whether second-mediator generation is different in the synovial 
tissue of old animals. 
Chondrocytes io the medial tibia appeared to be highly vulnerable to IL-
1-induced suppression of proteoglycan synthesis, and in old animals suppression 
was prolonged in this part of the articular cartilage. Interestingly, increased 
vulnerability of cartilage of the medial part of the femorotibial area is also a 
feature of human osteoarthrosis (39). We have found similar features (un-
published observations) in our recently developed osteoarthritis models in mice 
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(40,41). This may indicate that enhanced susceptibility of chondrocytes in this 
area is a general feature which can be generated by a variety of inflammatory 
mediators. On the other hand, it may provide indirect evidence that IL-1 is a 
key mediator in osteoarthrotic processes. Further studies with different media­
tors are needed to provide insight in potential differential sensitivity of chon­
drocytes in various areas in the joint and whether this may direct the charac­
teristic patterns of joint destruction. 
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INSULIN-LIKE GROWTH FACTOR STIMULATION OF ARTICULAR 
CHONDROCYTE PROTEOGLYCAN SYNTHESIS. AVAILABILITY AND 
RESPONSES AT DIFFERENT AGES. 
Henk M. van Beuningen, Onno J. Arntz and Wim В. van den Berg. 
(British Journal of Rheumatology 32:1037-1043, 1993) 
ABSTRACT 
It was found that recovery of articular chondrocyte proteoglycan (PG) 
synthesis was retarded in old mice after in vivo exposure to both inter-
leukin-1 (IL-1) or hydrogen peroxide. We examined whether this could be 
related to diminished serum levels of insulin-like growth factor 1 (IGF-1), 
the main anabolic factor, or to changes in cartilage IGF responsiveness with 
age. A small decline of IGF-1 concentration was observed in serum of old 
mice, but the level still appeared to be supra-optimal to maintain normal 
cartilage PG synthesis over a culture period of 1 to 3 days. Moreover, PG 
synthesis was at least equally stimulated in patellar cartilage from 18-
month-old mice compared to 3-month-old mice over a wide range of IGF-1 
concentrations, and similar findings were obtained after stimulation with 
serum. 
In addition, we studied the capacity of IGF-1 or serum to induce 
recovery of PG synthesis in vitro after IL-1 exposure in vivo. In a 3-day 
culture period normal cartilage PG synthesis was stimulated to the same 
extent with serum or IGF-1, but recovery from IL-1 mediated suppression 
of PG synthesis was more pronounced with serum. This latter capacity was 
similar for serum of mice aged 3 or 18 months and was noted for both 
young and old cartilage. 
Our data show that retarded recovery of chondrocyte PG synthesis 
in old mice cannot be explained by age-related changes in IGF-1 availability 
and cartilage responses to IGF. They also indicate that serum factors other 
than IGF-1 are important for recovery, either alone or in combination with 
IGF-1. 
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INTRODUCTION 
Insulin-like growth factors (IGFs) are polypeptides with structural and functional 
homology to proinsulin (1). In man two major IGFs (reviewed in 2), IGF-1 
(somatomedin C) and IGF-II, have been characterized by amino acid sequence 
analysis of peptides purified from serum (3,4) and by isolation of cDNAs 
encoding precursor forms of IGFs (5,6). IGFs play a part in the growth and 
development of many tissues during fetal and adult life (1,7), and are implicated 
in tissue hypertrophy and repair (8). Anabolic stimulation of cartilage cultured 
in serum and synovial fluid has been shown to be caused mainly by IGF-1, 
since stimulation of proteoglycan (PG) synthesis could be totally blocked by anti 
IGF-1 antibodies (9,10). IGF-1 has been shown to stimulate chondrocyte PG 
synthesis (9-13) and to suppress PG degradation (12-14). In addition, specific 
IGF-1 receptors have been demonstrated on rabbit and bovine articular chondro-
cytes (15,16) and the chondrocyte produces IGF-1 itself (17,18), suggesting 
local action of IGF-1 by autocrine or paracrine mechanisms. Cartilage destruc-
tion in osteoarthritis is supposed to be caused by an imbalance between degrada-
tive breakdown by cytokines and the effort of growth factors to maintain 
proliferative and synthetic cell responses. Low serum levels of IGF-1 and high 
levels of intracellular IGF-1 and IGF-1 mRNA in chondrocytes were detected in 
OA patients (19,18). In addition to these disturbances during joint pathology, 
age-related decreases of IGF-1 concentrations in human and rodent blood have 
been reported (20-23). 
In an earlier study (24) we showed that after intra-articular injection of 
interleukin-1 (IL-1) in vivo recovery of chondrocyte PG synthesis is retarded in 
cartilage of old mice compared to young animals. In the present study we show 
a similar age-related difference in restorative capacity after intra-articular 
injection of glucose oxidase, inducing hydrogen peroxide generation in the joint. 
This could be caused by intrinsic defects of the old chondrocyte, or insufficient 
anabolic stimulation of chondrocytes in old mice. Both possibilities were 
explored in the underlying study. For this reason IGF-1 levels were determined 
in the blood of young adult and old mice. Moreover, the stimulatory and 
restorative capacities of serum and recombinant human IGF-1 were studied in 
parallel experiments using patellar cartilage of young and old mice. 
MATERIALS AND METHODS 
Animate. C57B1/10 mice aged 3 and 18 months were used. Mice were killed by cervical 
dislocation and the whole patellae, with a standard amount of surrounding tissue, were dissected 
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from the клее joints as described by van den Berg et at (25). Murine blood was obtained from 
the orbital vein. Bovine cartilage slices were taken from the metacarpal-phalangeal joints of 1-2 
yr-old cows obtained from the local slaughterhouse. 
¡ntra-articular injections of inflammatory mediators. Glucose oxidase or IL-1 were 
dissolved in PBS and 6 μΐ of solution was injected into the joint space beneath the patella. The 
contralateral knee joint was injected with the same amount of PBS alone. At days 1, 2 and Э after 
injection of 300 LAF units IL-1 or l.S ßg amidated glucose oxidase (which induces H202 in vivo) 
patellae were dissected and pulse labeled with MS-sulfate. Incorporation of labeled sulfate into the 
patellae has been shown to be a reliable measure of PG synthesis in patellar cartilage (26). 
Stimulation of patellar cartilage PG synthesis in vitro. Murine patellae were dissected 
from the joint. This method leaves the cartilage intact (no slicing). Patellae with some adjacent 
tissue were kept for up to 72 hours in tissue culture in the presence of varying concentrations of 
recombinant human IGF-1 (Bochringer, Mannheim, FRG) or murine serum in RPMI 1640 (Dutch 
modification, Flow Laboratories, Irvine, UK) supplemented with 0.1% ultrapure BSA (Sigma, St. 
Louis, MO), 2mM glutamin and ImM pyruvate (37°C ,5%COJ). This culture medium was 
changed each 24 hours. After culture chondrocyte PG synthesis was measured. 
Measurement of PG synthesis. Immediately after dissection of patellae, or after culture, 
chondrocyte PG synthesis was determined using s5S-sulfate incorporation into patellar cartilage. 
After labelling 2 hours with radioactive sulfate the patellae with surrounding tissue were washed 
and fixed in formalin. They were decalcified in formic acid and thereafter the patellae were 
punched out of the surrounding tissue. The patellae were dissolved in Luma Solve (Lumac, Olen, 
Belgium) and ^-radiation was measured in a liquid scintillation counter. All experiments were 
performed twice, each time with six patellae per experimental group. 
Determination of IGF ¡eveb. 
IGF-1 radioimmunoassay. IGF-1 in plasma was determined by a commercially available 
radioimmunoassay (Nichols Institute, San Juan Capistrano, CA, U.S.A.) preceded by a C18 Sep-
Pak (Waters Assoc, Milford, MA) column extraction procedure. 
IGF-1 bioassav. Biologically active IGF in serum was determined using the culture system of 
Handley and Campbell (27), with minor modifications. Cartilage slices were cut from the 
metacarpal-phalangeal joints of 1-2-yr-old cows. The cartilage slices were cultured with complete 
medium (RPMI + 2 mM glutamine + 1 mM pyruvate + 0.1 % ultrapure BSA + 40 μg gentamy-
cine) or 20% murine serum diluted in this complete medium or known amounts of recombinant 
human IGF-1 in complete medium. Medium was replaced each 24 h. After 5 days, 33S-sulfate was 
incorporated over 2 hours. Incorporated label/mg wet tissue was compared to a standard curve 
obtained with recombinant human IGF-1. These bovine cartilage slices appeared to be about 10 
times more reactive to IGF stimulation compared to murine patellar cartilage and have been 
shown to be a convenient test system for IGF in sera and synovial fluids (10). 
RESULTS 
PG synthesis after ¡ntra-articular injections of inflammatory media-
tors. Figure 1 shows suppression of patellar chondrocyte PG synthesis induced 
by IL-1 and hydrogen peroxide and the subsequent in vivo restoration of 
synthesis. At day 1 both inflammatory mediators induced a marked suppression 
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1 2 3 
Time after single IL-1 injection (days) 
Time after single amidated glucose oxidase 
injection (days) 
FIG 1 —Effect of age on m vivo recovery of articular chondro­
cyte proteoglycan synthesis after suppression by inflammatory 
mediators The right knee joint was injected with (a) 300 LAF 
units IL-1 or (b) 1.5 μg amidated glucose oxidase (generates 
H 20 2) and ex vivo proteoglycan synthesis (35S-sulphate incorpor­
ation into patellar cartilage) was measured at different limes 
after injection. The left, untreated, knee was used as a control 
(100%). Each value represents the mean ± s D. of 12 patellae (six 
in each experiment). O, Cartilage of 3-month-old mice, Δ, car­
tilage of 18-monlh-old mice. 
of PG synthesis of about 50-70% at the dosages chosen. Suppression was 
comparable or even more severe in patellae of old mice. Recovery of PG 
synthesis appeared to be retarded in patellae of old animals in both protocols, 
suggesting the general character of this phenomenon. We examined whether it 
could be related to differences in IGF-1 levels or cartilage IGF-responsiveness 
in young and old mice. 
Determination of IGF-1 levels in murine blood. Both the radioim­
munoassay and the bioassay (Table I) showed an age-related decrease in the IGF 
concentration of murine blood, although this was only a trend in the bioassay. 
No sex-related differences in IGF concentrations were found (data not shown). 
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TABLE I 
INSULIN-LIKE GROWTH FACTOR-1 (IGF-1) CONCENTRATION IN 
MURINE BLOOD AT DIFFERENT AGES 
IGF-1 concentration 
Age Radioimmunoassay Bioassay 
3 months 559 ± 40 ng/ml 328 ± 45 ng/ml 
18 months 417 ± 39 ng/ml* 288 ± 59 ng/ml 
»Significantly different from IGF concentration in plasma of 
young mice {Ρ <0.0001; Student /-test). 
Each value represents the mean ± S.D. of six plasma pools 
(n = 3), obtained from 18 male C57B1/10 mice. 
Comparing the values obtained in both assays, most of the IGF (60-70%) 
appeared to be bioactive in the bovine test system. 
Effect of serum on murine articular cartilage PG synthesis. Whether 
or not the small decrease in IGF levels observed in blood of old animals 
influenced the PG synthesis of murine patellar cartilage was tested in cultures of 
anatomically intact patellae from young mice with sera obtained from young or 
old animals (table II). In a 24 hours culture period 100% serum slightly 
stimulated PG synthesis above the original synthetic level, whereas in basic 
medium, in the absence of serum, the synthetic rate dropped to below 50%. No 
major difference was noted between the stimulatory capacity of serum from 
animals aged 3 or 18 months. When 30% serum was used the level of stimula­
tion was slightly less. Upon prolonged culture (72 hours) it was noted that 
stimulation was less with 30% serum of old mice. Overall, the data indicate that 
the IGF-1 levels in 100% old serum are not rate limiting to normal PG syn­
thesis. 
Effects of recombinant human IGF-1 on PG synthesis in young and 
old murine cartilage. To investigate whether small changes in IGF-1 con­
centration may have a different impact in young and old cartilage, parallel dose-
response studies were performed in the range 0.01 - 1.0 μg IGF-l/ml (Fig. 2). 
The stimulation of PG synthesis appeared to be at least equivalent in cartilage 
from old patellae. Maximum stimulation caused an approximate doubling of the 
original PG synthesis and a plateau was reached at 0.3 /ig/ml for both ages. In 
this 24 hours assay 100% murine serum showed a stimulatory capacity roughly 
equivalent to 0.1 μg IGF-l/ml. In addition, a kinetic study was performed with 
0.5 μg IGF-l/ml (Fig. 3), a concentration in the physiological range. A rapid 
increase of PG synthesis was found, with a maximum at around 15 hours. 
Thereafter, a gradual decline to normal values took place within 3 days. It is 
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STIMULATION OF CARTILAGE PROTEOGLYCAN (Pu) SYNTHESIS BY 
SERUM FROM MICE OF DIFFERENT AGES 
Culture lime 
(h) Medium 
0 RPMI 
24 RPMI 
100% serum 3-month-old 
100% serum 18-monlh-old 
30% scrum 3-month old 
30% serum 18-month-old 
72 100% serum 3-month-old 
100% serum 18-month-old 
30% serum 3-month-old 
30% scrum 18-month-old 
"S-sulphate 
incorporation* 
993 ± 82 (100%) 
480 ± 53 (48%) 
1251 ± 146 (126%) 
1380 ± 210 (139%) 
1092 ± 151 (110%) 
1095 ± 180(110%) 
1261 ± 163 (127%) 
1271 ± 76 (128%) 
1201 ± 154(121%) 
904 ± 140 (91%)t 
* Each value represents the mean cpm ± s D of 12 patellae after 
2 h "S-sulphate incorporation Patellae were dissected from 
young (3-month-old) mice 
t Significantly different from PG synthesis after 72 h incubation 
with 30% serum taken from 3-month-old mice (Я<0005, 
Student's Mest) 
300 
0 0 1 0 05 01 02 03 0 4 05 
Recombinant human IGF-1 
1 0 serum 
FIG 2 —Comparative effect of cartilage age on concentration-
dependent stimulation of proteoglycan (PG) synthesis by recom­
binant insulin-like growth factor 1 (IGF-1) Murine patellae 
were dissected and cultured for 15 h in complete medium sup­
plemented with different concentrations of recombinant human 
IGF-1 PG synthesis after culture is expressed as % of normal PG 
synthesis, measured immediately after dissection Each bar 
represents the mean ± s D of 12 patellae •, Cartilage of 
3-month-old mice, Q. cartilage of 18-month-old mice, ^ , car­
tilage of 3-month-old mice, cultured in undiluted murine serum 
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worthy of note that PG synthesis was higher in old versus young cartilage at all 
time points tested, not always reaching statistical significance. 
For comparison, similar kinetic studies were performed with undiluted 
serum of young mice (Fig. 3). A plateau was reached much earlier (3 hours), 
but the high values observed with recombinant IGF-1 were not seen. Serum 
could maintain PG synthesis at the same level for at least 3 days and major 
differences in responses of old and young cartilage were not found. 
Recovery of PG synthesis after IL-1 exposure. In order to find out 
whether IGF besides its general stimulation of PG synthesis is also a deter­
mining factor in recovery of PG synthesis after IL-1 induced suppression, we 
cultured patellae dissected at day 1 after injection of 30 U IL-1. As shown in 
Fig. 4, IGF stimulated PG synthesis in control and IL-1 treated patellae to the 
same extent, over a 24 hours incubation period. The IL-1 mediated suppression 
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FIG 3 —Comparative effect of cartilage age on time-dependent 
stimulation of proteoglycan (PG) synthesis by (a) insulin-like 
growth faclor-1 (IGF-1) or (b) scrum Murine patellae were dis­
sected and cultured in complete medium supplemented with 
0 5μ§ recombinant human IGF-l/ml or in undiluted serum 
obtained from young (3-month-old) mice The medium was 
changed every 24 h PG synthesis after culture is expressed as % 
of normal PG synthesis, measured immediately after dissection 
Each value represents the mean + S D of 12 patellae O, Car­
tilage of 3-month-old mice, Δ, cartilage of 18-monlh-old mice 
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of PG synthesis relative to the control group was not changed by IGF. At the 24 
hours timepoint 30% murine serum only maintained PG synthesis at the initial 
level, while culture in RPMI alone resulted in further decrease of synthesis in 
both normal and IL-1 pretreated cartilage. 
In addition, we cultured such patellae for 3 days in the presence of 
either IGF or 30% murine serum (Fig. 4). Both IGF and serum maintained the 
PG synthesis at the original level. In contrast, serum showed a markedly 
enhanced capacity to stimulate recovery of IL-1 treated patellae, compared to 
IGF, indicating that additional factors, either alone or in combination with IGF, 
are important for recovery. Furthermore, we tested the capacity of serum from 
young and old mice in such recovery (72 hours) experiments, using both old 
and young patellae. However, in contrast to retarded recovery in old mice 
observed in vivo (Fig. 1), no major differences were noted in these in vitro 
recovery experiments (data not shown). 
Non-treated IL-1 treated 
FIG. 4.— Ex vivo recovery of proteoglycan (PG) synthesis after 
in vivo interleukin-1 (IL-1) exposure for (a) 24 h and (b) 72 h. 
The right knee joints of 3-month-old mice were injected with 
30 LAF units IL-1 and after 24 h the treated patellae and the 
contralateral controls were dissected. "S-sulphate was incor­
porated cither immediately •. or after culture during 24 or 72 h 
in RPMI ^ , in O^g IGF/ml RPMI Щ, or in 30% serum (diluted 
with RPMI) obtained from young mice §|]. The medium was 
changed every 24 h. PG synthesis is expressed as % of normal 
PG synthesis, measured immediately after dissection. Each bar 
represents the mean ± S.D. of 12 patellae. 
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DISCUSSION 
Our experiments show that old murine cartilage needs more time to restore PG 
synthesis after in vivo treatment with inflammatory mediators. Age-related 
differences in anabolic stimulation did not seem to be responsible for this 
phenomenon, because in spite of a significant decrease, the concentration of IGF 
in serum of old mice still appeared to be supra-optimal and because the response 
of old cartilage was at least comparable to cartilage of young animals. 
The age-related decrease in IGF levels in blood is a phenomenon that 
has been described before in several studies in humans (28,21) and in rodents 
(20,22,23). At the two ages studied there were no sex-related differences in 
IGF-1 concentrations. This is in contrast to measurements in human serum, 
showing higher levels in females (28,21), while in rats IGF-1 levels seem to be 
higher in males (20). 
To our knowledge, age-related responses of intact articular cartilage to 
IGF have not been studied before. The present investigation demonstrates no 
significant differences between young and old murine cartilage. In a study on 
human fibroblasts (29) it was shown that IGF-receptor levels and cellular 
responses to IGF did not change with age. Using isolated human articular 
chondrocytes Recklies et al. (30) found a decrease in the responsiveness to IGF-
1 in adult articular chondrocytes with increasing age. This apparent discrepancy 
with our work may be due to the system used (cartilage vs chondrocytes). 
Moreover, it cannot be excluded that old human chondrocytes are taken from 
early, ill-defined OA lesions. In a recent study (31) stimulation of PG synthesis 
by IGF-1 or 20% fetal bovine serum was compared in sliced bovine cartilage of 
15-week-old calves and 18-24-month-old steers. Similar IGF-1 effects were 
found at both ages studied, but stimulation by fetal bovine serum was higher in 
steers. However, these investigators did not actually study aging effects, as they 
compared cartilage of half-grown and adult cows, while we compared cartilage 
of full grown young mice and old mice. 
We measured high levels of IGF-1 in murine serum, but serum stimula-
tion of PG synthesis is less when compared to stimulation by comparable 
concentrations of human recombinant IGF-1. This, together with the obser-
vations that in 30% serum stimulation of PG synthesis often is of the same 
order, and recovery of suppressed synthesis is always enhanced compared to 
100% serum (data not shown), suggests the presence of suppressive factors in 
serum. The suppressive effect of higher serum concentrations on PG synthesis 
has been reported previously (32). This suppression could be caused by haemo-
globin released by damaged erythrocytes (33). Moreover, in serum between 
100% (34) and 90% (35) of IGF-1 is bound to specific carrier proteins, IGF-
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binding proteins (IGF-BPs). Six distinct IGF-BPs have now been identified 
(36,37), and IGF-BPs have been shown to inhibit or enhance the action of IGF 
(38-41). Suppression of 33S-sulfate incorporation into serum- or IGF-1-stimu-
lated cartilage by these proteins has been described (42-44), but the exact 
mechanism of this regulation is still unclear (45,46). Nothing is known about 
age-dependent changes in the concentration of IGF-binding proteins in murine 
blood. In rat (22) and human (47,48) plasma the concentration of the growth 
hormone-dependent large molecular weight IGF-binding protein declined with 
age after puberty. Neither do we know how much IGF-binding protein diffuses 
into the synovial fluid (49,50) and whether local production of both IGF-1 
(51,52,17) and its binding protein (53,54) is a major determinant. In addition to 
IGF binding proteins another factor suppressing cartilage PG synthesis has 
recently been detected in serum (43). In spite of the poor stimulation of PG 
synthesis induced by serum (compared to IGF-1), in long-term experiments we 
found that serum maintained PG synthesis at rates higher than those measured at 
day 0, longer than did IGF-1. The latter difference was also reported by Curtis 
et al. (55), who used bovine articular cartilage slices. 
Although IGF in serum stimulates PG synthesis to a lesser degree 
compared to similar concentrations of recombinant human IGF-1, the restorative 
capacity of serum exceeds that of recombinant human IGF-1. Early in culture 
IGF-1 stimulates IL-1 treated and untreated patellae to the same degree and 
therefore the percntage suppression of PG synthesis compared to the correspon-
ding controls is not changed by this general stimulation. This phenomenon was 
also reported by Tyler (12). Therefore, the specific stimulation of suppressed 
chondrocytes by serum cannot be attributed to IGF-1 alone. It is tempting to 
speculate that transforming growth factor-jS (TGF-j8) could be a relevant factor 
in this respect, as recent experiments in our laboratory have shown that TGF-/8 
can stimulate recovery of suppressed PG synthesis (13). TGF-j8 has also been 
shown to counteract IL-1 effects on chondrocyte PG metabolism in vitro 
(56,57,13) and in vivo (13). We have recently found that recovery of PG 
synthesis in our patella culture system might be impaired by local IL-1 produc-
tion, and possibly TGF-0 present in murine serum achieves its effect by 
neutralization of the suppressive effect of IL-1. 
So far we have described the phenomenon of prolonged suppression of 
chondrocyte PG synthesis in vivo in old mice. We do not know the mechanism 
involved, but we have found no evidence that IGF-1 plays a part in this pheno-
menon, as no defects in IGF-1 production and chondrocyte IGF-1 responsive-
ness were detected in old animals. However, we cannot exclude a role for IGF-
1, because we did not measure its local production in the joint. Also the fact 
that restorative capacity was found in serum, and not in IGF-1 alone, does not 
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îxclude the possibility that synergism between IGF-1 and other serum factors is 
reponsible for this serum effect. 
Possibly the retarded recovery is not related to age-dependent differen-
ces in stimulatory factors, but is more likely to be caused by prolonged ex-
posure to suppressive factors in articular tissues of old mice. The latter could be 
caused by enhanced production of inhibitory mediators, like IL-1, or to an 
impaired control by their natural inhibitors. We now have evidence which 
suggests that there is a different level of secondary mediators in patella speci-
mens of old animals. This aspect is presently under investigation. 
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Protection from interleukin 1 induced destruction of articular cartilage by 
transfoming growth factor β: studies in anatomically intact cartilage in vitro 
and in vivo. 
Henk M. van Beuningen, Peter M. van der Kraan, Ormo J. Arntz and Wim. В 
van den Berg. 
(Annals of the Rheumatic Diseases 52:185-191, 1993) 
ABSTRACT 
The modulation of interleukin-1 (IL-I) effects on proteoglycan metabolism in 
intact murine patellar cartilage by transforming growth factor ß (TGF-fl) 
was investigated in vitro and in vivo. In vitro TGF-/3 (400 pmol/l) had no 
effect on basal proteoglycan degradation. Proteoglycan degradation induced 
by IL-1, however, was suppressed by TGF-/3 in serum free medium alone 
and in medium supplemented with 0.5 /¿g/ml insulin-like growth factor 1. 
This suggests a specific regulatory role of TGF-/3 under pathological 
conditions. In contrast with the suppression of breakdown, synthesis of 
proteoglycans was stimulated by TGF-0 for both basal and IL-I suppressed 
proteoglycan synthesis in cultures without insulin-like growth factor. In the 
presence of insulin-like growth factor no extra effect of TGF-/S on proteo-
glycan synthesis was observed. With insulin-like growth factor, however, 
TGF-/3 potentiated the ex vivo recovery of IL-1 induced suppression of 
proteoglycan synthesis. Analogous to the in vitro effects, TGF-/3 injected 
intra-articularly suppressed IL-1 induced proteoglycan degradation. Fur-
thermore, TGF-0 injected into the joint counteracted IL-1 induced sup-
pression of proteoglycan synthesis. This indicates that in vivo also TGF-/3 
can ameliorate the deleterious effects of IL-1 on the cartilage matrix. 
INTRODUCTION 
Many studies have provided evidence for interleukin 1 (IL-1) being a key 
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mediator in inflammation in general and in arthritis inparticular. It causes an 
influx of inflammatory cells into the joint (1-4), suppresses chondrocyte 
proteoglycan synthesis, and stimulates cartilage degradation (5-12). Interleukin 1 
concentrations in arthritic joints are increased (13-15) and IL-1 could be respon­
sible for most of the cartilage damage that is characteristic of arthritis. 
It has been found that the ubiquitous and multifunctional regulatory 
peptide transforming growth factor β (TGF-ß) can counteract the effects of IL-1 
on several cell types (16,17), including chondrocytes (18,19). In arthritis it 
could be an important factor because of its immunosuppressive functions (16,20-
25) and its effects on articular cartilage. With regard to articular cartilage it was 
reported that TGF-jS in vitro can suppress IL-1 induced proteoglycan degradation 
in monolayers of articular chondrocytes and in sliced articular cartilage (18,19). 
As TGF-jS concentrations in arthritic joint fluids (26-29) are in the range 
yielding optimum TGF-/3 effects on chondrocytes in vitro (30-32), TGF-0 could 
play an important regulatory part in cartilage destruction during arthritis. 
In the present study we investigated TGF-/3 modulation of IL-1 effects 
on proteoglycan degradation and proteoglycan synthesis in intact articular 
cartilage. We studied this modulation in vitro in basal medium, to confirm 
earlier studies (18,19), and in presence of insulin-like growth factor 1 (IGF-1), 
which is the major stimulatory factor, with respect to cartilage proteoglycan 
synthesis, in serum and synovial fluid (33,34). In addition to these more 
extensive in vitro experiments, we showed for the first time that TGF-/3 injected 
into the joint modulates the effects of IL-1 on proteoglycan metabolism. 
MATERIALS AND METHODS 
Animals. C57B1/10 mice aged 12 weeks or 18 months were used. They were fed a 
standard diet and tap water ad libitum. 
ChemicaL·. RPM1 1640 culture medium (Dutch modification) was obtained from Flow 
Laboratories (Irvine, UK). Recombinant murine interleukin-la was kindly supplied by Dr I.G. 
Ottemess (Pfizer Central Research, Groton, CT). 10-40 pg IL-la corresponded to one unit in the 
lymphocyte activating factor (LAF) assay. Transforming growth factor-01, purified from human 
platelets (Calbiochem Corp., La Jolla, CA) was decontaminated of trifluoroacetic acid and 
acetonitrile with a vacuum concentrator (Savant Instruments Inc., Formingdale , NY) and resus-
pended in 4 mM HCl for activation. Recombinant human insulin-like growth factor 1 (IGF-1, 
Boehringer, Mannheim, FRG) was dissolved in 0.1 M acetic acid (Merck, Darmstadt, FRG). All 
medium used in these experiments was supplemented with 0.1% ultrapure BSA (Sigma, St. Louis, 
MO). In vivo injections with TGF-j3 were performed with purified human TGF-/31, kindly sup-
plied by Dr A Purchio (Oncogen, Seattle, WA) or by Dr CR Steffen (Collagen Corp., Palo Alto, 
CA). 
64 
Chapter 5 
In vitro effects of IL-1/TGF-ß on cartilage proteoglycan metabolism. Mice were killed 
jy cervical dislocation and the whole patellae, with a standard amount of surrounding tissue, were 
Jissected from the knee joints as described by van den Berg et al (33). In studies on proteoglycan 
legradation patellae were prelabeUed with 35S-sulfate for 3 hours, and rinsed to remove non-
incorporated label prior to culture with IL-1 and growth factors. Six patellae were placed in 1 ml 
}f incubation medium consisting of RPMI 1640 supplemented with L-glutamin (2mM), pyruvate 
[ImM) and gentamycin (40/ig/ml) at 37°C in a humidified 5% CC^ atmosphere. At the start of 
[he incubation, TGF-/3 (10ng/ml=4O0pM) or IL-1 (30 Units/ml) or both were added, alone or in 
Kombination with 0.S pg IGF-l/ml. An equivalent quantity of 4 mM HCl and/or 0.1 M acetic 
icid was added to the control cultures . The chosen IL-1 and IGF-1 concentrations appeared to 
bave optimal effect on patellar cartilage proteoglycan synthesis; the 10 ng TGF-/3 concentration 
was optimal in many reports, describing its effects on cartilage in vitro. Proteoglycan degradation 
experiments were stopped after 24 hours culture, but in proteoglycan synthesis experiments 
medium was changed at 24 hours and cultures were continued for another 24 hours in order to 
obtain a maximal IL-1 effect on proteoglycan synthesis. In proteoglycan synthesis experiments, 
patellae were placed in medium with 30 дСі/тІ ,5S-sulfate (Lumac, Olen, Belgium) for two hours 
it the end of the incubation with IL-1 and growth factors. Thereafter the patellae were rinsed 
three times with physiological saline to remove non-incorporated label and subsequently fixed 
overnight in 10% formalin. The next day they were decalcified in 5% formic acid during four 
hours. After this treatment the patellae could easily be punched out of the surrounding tissue. The 
patellae were dissolved in Luma Solve (Perstorp Analytical, Oud-Beyerland , The Netherlands) at 
60°C. The 33S content of each patella, which is a reliable measure of cartilage proteoglycan 
production (36), was measured by liquid scintillation analysis. 
In vivo effects ofIL-1/TGF-ß on cartilage proteoglycan metabolism. 
Intraarticular injections. TGF-/3 (40, 200 or 1000 ng/όμΙ) was injected into the joint 
space of the right knee, and the contralateral joint received an equal volume (6 μΙ) of phosphate-
buffered saline (PBS). One hour after the TGF-/J injections IL-1 (30 Units) was injected into the 
right knee while the left knee received a second injection with PBS. In controls for the effects of 
IL-1 or TGF-0 alone, respectively the first or the second injection into the right knee was 
performed with PBS. In vivo experiments on proteoglycan degradation were preceded by a 
prelabelling of articular cartilage with 2μΟί 3SS-sulfate/g body weight, injected subcutaneously 24 
hours before intraarticular injections. 
Histology. Histology was used to compare cartilage depletion and cellular influx into the 
joints treated with IL-1, TGF-0, or the combination. Whole knee joints were dissected and 
processed as described previously (37). Semiserial frontal sections were stained with safranin O, 
or hematoxylin-eosin to be used in studies on cartilage proteoglycan depletion and cellular influx, 
respectively. 
Statistical analysis. Differences between experimental groups were tested using 
Student's t test, unless stated otherwise. 
RESULTS 
Effect of TGF-0 on IL-1 induced proteoglycan degradation in vitro. 
Although basal proteoglycan turnover rates in murine cartilage are already 
relatively high, markedly enhanced proteoglycan degradation was observed in 
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patellae cultured without growth factors. In one day cultures of patellae in 
medium without IGF-1 (Table 1) 52% of the 35S-labeled proteoglycans was 
released from the patellar cartilage. IL-1 caused a small but significant extra 
release of 27% of the label, compared with control cultures. In IL-1 treated 
patellae the release of labeled sulfate was significantly suppressed by 400 pM 
TGF-jS. This regulation was also present and of the same order of magnitude in 
cartilage derived from old animals (18 month old; data not shown). 
Similar studies were performed in the presence of IGF-1 (0.5 μg/ml). In 
these cultures the release of 35S labeled proteoglycans was 13% (Table 1). This 
is comparable with the proteoglycan degradation measured in patellar cartilage 
in vivo (38,39). IL-1 caused a significant extra release of 35% of the label 
compared with control cultures. Also under these conditions (with IGF-1), TGF-
jS diminished only the IL-1 induced proteoglycan release (37% reduction), not 
the IL-1 independent release. This indicates that suppression of IL-1 induced 
release by TGF-/3 is not a general suppression of degradation, but a specific 
regulation that counteracts IL-1 effects. 
Table 1. In vivo modulation of interleukin 1 (IL-1) induced proteoglycan 
degradation by transforming growth factor ß (TGF-ß) 
Addition' 
No addition 
TGF-ß 
IL-1 
IL-1 + TGF-ß 
35S-proteoglvcan content* 
No addition 
715 (134) 
760 (164) (NS) 
522(119)(p<104*) 
596 (104) (p< 0.05») 
Insulin-like 
growth factor 1 
1296 (268) 
1192 (253) (NS) 
849 (164) (p< IO"3) 
1023 (224) (ρ < 0.05) 
Patellae were prelabelled with 3SS-sulfate (three hours) and the 3ÎS content was measured 
immediately (1490 (180) counts/ minute), or after 24 hours of culture in medium with the various 
additions. 
' TGF-ft (400 pmol/1) and IL-1 (30 U) effects were compared with the corresponding controls. 
5
 IL-1 plus TGF-ß effects were compared with the effects of IL-1 alone. 
1
 In cultures without insulin-like growth factor 1 each experimental group consisted of 24 patellae, 
and in cultures with insulin-like growth factor 1 consisted of 18 patellae. 
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Effect of TGF-0 on IL-1 induced suppression of chondrocyte proteo­
glycan synthesis in vitro. Since cartilage homeostasis is the result of a balance 
between degradation and synthesis, in addition to proteoglycan breakdown we 
also studied proteoglycan synthesis. In the absence of IGF-1 (Table 2), proteo­
glycan synthesis rapidly decreased during culture. Suppression of 3iS-sulfate 
incorporation after 2 days was 59% compared with synthesis immediately after 
dissection of patellae. IL-1 caused 52% extra suppression of proteoglycan 
synthesis compared with synthesis after parallel cultures without the cytokine. 
Addition of TGF-0 (400 pM) led to a stimulation of proteoglycan synthesis, 
both with and without IL-1. In the presence of IGF-1 (Table 2) the proteoglycan 
synthesis was stimulated to 140% of synthesis levels measured immediately after 
dissection of patellae. IL-1 caused 70% extra suppression of patellar proteogly­
can synthesis compared with cultures without the cytokine. Under insulin-like 
growth factor conditions, TGF-0 had no extra effect on proteoglycan synthesis 
in both IL-1 treated and non-treated patellae. 
Table 2. In vitro modulation of interleukin 1 (IL-1) induced suppression of 
proteoglycan synthesis by transforming growth factor β (TGF β) 
Addition' 
No addition 
TGF-ß 
IL-1 
IL-1 + TGF-ß 
33S-sulfate incorporation* 
No addition 
459 (78) 
594 (90) (p< 0.001*) 
224(78)(ρ<10^ 
325(112)(p<0.001$) 
Insulin-like 
growth factor 1 
1568 (302) 
1411 (381) (NS) 
470 (112) (p< 10«) 
515 (202) (NS) 
Patellae were pulse labelled as a measure of proteoglycan synthesis with 33S-sulfate either 
directly (1120 (198) counts/ minute), or after 48 hours of culture in medium with the various 
additions. 
' TGF-ß (400 pmol/1) and IL-1 (30 U) effects were compared with the corresponding controls. 
* IL-1 plus TGF-ß effects were compared with the effects of IL-1 alone. 
' In cultures without insulin-like growth factor 1 each experimental group consisted of 36 patellae, 
and in cultures with insulin-like growth factor consisted of 18 patellae. 
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Restoration of IL-1 suppressed proteoglycan synthesis. To conserve 
articular cartilage extracellular matrix integrity it is of utmost importance that 
IL-1 induction of matrix proteoglycan depletion is downregulated, but repair of 
established depletion is also a crucial mechanism. Therefore, we studied TGF-/S 
effects in a phase of ex vivo recovery of IL-1 induced suppression of proteogly­
can synthesis. TGF-/3 clearly enhanced restoration of the proteoglycan synthesis 
after IL-1 induced suppression (Figure). In these experiments TGF-/3 caused an 
extra stimulation, superimposed on stimulating effects of IGF or serum. More 
specifically, TGF-/S prolonged insulin-like growth factor stimulation of proteo­
glycan synthesis and caused an accelerated stimulation of proteoglycan synthesis 
in cultures with 30% murine serum. Effects of TGF-0 on proteoglycan synthesis 
in control patellae (no IL-1 treatment) in 4-days cultures in presence of IGF-1 
or serum were minimal (data not shown). 
100 r-
p < 0005 
Days in culture 
1 2 
Days in culture 
Effect of transforming growth factor β (TGF-ß) (400pmol/l) on ex vivo recovery of proteoglycan synthesis after in vivo 
suppression induced by interlcukm I (IL-1) One day after mtra-articular injection of IL-1 (30 U) the patellae viere 
dissected and cultured with insulm-hke growth factor (A) or 30% murine serum (B) The effect of TGF-ß on proteoglycan 
synthesis was determined at different times. Proteoglycan synthesis was expressed as a percentage of normal proteoglycan 
synthesis. Each value represents the mean (SD) of 18 patellae (from three different experiments) At the start of the culture 
["SJsulphate incorporation in IL-1 treated patellae was 325(43) counts/mm, whereas in normal, untreated patellae it was 
855(157) Transforming growth factor β also had significant stimulatory effects when these data were analysed using three 
way ANOVA, (ty With TGF-ß; (о) without TGF-ß. 
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Table 3. Modulation of interleukin 1 (IL-1) induced stimulation of proteoglycan 
release in vivo 
Treatment' ÎSS-proteoglycan content of cartilage 
IL-1 R 178 (51) (77%) 
L 230 (69) (n=30) 
IL-1 + 40 ng TGF-ß R 200 (50) (88%); p=0.0116* 
L 226 (57) (n=30) 
IL-1 + 1000 ng TGF-ß R 223 (36) (91%); p=0.0092' 
L 245 (38) (n= 12) 
40 ng TGF-ß R 217 (50) (90%); p=0.042# 
L242(37)(n=18) 
200 ng TGF-ß R 208 (59) (90%); p=0.0015' 
L 232 (56) (n=30) 
" Effect of the combination of IL-1 and TGF-ß on release of labelled proteoglycans was compare« 
with the release induced by IL-1 alone. 
' Treated (R) and contralateral (L) patellae of each individual animal were compared by Student': 
(t) test for paired samples. 
1
 Twenty four hours after J5S-sulfate was injected subcutaneously, IL-1/ transforming growtl 
factor 0 (TGF-ß) was injected into the right knee joint. The amount of ,5S-labelled proteoglycai 
in the patellae was determined after another twenty four hour period. R is the "S content of th< 
right (experimental) patellae, and L of the left (untreated) patellae of the same animals. Groups о 
six mice were used; η=30 represents five different experiments. 
Effects of intra-articularly injected TGF-/S. To answer the questioi 
whether modulation of IL-1 effects by TGF-/8 is also possible in vivo, w< 
studied patellar proteoglycan metabolism after injection of both IL-1 and TGF-/Í 
into the knee joint. Cartilage proteoglycans were prelabeled with a singli 
subcutaneous injection of MS-sulfate at day -1. IL-1 (30 Units) injected intraar 
ticularly at day 0 caused 21 ± 14% release of labeled proteoglycans within 2' 
hours compared with saline injection (Table 3). When TGF-/3 was injected on« 
hour prior to IL-1 into the murine knee, the release of labeled proteoglycans in ; 
24 hour chase period was reduced. This suppression of IL-1 induced proteogly 
can degradation was significant in both the 40 ng and the 1000 ng TGF-/3 dosis 
No dose response effect was seen in this dose-range. Surprisingly, TGF-/ 
injected alone (40 or 200 ng) significantly stimulated proteoglycan degradation 
which may mask part of the protection against IL-1 induced proteoglycai 
degradation offered by TGF-0. 
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Table 4. Modulation of interleukin 1 (IL-1) induced suppression of proteoglycan 
synthesis in vivo 
Treatment' Proteoglycan synthesis in cartilage 
IL-1 R 486 (191) (43%) 
L 1191 (205)(n=18) 
IL-1 + 40 ng TGF-ß R 629 (76) (56%); ρ=0.007* 
L1130(217)(n=18) 
IL-1 -I- 200 ng TGF-ß R 646 (119) (59%); p=0.006* 
L 1097 (195) (n= 18) 
40 ng TGF-ß R 1116 (179) (103%); NS' 
L 1088 (160) (n= 12) 
200 ng TGF-ß R 1204 (247) (106%); NS' 
L 1135 (224) (n= 18) 
* Proteoglycan synthesis after treatment with the combination of IL-1 and TGF-D was compared 
with proteoglycan synthesis after treatment with IL-1 alone. 
' Treated (R) and contralateral untreated (L) patellae were compared. 
1
 Twenty four hours after intra-articular injection of IL-1/transforming growth factor β (TGF-ß), 
patellae were dissected and labelled with ,5S-sulfatc for two hours as a measure of proteoglycan 
synthesis. R is the "S incorporation in the right (experimental) and L in the left (untreated) 
patellae of the same animals. Groups of six mice were used; n = 18 represents three different 
experiments. 
We also studied proteoglycan synthesis after intraarticular injections of 
TGF-/3 and/or IL-1. Proteoglycan synthesis was measured ex vivo in patellae 
isolated one day after injection. IL-1 caused 57% suppression of PG synthesis, 
compared with normal synthesis (Table 4). Combination of IL-1 with 40 or 200 
ng TGF-/S significantly decreased this suppression. Again, no dose response 
effect of TGF-/S was seen, suggesting that the 40 ng dose already yields the 
maximum effect. TGF-/S alone did not influence proteoglycan synthesis in vivo. 
Histology (not shown) showed that the injected TGF-/8 had clear 
chemoattractive capacity. At six hours and to a lesser extent at 24 hours after 
injection, considerable infiltration and exudation of inflammatory cells was seen. 
The predominant cells were polymorphonuclear leukocytes. In combination with 
IL-1, the injected TGF-/9 had an additive effect in mediating the attraction of 
inflammatory cells. Our histology was not suited to confirm the protective effect 
of TGF-ß, because single IL-1 injections caused no visible proteoglycan depleti-
on in articular cartilage in the mouse, as determined with safranin О staining. 
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Studies using repeated injections of IL-1 alone or in combination with TGF-/3 
are in progress. 
Discussion 
To study effects of combinations of cytokine and growth factors on articular 
cartilage proteoglycan synthesis we cultured anatomically intact patellar cartilage 
embedded in a minimal area of surrounding tissue (35). Other workers have 
used sliced cartilage or isolated chondrocytes in the absence of underlying bone 
and synovial tissue (18,19,40). 
We used an IL-1 cocentration yielding the maximum effects on patellar 
cartilage proteoglycan metabolism. The chosen TGF-ß concentration (10 ng/ml) 
has been reported to have an optimum effect on chondrocytes and is physiologi-
cally relevant because comparable concentrations of active TGF-ß have been 
found in arthritic joints (26,28). For the first time we tested the effects of TGF-
ß in the presence of insulin-like growth factor 1. In an attempt to create a 
physiologically relevant situation we used an insulin-like growth factor 1 con-
centration equal to the levels found in murine serum samples. 
We found that in the presence of insulin-like growth factor 1 the 
spontaneous release of proteoglycan from cultured cartilage was reduced, 
reaching levels comparable with basal proteoglycan release in vivo (38,39). This 
is in line with reports describing TGF-j8 effects on cartilage or isolated chondro-
cytes in serum-free conditions (18,19). In the presence of IGF the spontaneous 
proteoglycan release from cultured cartilage was reduced, reaching levels 
comparable to basal proteoglycan release in vivo (38,39). The protective 
potency of insulin-like growth factor 1 in cartilage degradation has been 
reported previously (41-43). TGF-jS inhibited IL-1 induced proteoglycan degra-
dation but had no effect on the spontaneously occurring loss of newly formed 
proteoglycans. In an earlier report describing in vitro TGF-ß effects on proteo-
glycan loss from sliced cartilage (19) TGF-ß also inhibited spontaneously 
occurring proteoglycan loss. The importance of our observation is that for the 
first time we found evidence indicating that TGF-/3 modulation of IL-1 induced 
proteoglycan degradation is specific, independent of TGF-/S effects on basal 
degradation. Possibly IL-1 induces a separate set of proteases, different from the 
proteases taking part in normal turnover, that can be modulated specifically by 
TGF-/3. Whether TGF-0 mainly influences the production of proteases or 
protease inhibitors (32,44-46) remains to be investigated. Another possible 
mechanism for specific TGF-/3 modulation of IL-1 induced proteoglycan degra-
dation could be that TGF-/5, in contrast with other growth factors, downregu-
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lates IL-1 receptor expression (17,47). Induction of an interleukin-1 receptor 
antagonist protein by TGF-/3 in peripheral blood monocytes has also been 
reported (48). 
The only previous report describing TGF-/3 effects on proteoglycan 
synthesis in articular cartilage was that by Morales and Roberts (40). They used 
long-term cultures of sliced bovine cartilage. In our studies we cultured for only 
2 days, the time necessary to obtain a maximum IL-1 effect on proteoglycan 
synthesis. Again, the presence of IGF appeared to be important for stabilization 
of proteoglycan metabolism in our patella culture system. In the absence of 
IGF-1, TGF-j8 (400 pM,48h) stimulated both IL-1-suppressed and spontaneously 
occurring proteoglycan synthesis. Chandrasekhar and Harvey (18) found the 
same trend in monolayers of articular chondrocytes. In earlier studies performed 
in our laboratory (43), TGF-/3 (0 - 200 pM) was found to have no effect on 
proteoglycan synthesis in short term experiments. In addition, also in vivo, we 
saw no effect of TGF-/3 on basal proteoglycan synthesis 24 hours after intra-
articular injections. A trend is noted that stimulating TGF-0 effects only appear 
when cartilage slices have been in culture for some time. A plausible explana-
tion seems to be that TGF-ß has no stimulating effect on proteoglycan synthesis 
of normal articular chondrocytes, but becomes effective when the phenotype of 
articular chondrocytes has changed owing to prolonged culture or exposure to, 
for example, cytokines. Phenotype-dependent receptor expression could be an 
explanation for the late onset of stimulating responses to TGF-/3. Moreover, it 
has been reported that TGF-0 induces phenotype changes itself (49).This could 
indicate that after 48 hours of culture in the presence of TGF-/3 and without 
IGF-1, the effects of TGF-0 on proteoglycan synthesis no longer reflect the in 
vivo situation. In our studies, when we cultured for two days in the presence of 
IGF-1, which is known to stimulate proteoglycan synthesis on its own 
(33,34,43) and to protect against phenotype changes (49), TGF-/8 had no extra 
effect on either IL-1 suppressed or basal proteoglycan synthesis. 
Of interest, conditions do exist where TGF-/3 influences proteoglycan 
synthesis in spite of the presence of growth factors. During a phase of ex vivo 
recovery of IL-1 suppressed proteoglycan synthesis, TGF-/3 can stimulate this 
process, whatever the mechanism involved. 
In accordance with previously published work (50-53), TGF-/3 injected 
into the knee joint had a clear chemoattractive capacity. The predominant 
inflammatory cells were polymorphonuclear leukocytes. This was also noted in 
studies performed in the knee of rats (52), while in ankle joints of rats (51) the 
majority of infiltrating leukocytes were of monocytic lineage. 
In vivo modulation of basal and IL-1 affected proteoglycan metabolism 
in articular cartilage by TGF-0 has not been described previously. TGF-0 
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injected into the joint caused a significant reduction of IL-1 induced proteoglycan 
degradation. This is in accordance with the in vitro observations. In contrast 
with the in vitro treatments, where TGF-ß had no significant effect, basal 
proteoglycan degradation was stimulated after TGF-/3 injections. A possible 
explanation for this difference could be the inflammatory potential of TGF-/3. It 
clearly induces inflammation and may therefore be indirectly responsible for 
enhanced degradation. The proinflammatory effect of TGF-ß could thus mask 
part of the protection against IL-1 induced proteoglycan degradation that is 
offered by TGF-0. The fact that TGF-/3 injected intra-articularly caused marked 
effects, namely extra proteoglycan degradation and influx of inflammatory cells, 
indicates that the endogenous TGF-/3 in the non-inflamed joint is either in a 
latent form or present in too low amounts, or controlled by inhibitors. 
In vivo studies on proteoglycan synthesis show that TGF-/8 had different 
effects on basal proteoglycan synthesis and suppressed proteoglycan synthesis 
after IL-1 treatment. The observation that basal proteoglycan synthesis is not 
influenced by TGF-/3 is in agreement with its in vitro effects in the presence of 
a physiological IGF-1 concentration, maintaining in vitro proteoglycan metabo-
lism at levels similar to the normal in vivo conditions. In contrast with IGF-1 
cultures, TGF-/3 in vivo decreased the suppression of proteoglycan synthesis 
induced by IL-1. Maybe this specific TGF-/3 modulation of IL-1 effects acts via 
TGF-j8 downregulation of IL-1 receptors (47). Whatever is the mechanism of 
TGF-/3 inhibition of IL-1 induced suppression of proteoglycan synthesis in vivo, 
histology shows that TGF-/S did not inhibit the IL-1 induced influx of inflam-
matory cells into the joint; TGF-/8 might, however, suppress the production of 
cytokines (54), oxygen metabolites (55-57), or proteases by these cells. It has 
been reported that TGF-/3 can cause defective phagocytic function of polymor-
phonuclear leukocytes (58). Moreover, TGF-j8 can also regulate the production 
of other growth factors or their receptors, or both (59-62). 
We conclude that TGF-0 is able to block a considerable part of the IL-1 
induced proteoglycan degradation and suppression of proteoglycan synthesis in 
articular cartilage. In the light of the destructive effect of IL-1 during arthritis 
we suggest an important protective function of TGF-/3 for articular cartilage 
extracellular matrix. 
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Transforming growth factor-ßl stimulates articular chondrocyte proteo-
glycan synthesis and induces osteophyte formation in the murine knee joint. 
Henk M. van Beuningen, Peter M. van der Kraan, Onno J. Arntz, and Wim В. 
van den Berg 
(Laboratory Investigation, in press) 
ABSTRACT 
BACKGROUND: High concentrations of active transforming growth factor-
ß (TGF-ß) have been found in synovial fluids from arthritic joints. TGF-ß 
stimulates articular cartilage proteoglycan synthesis and suppresses proteo-
glycan degradation in vitro. In an ealier study we found no effect on 
cartilage proteoglycan metabolism shortly after a single intra-articular 
injection of TGF-01. In the present study we used multiple intra-articular 
injections and a longer time-scale. 
EXPERIMENTAL DESIGN: TGF-ß 1 was injected into the murine knee 
joint to gain insight in the consequences of its overproduction in joint 
diseases. This was evaluated using histological sections of he whole knee 
joint and measurements of articular cartilage proteoglycan synthesis and 
content. 
RESULTS: At 6 hours after a single TGF-ßl injection recruitment of 
polymorphonuclear leukocytes (PMNs) was observed. Already after 24 
hours the amount of inflammatory cells had decreased. Multiple TGF-ßl 
injections induced synovial hyperplasia and synovitis predominantly consis-
ting of cells of the macrophage/monocyte lineage. Both single and multiple 
TGF-ßl injections induced strong and longlasting stimulation of articular 
cartilage proteoglycan synthesis. This in vivo stimulation of proteoglycan 
synthesis was similar in cartilage of young (3 mo) and old mice (18 mo). 
Multiple TGF-ßl injections resulted in an increased GAG content in 
patellar cartilage. After triple TGF-ßl injections impressive osteophyte 
formation was noted at specific sites. The size and the localization of 
osteophytes was identical in young and old mice. Interestingly, the localiza-
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tíon of TGF-ßl-induced osteophytes was very similar to that of osteophytes 
observed in experimental arthritis and osteoarthritis models, suggesting a 
role for endogenous TGF-ß in osteophyte formation during joint pathology. 
CONCLUSIONS: Our data indicate that TGF-B1 injection into a normal 
joint induces inflammation, synovial hyperplasia, osteophyte formation, and 
prolonged elevation of proteoglycan synthesis and content in articular 
cartilage. 
INTRODUCTION 
Of all growth factors, none has been found to have the diversity of effects 
ascribed to transforming growth factor (TGF-ß). This peptide plays a crucial 
role in cell proliferation and differentiation and also in the synthesis and 
degradation of extracellular matrix (1,2). Five distinct isoforms have now been 
described, and three of these, called TGF-ßs 1, 2, and 3, are found in mam-
malian species (1). The biological activities of the various isoforms, which are 
60 to 80% homologous in terms of amino acid sequence, most often are similar. 
The ability of nearly all cells to both produce and respond to the TGF-ßs 
suggests there may be autocrine and/or paracrine effects. 
Under normal circumstances TGF-ß is secreted as an inactive high 
molecular weight complex which has to be dissociated before functional 
activation. High levels of active TGF-ß, were found in affected joints of 
osteoarthritis (OA) and rheumatoid arthritis (RA) patients (3-7), where it may 
have profound effects on chondrocyte, synoviocyte, osteoblast and osteoclast 
metabolism. In vitro and in vivo studies have already shown that TGF-ß can act 
upon all these cell types. 
Incubation of isolated chondrocytes with TGF-ß resulted in stimulated 
synthesis of proteoglycans (8-12) and collagen (11,12), whilst synthesis of 
stromelysin and collagenase was inhibited (13). Effects of TGF-ß on proteogly-
can synthesis in intact articular cartilage were minimal in short-term cultures 
(14-16), but stimulation was found after prolonged incubation in basal medium 
(17). No such stimulation was seen when basal medium was supplemented with 
insulin or insulin-like growth factor-1 (16,18). TGF-ß did not affect articular 
chondrocyte proteoglycan synthesis shortly after a single intra-articular injection 
(16), but it was found to stimulate proteoglycan degradation, probably related to 
its induction of joint inflammation (16,19). 
Apart from its inflammatory potential, TGF-ß may affect connective 
tissue cells in vivo. Stimulation of fibroblast migration, proliferation, and 
extracellular matrix production has been shown in synovium after intra-articular 
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injections (19-21), and around subcutaneously implanted mini-osmotic pumps 
(22). Moreover, it induced bone formation, after local injection into the 
periosteum (23-25). 
In the present study we extended our observations on the effect of local 
intra-articular injection of TGF-ß. Upon repeated injection into the murine knee 
joint we confirmed earlier observations of synovial inflammation and hyper-
plasia (19-21). However, in marked contrast to the findings shortly after a 
single injection, the multiple injection protocol resulted in pronounced stimula-
tion of chondrocyte proteoglycan synthesis and a significant increase in cartilage 
matrix proteoglycan content. Another striking finding was the impressive 
osteophyte formation at sites that are also reactive in experimental arthritis and 
osteoarthritis models, suggesting a key role for TGF-ß in osteophyte formation 
in these models. 
EXPERIMENTAL DESIGN 
TGF-ßl was injected into the knee joint of male C57B1/10 mice. A dose of 0.1 
μg TGF-ßl was injected once, or three times, at alternate days. Mice were 
killed at days 1, 4, and 7 after the last of three injections, or at the correspon-
ding time-points days 5, 8, and 11 after a single injection. Additional groups 
were sacrificed at 6 and 24 hours after a single injection. Histological changes 
were studied from semiserial frontal sections of the knee joint. Articular 
cartilage proteoglycan synthesis was examined with "S-sulfate incorporation. 
Patellar cartilage proteoglycan content was measured with histochemical and 
biochemical methods. For histology experimental groups consisted of 10 mice, 
and for proteoglycan measurements the number of mice included in each 
experimental group was at least 5. TGF-ßl effects were compared in young (3 
mo) and old (18 mo) mice. 
RESULTS 
Histological observations of synovial tissue. Within a few hours after 
the local administration of TGF-ßl intra-articular accumulation of inflammatory 
cells became apparent. At 6 hours and to a lesser degree at 24 hours after a 
single injection of 0.1 μg TGF-ßl, considerable cell infiltration into the synovial 
tissue and exudation into the synovial cavity was seen. (fig. 1). The predomi-
nant inflammatory cell appeared to be the PMN. At 24 hours after the last of 
three intra-articular TGF-ßl injections (= S days after the first injection) only 
few PMNs were present, and most inflammatory cells were of monocyte/ma-
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crophage lineage (fig. ld+e). After another three days, inflammation had 
declined and PMNs were absent. In addition to the infiltrated inflammatory 
cells, synovial hyperplasia was seen at days 1 and 4 after the last of three TGF-
ßl injections. This increase of synovial cell mass was caused by an increase in 
synovial fibroblast-like cells, synovial lining cells and periosteal cells. Ac-
cumulation of cells was also seen along the periarticular side of the collateral 
ligaments (fig. If) and around the cruciate ligaments. 
Articular cartilage proteoglycan metabolism. Autoradiography (fig. 2) 
shows that at days 1 and 4 after the last of three intra-articular injections, 
proteoglycan synthesis ("S-sulfate incorporation) was clearly stimulated in 
articular cartilage. This stimulation was not confined to the non-calcified part of 
the cartilage. Also the calcified layer, which is generally considered to have low 
proteoglycan synthetic activity, showed stimulation of proteoglycan synthesis. 
Stimulation of proteoglycan synthesis was also present in the menisci, cruciate 
and collateral ligaments and synovial connective tissue. Enhanced articular 
cartilage proteoglycan synthesis was seen throughout the knee joint, but inte-
restingly, stimulation of proteoglycan synthesis in articular cartilage of the 
medial tibia was retarded. At 1 day after the last injection of TGF-ßl, proteo-
glycan synthesis in the central medial tibia was still normal or even suppressed 
(fig. 2e), whereas at day 4 after the last of three TGF-ßl injections clear 
stimulation was seen also in this area. 
To enable quantitation of articular cartilage proteoglycan synthesis, 35S 
incorporation was also measured ex vivo, using the patella assay (table 1). 
Proteoglycan synthesis in patellar cartilage appeared to be unaffected at 24 
hours after a single TGF-ßl injection, but considerable stimulation of proteogly-
can synthesis was noted at day 5 after single TGF-ßl injection. At a correspon-
ding time-point, 24 hours after the last of three TGF-ßl injections comparable 
stimulation of patellar proteoglycan synthesis was seen. This stimulation was 
still present at the last time-point studied, 7 days after the last of three injec-
tions. Strong stimulation of proteoglycan synthesis was also measured in patellar 
cartilage of old mice. 
Densitometrie quantification of Safranin О staining intensity in his­
tological sections of TGF-ßl treated knee joints (table 2) showed that the 
patellar cartilage proteoglycan content had increased, indicating that newly 
produced proteoglycans are capable to reside in the cartilage matrix. Significant-
ly increased Safranin О staining was found both in the non-calcified and in the 
calcified cartilage layer. This was seen at days 1, 4, and 7 after the last of three 
TGF-ßl injections. One day after a single TGF-ßl injection the patellar 
cartilage proteoglycan content was not affected. At 8 and 11 days after a single 
TGF-ßl injection proteoglycan content had increased in the non-calcified layer, 
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Figure 1. Hematoxylin/eosin stained sections of murine knee joints after intra-articular injection 
of 0.1 μg TGF-ßl. a) Normal, untreated joint. Note the thin synovial lining, b) PMN influx 
present at 6 hours after a single injection, c) At 24 hours after a single injection inflammation had 
already decreased and there was some thickening of the synovial lining, d) One day after the last 
of three injections synovial hyperplasia had developed, e) Detail of the synovium in d), showing 
fibroblasts and monocyte-like cells, but no PMN's. f) Hyperplasia of lining was also seen along 
ligaments. Ρ = patella; F = femur; Τ = tibia; M = meniscus; С = collateral ligament; 
(Original magnification, le χ 400; other figures χ 100) 
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Figure 2. Autoradiographs (hematoxylin and eosin-stained sections) showing cartilage proteogly-
can synthesis (35S-sulfate incorporation) after triple TGF-ßl injections, a) Incorporated label in a 
control patella, b) One day after the last of three TGF-ß injections proteoglycan synthesis was 
stimulated in all articular chondrocytes of the patella, c) This stimulation of chondrocytes was still 
present after another three days, throughout the whole patellar cartilage, d) Incorporated label in 
the femoro-tibial area of a control knee (left), e) One day after the last of 3 injections articular 
cartilage proteoglycan synthesis was stimulated in the whole knee (right), except in the central 
part of the medial tibia, f) Three days later, stimulation of proteoglycan synthesis was present in 
all cartilage areas. See also legends to figure 1. (Original magnification; χ 400) 
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Table 1. Stimulation of patellar proteoglycan synthesis induced by intra-articular 
TGF-ßl injections. 
proteoglycan synthesis compared to control*^) 
young mice old mice$ 
time* expl exp2 ехрЗ expl exp2 
day 1(1)* 105+14 
day 5(5)* 155±21 233 ±28 
day 5(1) 260±30 192+22 167±15 195±26 210+28 
day 8(4) 331±39 224+31 202±21 274±35 
day 11(7) 138±19 166±20 236+38 
# patellar proteoglycan synthesis was determined ex vivo, using ,5S-sulfate incorporation. The 
contralateral patella was used as a control (100%). TGF-B injections into the right knee had no 
effect on patellar cartilage proteoglycan synthesis in the contralateral (vehicle-injected) knee. Each 
value represents the mean ± SD of 5 patellae. 
* time after the first TGF-ß injection; time after the last injection is placed in parentheses. 
5 mice aged 3 months (young) or 18 months (old) were used. Experiments 1 and 2 were 
performed simultaneously in old and young animals. 
6 single injection. 
but significantly less than after 3 injections. 
The finding of increased proteoglycan content in TGF-ßl treated patellar 
cartilage was confirmed by the results of the Farndale assay. In one experiment, 
measurements of patellar cartilage GAG content and patellar cartilage proteogly-
can synthesis were combined (table 3). The low amounts of GAG per patella are 
near to the detection limit, but still GAG content in TGF-ßl treated patellae 
appeared to be significantly increased. In the same experiment TGF-ßl had 
stimulated incorporation of 3SS-sulfate in isolated patellar cartilage. This in-
dicates that stimulation of 35S-sulfate incorporation measured in whole patellae is 
not caused by the activation of periosteum, as seen one day after the last 
injection of TGF-ßl 
Osteophyte formation. Induction of chondrogenesis in the periosteum 
(fig. 3) as a result of injection of TGF-ßl into the joint cavity was a striking 
finding. One day after the last of three TGF-ßl injections chondroid tissue 
formation was hardly detectable. However, in autoradiographs, cells in the 
periosteum near to the margins of the articular cartilage showed enhanced 
incorporation of 35S-sulfate. At day 4 after the last injection pronounced 
chondroid tissues, staining red with safranin O, had developed at the same sites 
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ГаЫе 3. Increase in glycosaminoglycan (GAG) content and proteoglycan syn­
thesis in patellar cartilage caused by TGF-ßl. 
GAG content^* 3iS-sulfate ine' 
time* control TGF-ß control TGF-ß 
day 5(1) 3.70 ± 0.24 4.24 ± 0.84® 456 ± 80 762 ± 194 
day 8(4) 3.24 ± 0.14 4.16 ± 0.96 360 ± 20 730 ± 214 
S patellar GAG content was determined using the Famdale assay. 
0 patellae were pulse-labeled ex vivo with ,5S-sulfate. The cartilage layer was stripped off the 
patella. After digestion of cartilage with papain, one half of the digest was used for GAG 
measurements and the other half for measurement of incorporated label. The amount of incor-
porated label was expressed as cpm ± sd. 
Each value represents 5 patellae. 
* time after the first TGF-/3 injection; time after the last injection is placed in parentheses. 
0
 no significant effect of TGF-ß on GAG content was found at days 5 and 8 individually, but if 
the results of both timepoints were taken together GAG content was significantly higher in the 
TGF-ß treated group (p = 0.025). 
in 30 out of 30 mice. This occurred in the femoro-patellar area and to a lesser 
degree in the femoro-tibial area. Also around the insertion sites of the collateral 
ligaments on the femur, and at the basis of the menisci, similar tissue was 
formed (fig. 4 + 5). The margins of the original bone were unchanged, sugge-
sting that the old bone was only used as a template (fig. 4). The chondroid 
tissue was deposited on the unaffected margins of the preexisting bone, and 
seemed to originate from the periosteum. 
On day 7 after the last of three injections even more chondroid tissue 
had been formed, but autoradiography showed that the 35S-sulfate incorporation 
in these early osteophytes had already declined, as compared to earlier time-
points (fig. 3). This suggests that on day 7 after the last injection, the chondro-
cyte-like cells in the developing osteophytes are differentiating into bone cells. 
We also looked for chondroid tissue formation at corresponding time-points 
after a single TGF-ßl injection, but in this protocol only minimal changes were 
found (not shown). At places similar to those where triple TGF-ßl injections 
induced osteophyte development in young mice, chondroid tissue formation was 
also seen in TGF-ßl-treated old animals. Size and structure of TGF-0-induced 
early osteophytes in old mice were comparable to those in young animals (fig. 
5). Different from the young animals, in old C57BI/10 mice spontaneous bone 
depositions around the collateral ligaments and at the basis of menisci were 
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often found. Triple injections of TGF-ß induced chondroid tissue formation 
around these structures (fig. 5). 
Interestingly, the localization of TGF-ß-induced early osteophytes was 
very similar to the location of mature osteophytes seen in later stages of murine 
antigen-induced arthritis and collagenase-induced osteoarthritis (fig. 6), sugges-
ting that endogenous TGF-ß plays a role in osteophyte formation during joint 
pathology. 
Figure 3. Autoradiographs (hematoxylin and eosin-stained sections) illustrating osteophyte 
development, a) One day after the last of three TGF-ßl injections, at the margins of articular 
cartilage (arrows) patellar periosteum incorporated even more 35S-sulfate than the adjacent 
synovium, b) Three days later chondroid tissue had developed at these sites. Arrows indicate the 
margins of preexisting bone in figures 3b and Зс. c) After another three days the developing 
osteophytes had reached their maximum size, and proteoglycan synthesis in this chondroid tissue 
had decreased. Ρ = patella; JS = joint space. (Original magnification, χ 250) 
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Figure 4. TGF-ß induced osteophytes in hematoxylin and eosin-stained sections, a) Osteophytes 
developing around the femoro-patellar joint at day 7 after the last of three injections. The 
chondroid tissue was of different structure compared to preexisting bone and used the old bone as 
a template. Arrows indicate the unaffected old bone margins, b) The same phenomenon was seen 
in the tibia. Besides these early osteophytes growing around the cartilage margins, chondroid 
tissue formation (large arrows) was also observed at the insertion sites of collateral ligaments. See 
also legends to figure 1. (Original magnification, 4a χ 250; 4b χ 100) 
Chapter 6 
Figure 5. Autoradiographs (hematoxylin and 
eosin-stained sections) showing localization 
of periost activation (35S-sulfate incor-
poration) in whole joint sections. In both 
young a) and old b) animals at day 4 after 
the last of three TGF-ß injections osteophytes 
were developing around articular cartilage 
margins, at the insertion sites of collateral 
ligaments, and at the basis of menisci. Extra, 
in old animals with spontaneous osteoarthritis 
chondroid tissue was formed by the perios-
teum of preexisting osteophytes lying around 
ligaments (arrows), and c) at the basis of 
menisci. Large arrow: bone marrow. See 
also legends to figure 1. (Original mag-
nification, 5a+b χ 25; 5c χ 100) 
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Figure 6. Safranin О and fast green-stained sections showing localization of osteophytes in 
experimental arthritis and osteoarthritis, a) Normal joint, b) 4 days after the last of three TGF-ßl 
injections c) Day 28 of mBSA induced arthritis d) Day 42 after collagenase (1%) injection. 
Methods of arthritis induction are described in references 38 and 39. Arrows indicate osteophyte 
margins. (Original magnification χ 25) 
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DISCUSSION 
We have shown that TGF-ßl injected into the murine knee joint can induce 
transient inflammation and more persistent changes in cartilage, bone and soft 
connective tissue. Earlier investigations on the effects of intra-articularly 
injected TGF-ß in other species like the rat (20,21) and the rabbit (19) focused 
on inflammatory cell influx and synovial hyperplasia. Our histology showed that 
6 hours after a single intra-aticular injection TGF-ßl had induced influx of 
many inflammatory cellls, predominantly PMN,s. At 24 hours only few inflam-
matory cells were left, which is comparable to the observations of Fava et al. 
(21) in the rat knee joint. At 24 hours after the last of three TGF-ßl injections 
we found mainly cells of the monocyte/macrophage lineage. This is in line with 
studies in the rat and the rabbit (19,20), mentioning fibroblastic hyperplasia with 
a diffuse monocytic infiltrate, but with few or no neutrophils, after multiple 
intra-articular injections of TGF-ß. 
This is the first study reporting stimulation of proteoglycan synthesis by 
TGF-ß in articular cartilage in vivo. This stimulation is not likely to be caused 
by the TGF-ß-induced inflammation, because experimental arthritis has been 
shown to induce the opposite effect, ie inhibition of patellar cartilage proteogly-
can synthesis (26-28). Moreover, the effects of TGF-ßl could not be ascribed to 
non-specific responses to foreign proteins, because in each injection, including 
vehicle controls, 6μζ bovine serum albumin was present. Similar doses TGF-ß 
injected subperiosteal^ in growing bone have been shown (24) to induce 
chondrogenesis and osteogenesis in vivo. Stimulation of articular cartilage 
proteoglycan synthesis by 0.1 μg TGF-ßl occurred after a lag time of at least 
24 hours, and was still present at one week after the last intra-articular injec-
tion. Four days after the last of three injections, homogeneous stimulation of 
articular cartilage proteoglycan synthesis was seen troughout the knee joint. An 
intriguing finding was the retarded stimulation of cartilage proteoglycan syn-
thesis in the medial tibia. This could be related to our earlier observation that 
this site of the knee joint is exceptionally vulnerable to IL-1 induced suppression 
of proteoglycan synthesis in vivo (27). Maybe the injection of IL-1 stimulates 
production of TGF-ß as a feed back mechanism, having less antagonizing effect 
in the medial tibia. 
The long time required before TGF-ßl exerts its effects on articular 
cartilage proteoglycan synthesis in vivo is in line with in vitro studies. While 
TGF-ß effects on isolated chondrocytes occur within a few hours, proteoglycan 
synthesis in intact murine patellae in culture was not affected by up to 10 ng/ml 
TGF-ß in presence of physiological concentrations of IGF-I, in short-term (up to 
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48 hours) cultures (15,16). Also in bovine (17) and human (29) cartilage 
expiants TGF-ß stimulated proteoglycan synthesis after a lag time of several 
days. Possible reasons for the delay in reactivity to TGF-/3 of intact articular 
cartilage could be that a second mediator has to be produced first or that the 
chondrocyte phenotype must change before this cell responds to TGF-/3 by 
enhancement of proteoglycan synthesis. Maybe prolonged production of TGF-0 
by the chondrocyte itself is needed (30). 
The long-continued stimulatory effect of TGF-/31 on cartilage proteogly-
can synthesis in vivo seems contradictory to its short halflife in the knee joint; 1 
hour in the rat knee (21). A possible explanation could be autoinduction, leading 
to local TGF-/3 production by the synovial fibroblast (31) the monocyte/macro-
phage (31,32) and the chondrocyte itself (30). 
Besides stimulation of proteoglycan synthesis, patellar cartilage from 
TGF-ß 1 treated knees showed a significant increase in proteoglycan content. To 
our surprise, increased proteoglycan content, reflected by increased safranin О 
staining, was present both in the non-calcified cartilage and in the deeper, 
calcified layer. The normally less reactive calcified layer showed an increase in 
proteoglycan content, but only in the triple injection protocol. Activation of this 
resting layer was evident from 3JS-sulfate incorporation seen on autoradiographs. 
After a single injection only the non-calcified layer responded to TGF-ß 1 treat-
ment. 
The finding of increased articular cartilage proteoglycan content after 
TGF-ß 1 treatment suggests that the newly produced proteoglycans are still 
capable to reside within the cartilage matrix. Because TGF-ß has been shown to 
induce also qualitative changes in proteoglycan synthesis (33-35), the increase in 
proteoglycan content could also be due to increased proteoglycan retention (36). 
Moreover, the increased proteoglycan content also may reflect inhibition of 
proteoglycan degradation by TGF-ß 1 in vivo. In contrast to our observation of 
increased cartilage proteoglycan content upon microscopic examination, Elford 
et al. (19) found considerable cartilage proteoglycan loss after multiple intra-
articular injections of TGF-B2 in the rabbit. This difference could be due to the 
use of a different TGF-ß isoform, or the use of a different species. The results 
of Elford et al. (19) are also in contradiction to several in vitro studies showing 
that TGF-ß inhibits IL-1 induced proteoglycan degradation, in cultures of 
isolated chondrocytes (10), cartilage slices (37), and intact murine patellae (16). 
It has been shown in earlier studies that local administration of TGF-/5 
to bone promotes bone formation in vivo (23-25). After injection into the joint 
space we found developing osteophyte at several places in the joint. Maximum 
size was reached in about one week after the last of three TGF-ß 1 injections. 
Most likely, from this time-point the chondrocyte-like cells in the developing 
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osteophytes differentiate into bone cells. From autoradiographic images and 
from the localization of osteophytes we conclude that TGF-fll-induced osteop­
hytes most likely originate from the periosteum. A previous study (38) has 
shown that also in a murine arthritis model the epiphyseal cartilage was not 
involved in new bone apposition. The localization of the TGF-/31-induced os­
teophytes appeared to show striking similarity with the localization of osteo­
phytes seen in the chronic phase of antigen induced arthritis (38) and in ex­
perimental and spontaneous osteoarthritis (39) in the mouse. In the experimental 
arthritis and osteoarthritis models the chondroid tissue of early osteophytes 
develops into a mature bony structure, containing bone marrow. Because of the 
before-mentioned similarities in appearance and location, the same is likely to 
occur with TGF-ß-induced chondroid tissue at later timepoints. 
The similarity in localization of TGF-ßl -induced osteophytes and those 
in experimental arthritis (38) and in experimental and spontaneous osteoarhritis 
(39) suggests a role for TGF-ß in osteophyte formation during joint pathology. 
However, the periosteal new bone formation found in these murine models 
contrasts with the periarticular osteopenia observed in human rheumatoid 
arthritis (RA), in spite of high levels of TGF-ß in synovial fluid. The reason for 
this difference might be that in RA TGF-ß is counteracted by factors which 
inhibit osteophyte formation, or TGF-ß-induced bone formation is overshadowed 
by more pronounced resorption of bone. Another possible explanation is that 
human periosteum might be less responsive to TGF-ß, compared to rodent 
periosteum. 
Our data indicate that TGF-ßl injected into a normal murine knee joint 
can cause osteophyte formation and prolonged elevation of proteoglycan 
synthesis and content in articular cartilage. This could lead to changes in 
physicochemical properties, eg increases in cartilage stiffness. In the long run 
these disturbances could cause loss of articular cartilage matrix integrity and 
loss of joint motility, because of excessive osteophyte formation, suggesting a 
negative role of TGF-ßl. However, high levels of active TGF-ß are only pre-
sent during joint diseases and it would be highly relevant to evaluate its role 
during experimental arthritis. Under these circumstances TGF-ß could be 
protective, because of its immunosuppressive capacity (40-42), because it might 
compensate for inflammation-induced suppression of chondrocyte matrix 
production (10,16), and because osteophyte formation could be a compensatory 
mechanism in cases of inflammation-induced instability of the joint (43). Studies 
using exogenous TGF-ß or neutralizing antibodies showed that TGF-ß can 
suppress (44,45) or stimulate (46,47) arthritis development, but successful 
interference with established disease has never been reported. In order to learn 
more about effects of TGF-ß on articular cartilage during arthritis we recently 
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injected TGF-ßl together with IL-1 into a normal knee joint, because IL-1 is 
responsible for most of the suppression of articular cartilage proteoglycan 
synthesis seen during experimental arthritis (48,49). Preliminary results indicate 
that TGF-ßl antagonizes deleterious effects of IL-1 on articular cartilage in 
vivo. 
MATERIALS AND METHODS 
Growth factor. Purified human TGF-ßl was a generous gift of Dr A.F. Purchio 
(Oncogen, Seattle, WA). TGF-fl was kept in 4 mM HCl. Purity of TGF-fl was verified using 
SDS-PAGE, showing a single 25 kD band. Moreover, a neutralizing antibody to TGF-fl 
(IDI 1.16) completely blocked the inhibiting effect of this TGF-ß on IL-1-induced production of 
IL-2 by NOB-1 cells. 
Animab. Male C57B1/10 mice aged 12 weeks or 18 months were used. They were fed a 
standard diet and tap water ad libitum. 
lntra-articular injections. 0.1 /ig TGF-β in 6 μΐ phosphate-buffered saline (pH 7.0) + 
0.1% ultrapure bovine serum albumin (Sigma, St Louis, MO) was injected into the joint cavity of 
the right knee three times, at alternate days. Simultaneously the contralateral joint received an 
equal volume of saline + 0.1 % bovine serum albumin. 
Histology. Whole knee joints were dissected and processed as described previously (26). 
Semiserial frontal sections were stained with hematoxylin/eosin or safranin O/fast green for 
examination of cells and cartilage matrix, respectively. For autoradiographic analysis of 55S-sul-
fate incorporation (26), radiolabeled sulfate was injected intraperitoneally 6 hours before dissec­
tion of the knee joints. After histological processing, 6 μπι sections were prepared and mounted 
on gelatin coated slides. These were dipped in K3 emulsion (Ilford, Basildon, Essex, UK) and 
exposed for three to five weeks. After this period the slides were developed and stained with 
hematoxylin and eosin. 
Determination of patellar proteoglycan synthesis. Proteoglycan synthesis was measured 
ex vivo. Whole patellae, with a standard amount of surrounding tissue, were dissected from the 
knee joints. Patellae were then pulse-labeled (2h,37°C) with "S-sulfate. Subsequently, they were 
washed, fixated, decalcified, punched out of the surrounding tissue, and dissolved as described 
before (SO). The J5S content of each patella, which is a reliable measure of patellar cartilage 
proteoglycan synthesis (SI), was measured by liquid scintillation counting. 
Determination of patellar proteoglycan content. Articular cartilage proteoglycan content 
is reflected by Safranin О staining intensity in histological sections. This was measured using an 
automated image analysis system (VIDAS, Kontron Elektronik GMBH). Microscopic images were 
recorded by a CCD video camera (SONY) and stored and processed by a 386 personal computer. 
Optical density was measured by integral measurement in a 20 μπι layer, along the cartilage 
surface of the patella. Densitometry was also performed in a 10 μπ\ layer, in the calcified 
cartilage beyond the tidemark, at a distance of SO μπι from the cartilage surface. The total zone 
of non-calcified cartilage is approximately 30-40 μπι in width. Fast green staining was neutralized 
by use of a green filter. Measurements were corrected for lacunae. 
In addition to histochemical analysis of articular cartilage proteoglycan content we 
determined glycosaminoglycan (GAG) content in patellar cartilage digests using the Famdale 
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assay (52). After fixation in 70% ethanol and decalcification in 5% formic acid, patellar cartilage 
was stripped from the underlying bone. With this method both the non-calcified and the calcified 
layer were obtained. The isolated cartilage was subjected to papain digestion (12h,60°C). One 
half of the digest was used for determination of patellar cartilage GAG content; the other half was 
used for "S-sulfate measurements. The digest was mixed with dimehylmethylene blue and 
immediately thereafter the GAG content was determined with spectrofotomctric analysis of 
dimethylmethylene blue-glycosaminoglycan complex formation. The latter method understimates 
changes in GAG content because it measures the whole patellar cartilage, while the image 
analyzer measures in the most responsive part, in the non-calcified layer. 
Statistical analysis. Differences between experimental groups were tested using the 
Student's T-test. Differences were considered significant if Ρ < 0.05. 
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IN VIVO PROTECTION AGAINST INTERLEUKIN-1-INDUCED AR-
TICULAR CARTILAGE DAMAGE BY TRANSFORMING GROWTH 
FACTOR-ß,: AGE-RELATED DIFFERENCES. 
Henk M. van Beuningen, Peter M. van der Kraan, Onno J. Arntz, and Wim В. 
van den Berg. 
(Annals of the Rheumatic Diseases, in press) 
ABSTRACT 
Objectives. Transforming growth factor-ß (TGF-ß) has been shown to an-
tagonize interleukin-1 (IL-1) effects in different systems. We investigated 
whether TGF-ßl modulates IL-1 induced inflammation and IL-1 effects on 
articular cartilage in the murine knee joint. 
Methods. IL-1, TGF-ßl or both factors together were injected into the knee 
joint. Inflammation was studied in whole knee histological sections. Patellar 
cartilage proteoglycan synthesis was measured using "S-sulfate incor-
poration while patellar cartilage glycosaminoglycan content was determined 
with automated image analysis on joint sections. 
Results. Coinjection of TGF-ßl and IL-1 resulted in synergistic attraction of 
inflammatory cells. In contrast, TGF-ßl counteracted IL-1 induced suppres-
sion of articular cartilage proteoglycan synthesis. Proteoglycan depletion 
was similar shortly after the last injection of IL-1 or IL-1/TGF-ßl, but 
accellerated recovery was found with the combination at later days. This 
protective effect of TGF-ßl could not be demonstrated in old mice. 
Conclusions. TGF-ßl aggravates IL-1 induced knee joint inflammation, but 
counteracts the deleterious effects of IL-1 on articular cartilage proteogly-
can synthesis and content. Our data indicate that TGF-ßl could play an 
important part in articular cartilage restoration after IL-1 induced proteo-
glycan depletion. 
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INTRODUCTION 
Proteoglycans are important components of the articular cartilage matrix, 
determining a large part of its unique properties. The cytokine interleukin-1 
(IL-1) suppresses synthesis of articular cartilage proteoglycans and stimulates 
their degradation in vitro. From studies using neutralizing antibodies against IL-
1 we know that this cytokine is responsible for a considerable part of the 
inhibition of cartilage proteoglycan synthesis seen during antigen induced arthri-
tis (1). Injection of IL-1 into the joint space causes transient inflammation, 
suppression of articular cartilage proteoglycan synthesis, and stimulation of 
proteoglycan degradation (2-4). 
IL-1 (5,6) and IL-1-inhibiting molecules such as transforming growth factor-ß 
(TGF-ß) (7-10) have been found in high concentrations in synovial fluids of RA 
patients (RASF). TGF-ß plays an important role in cell proliferation and 
differentiation and also in die synthesis and degradation of extracellular matrix 
(11,12). TGF-ß has been shown to have a dual effect in inflammation: it is a 
potent chemoattractant for inflammatory cells and fibroblasts (13-16), but on the 
other hand it has suppressive effects on many components of the immune system 
(17 review). For instance, TGF-ß in RASF severely suppressed stimulation of 
lymphocyte proliferation by IL-1 (10,18). TGF-/3 itself is able to stimulate 
cartilage proteoglycan synthesis in vitro (19-23) and in vivo (24). Because TGF-
ß has also been shown to antagonize IL-1 effects on articular cartilage prote-
oglycan synthesis (19,22) and degradation (19,22,25) in vitro, a role in protec-
tion against proteoglycan depletion in articular cartilage during arthritis can be 
expected. In the present study we investigated whether TGF-ß 1 could modulate 
in vivo IL-1 effects on inflammation, and on articular cartilage proteoglycan 
synthesis and content. 
MATERIALS AND METHODS 
Animate. Male C57B1/10 mice aged 12 weeks or 18 months were used. They were fed a 
standard diet and tap water at libitum. 
Materiate. Purified human TGF-ß 1 (Oncogen, Seattle, WA) showed a single 25 kD band 
upon SDS-PAGE. Moreover, a neutralizing antibody to TGF-fl (1D11.16) completely blocked the 
inhibiting effect of this TGF-fl on IL-1-induced production of IL-2 by NOB-1 cells. In the 
lymphocyte activating factor assay, 1 unit corresponded to 10-40 pg of the recombinant murine 
IL-la (Pfizer, Groton, CT). IL-la and TGF-fl 1 stocks were diluted in phosphate-buffered saline 
(PBS, pH 7.4), supplemented with 0.1% ultrapure bovine serum albumin (Sigma, St Louis, MO), 
immediately before use. 
Intra-articular injections. Six μ\ PBS + 0.1% bovine serum albumin including 0.1 pg 
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TGF-ßl, 1 ng IL-Ια, or both, was injected into the joint cavity of the right knee. This was done 
three times, at alternate days. The left knee joint (control) was injected with PBS + 0.1% bovine 
serum albumin. The selection of doses of cytokines was based on earlier studies. Intra-articular 
injection of 1 μg TGF-ßl has been shown to induce influx of inflammatory cells into rat joints 
(14,15), and in mice a 40-200 ng dose range caused inflammation and partial inhibition of effects 
of 1 ng IL-1 on articular cartilage proteoglycan metabolism at 24 hours after a single injection 
(22). 
Histology. For histological examination of effects of injected substances at least 10 mice 
were used per experimental group. Whole knee joints were dissected and processed as described 
previously (26). Semiserial frontal sections were stained with hematoxylin/eosin or safranin O/fast 
green for examination of cells or cartilage matrix, respectively. For autoradiographic analysis of 
},S-sulfate incorporation (26), radiolabeled sulfate (74 kfiq/g body weight) was injected intraperi-
toneally 3 hours before dissection of the knee joints. After histological processing, 6 μτη sections 
were prepared and mounted on gelatin coated slides. These were dipped in Kj emulsion (llford, 
Basildon, Essex, UK) and exposed for three to five weeks. After this period the slides were 
developed and stained with hematoxylin and eosin. 
Determination of patellar proteoglycan synthesis. Proteoglycan synthesis was measured 
ex vivo. Whole patellae, with a standard amount of surrounding tissue, were dissected from the 
knee joints. Patellae were then pulse-labeled (2 hours, 37°C) with "S-sulfate (1.1 MBq/ml). 
Subsequently, they were washed, fixated, decalcified, punched out of the surrounding tissue, and 
dissolved as described before (27). The 35S content of each patella, which is a reliable measure of 
patellar cartilage proteoglycan synthesis (28), was measured by liquid scintillation counting. 
Determination of patellar proteoglycan content. Patellar cartilage proteoglycan content is 
reflected in safranin О staining intensity in histological sections. This was measured using an 
automated image analysis system (VIDAS, Kontron Elektronik GMBH). Microscopic images were 
recorded by a CCD video camera (SONY) and stored and processed by a 386 personal computer. 
Optical density was examined by integral measurement in a 20 μιη layer along the cartilage 
surface of the patella. The total thickness of the non-calcified cartilage was approximately 30-40 
μπι. Fast green staining was neutralized by use of a green filter. Measurements were corrected 
for chondrocyte lacunae. 
In addition to histochemical analysis of articular cartilage proteoglycan content we 
measured the proteoglycan content of patellar cartilage digests, using the dimethylmcthylcnc blue 
(DMB) method (29). After fixation in 70% ethanol and decalcification in 5% formic acid, patellar 
cartilage was stripped from the underlying bone. With this method both the non-calcified and the 
calcified cartilage layer were obtained. The isolated cartilage was subjected to papain digestion 
(12h, 60°C). The digest was mixed with DMB and immediately thereafter the proteoglycan 
content was determined with fotospectrometric analysis. 
Intra-articular injection of 0.5% papain results within one day in absence of visible safranin О 
staining in patellar cartilage. However, proteoglycan depletion measured by VIDAS in the same 
cartilage is approximately 50%. Proteoglycan depletion measured in the same experiment with the 
DMB method was 30%. The latter method underestimates depletion because it determines the 
proteoglycan content of the whole patellar cartilage, while the image analyzer measures in the 
non-calcified, IL-1-reactive, cartilage layer. 
Statistical analysis. Differences between experimental groups were tested using 
Student's t test. Differences were considered significant if ρ < 0.05. 
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RESULTS 
Inflammatory signs after intra-articular injections. One day after the 
last of three TGF-ßl injections in young mice (fig lb) PMN's were scanty, and 
microscopic examination of the synovium revealed a fibroblastic hyperplasia 
with a diffuse mononuclear infiltrate. No inflammatory cells had exudated into 
the joint space in most cases, and if there were cells present, these were 
monocytes, not PMN's. Three days later (fig 2a) the synovial hyperplasia had 
somewhat decreased, and consisted mainly of fibroblasts and lining cells. At this 
time point Chondro id tissue, staining red with safranin O, had developed along 
the articular cartilage margins. Probably these structures will mature into 
osteophytes at later timepoints. 
One day after the last of three IL-1 injections into the knee joint of 
young adult mice polymorphonuclear neutrophils (PMN's) were present in the 
joint space (fig lc), in line with earlier observations (3,4). Relatively few 
inflammatory cells were located in the synovium, and no distinct morphological 
change of the synovium was seen. At day 4 after the last injection (fig 2b), 
signs of inflammation had waned. 
When IL-1 and TGF-ßl were injected together, at 1 day after the last 
injection (fig Id) a severe synovitis was present, including synovial lining 
hyperplasia. PMN's were numerous, exceeding by far the amounts seen after 
IL-1 injection. Besides the difference in amount, also the distribution of PMN's 
was different from that seen after injections with IL-1 only. Most of the PMN's 
were located in the synovium, while after injection of IL-1 only, they were 
found mainly in the joint space. At day 4 after the last injection of both factors 
the PMN's in the synovium had already disappeared (fig 2c), leaving a synovial 
hyperplasia comparable to that induced by TGF-ßl alone (fig 2a). At this time 
point early osteophytes had developed that were identical in localization, size, 
and structure, to those induced by treatment with TGF-ßl alone. Development 
of TGF-ßl induced osteophytes from activated periosteum into early osteophytes 
consisting of chondrocyte-like cells was illustrated by autoradiographs showing 
35S-sulfate incorporation (fig 3). 
In parallel experiments, young adult (3mo) and old (18mo) mice were 
injected. Inflammation and osteophyte development upon intra-articular injec-
tions of IL-1, TGF-ßl, or both, were similar at both ages. 
Patellar cartilage proteoglycan synthesis. The effect of triple intra-
articular injections on patellar cartilage proteoglycan synthesis was quantitated 
using ex vivo 35S-sulfate incorporation. Figure 4 shows that one day after the 
last injection of IL-1, proteoglycan synthesis was severely suppressed, while at 
the same time point after three TGF-ßl injections proteoglycan synthesis was 
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Figure 1. Hematoxylin/eosin stained sections of murine knee joints dissected from young mice 
one day after the last of three injections, a) Control joint injected three times with PBS + 0 . 1 % 
BSA. b) Synovial hyperplasia caused by TGF-ßl. с) PMN influx caused by IL-1. d) Synovial 
hyperplasia and synergistic PMN infiltration caused by IL-1 + TGF-ßl. The appearance of this 
synovitis was similar to hat seen during early antigen-induced arthritis (1,26). (Original mag-
nification χ 100). Ρ = patella, F = femur, С = cartilage, S = synovium. 
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Figure 2. Hematoxylin/eosin stained sections of murine 
knee joints dissected from young mice four days after 
the last of three injections, a) Synovial hyperplasia 
caused by TGF-ßl was still present, and at the cartilage 
margins chondroid tissue had developed (arrows), most 
probably representing early osteophytes, b) At the same 
time point IL-1-induced inflammation had waned, c) 
Four days after the last injection with IL-1 + TGF-ßl, 
the appearance of synovium and osteophytes was similar 
to that in joints treated with TGF-ßl alone. (Original 
magnification χ 100). 
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Figure 3. Autoradiographs (hematoxylin and eosin-stained) showing 35S-sulfate incorporation 
during osteophyte development in young mice, a) One day after the last injection of TGF-ßl + 
IL-1 periosteum near the patellar cartilage margins (arrow) had become highly activated, b) Three 
days later early osteophytes (arrows) with chondrocyte-like, proteoglycan producing cells were 
present at the same site, while periosteum activity had declined. (Original magnification χ 250). 
JS = joint space. 
% proteoglycan synthesis 
300 ι 1 
260 
200 -
150 -
100 -
5 0 -
0 -
saline IL-1 IL-1«TGF-ß TGF-B 
Figure 4. Counteraction by TGF-ßl of IL-1-induced suppression of articular cartilage proteogly-
can synthesis.Patellar cartilage proteoglycan synthesis in young mice, one day after the last of 
three mtra-articular injections of saline, 1 ng IL-la, 0.1 μg TGF-ßl, or IL-1 + TGF-ßl. Proteo-
glycan synthesis was measured by 35S-sulfate incorporation. Proteoglycan synthesis in the left, 
untreated, patella was stated 100%. Each value represents mean proteoglycan synthesis ± SD of 
15 patellae. 
107 
Chapter 7 
stimulated to twice the normal level. Most interestingly, when TGF-ßl was co-
injected with IL-1, it was able to counteract IL-1-induced suppression of 
proteoglycan synthesis. This counteraction was confirmed by autoradiographs, 
showing 35S-sulfate incorporation (fig 5). Articular cartilage reactions were 
similar throughout the knee joint, except for cartilage of the medial tibia. At this 
site TGF-ßl could not overcome the IL-1 mediated inhibition. In addition to day 
1, effects on patellar proteoglycan synthesis were also measured at later time 
points (table 1). At day 2 after the last combined IL-1/TGF-ßl injection patellar 
proteoglycan synthesis was considerably stimulated, while at the same time 
point IL-1 treated cartilage still synthesized at subnormal levels. At later days 
stimulated proteoglycan synthesis was seen in all experimental groups. This was 
confirmed by autoradiographs, showing stimulated 3SS-sulfate incorporation in 
all cartilage regions of the knee joint (fig 5). 
Patellar cartilage responses were compared in young adult (3 mo) and old (18 
mo) mice (table 2). IL-1-induced suppression of proteoglycan synthesis was 
more severe in old mice. Although TGF-ßl injections almost doubled proteogly-
can synthesis in patellae of old mice, TGF-ßl could not overcome the IL-1-
induced suppression of proteoglycan synthesis at day 1. 
Patellar cartilage proteoglycan content. We investigated whether 
modulation by TGF-ßl of IL-1-induced suppression of proteoglycan synthesis 
was reflected in the degree of proteoglycan depletion. Patellar cartilage proteo-
glycan content was determined by measurement of safranin О staining intensity 
in histological sections of knee joints (table 3). This method offered the oppor­
tunity to measure specifically in the uncalcified, IL-1 reactive, cartilage layer. 
At day one after the last of three injections, IL-1 had caused significant proteo­
glycan depletion in patellar cartilage. This was not prevented by the presence of 
TGF-ßl. Remarkably, four days after the last injection TGF-ßl had significantly 
accelerated restoration of proteoglycan content. This indicates that TGF-ßl 
stimulates repair responses after IL-1-induced proteoglycan depletion. TGF-ßl 
injected alone caused a significant increase in proteoglycan content compared to 
the content of non-treated joints, at both time points studied. 
In addition, we confirmed these findings, using the dimethylmethylene blue 
method for determination of patellar cartilage glycosaminoglycan content (table 
4). Since it is not possible to separate calcified and non-calcified, IL-1- reactive, 
patellar cartilage, this method underestimates cytokine effects on proteoglycan 
content in the reactive layer. Moreover, the low amounts of GAG per patella 
are near the detection limit of the DMB method. 
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Figure 5. Autoradiographs (hematoxylin and eosin-stained sections) showing patellar cartilage 
proteoglycan synthesis (35S-sulfate incorporation) at one day (a,b,c,d) or four days (e,f,g) after the 
last of three intra-articular injections, a) Control patella, b) TGF-ßl stimulation of patellar 
proteoglycan synthesis, c) IL-1-induced suppression of proteoglycan synthesis, d) Counteraction 
of IL-1-induced suppression by TGF-ß. At day 4 after the last injection stimulated proteoglycan 
synthesis was seen with e) TGF-ßl, f) I L I , g) IL-1 + TGF-ßl. (Original magnification χ 400). 
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Table 1. Proteoglycan synthesis in patellar cartilage after triple intra-articular 
injections 
Injected 
substance 
IL-1 
IL-1 + TGF-ßl 
TGF-ßl 
vehicle 
% proteoglycan svnthesis# (%) 
day 1 day 2 day 3 
53 ± 1 4 89 ± 20 190 ± 30 
89 ± 21 157 ± 19 186 ± 41 
192 ± 33 281 ± 48 234 ± 35 
92 + 16 110 + 20 124 ± 25 
day 4 
316 ± 57 
268 ± 67 
224 ± 36 
113 ± 14 
§ proteoglycan synthesis in patellar cartilage of young mice was determined ex vivo, using ,5S-
sulfate incorporation (2 hours; 37°C). The patella of the contralateral knee was used as a control 
(100 %). Injection of IL-1 or TGF-ßl into the right knee had no effect on patellar cartilage 
proteoglycan synthesis in the contralateral (untreated) knee. In all the other experiments the left 
knee was injected with vehicle (PBS + 0.1% bovine serum albumin). Each value represents the 
mean ± SD of 5 patellae. 
Table 2. Age-related differences in the effects of IL-1 and TGF-ßl on patellar 
cartilage proteoglycan synthesis. 
proteoglycan synthesis (%Y 
Injected day Г day 4 
substance young* old young old 
IL-1 6 1 + 9 44 ± 12 221 ± 31 166 + 30 
IL-1 + TGF-ßl 132 ±18 47 ± 10 274 ± 6 0 224 ± 29 
TGF-ßl 260 ± 21 195 ± 29 331 ± 76 275 ± 58 
Jf see legends of table 1 for methods of proteoglycan synthesis measurement and data processing. 
* days after the last of three intra-articular injections 
$ mice aged 3 months (young) and 18 months (old) were treated simultaneously in this ex-
periment, 
each value represents the mean ± SD of 5 patellae. 
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Table 3. Patellar cartilage proteoglycan content determined in histological 
sections after triple intra-articular injections. 
injected 
substance day' Safranin О staining intensity 
none 
vehicle 
IL-1 
IL-1 + TGF-ßl 
TGF-ßl 
IL-1 
IL-1 + TGF-ßl 
TGF-ßl 
1 
1 
1 
1 
4 
4 
4 
5.5 ± 0.3 
5.8 ± 0.4 
4.5 ± 0.5 
4.6 ± 0.4 
6.4 ± 0.7 
4.0 ± 0.2 
5.7 ± 0.6* 
6.5 ± 0.4 
It Days after the last of three injections 
* Significantly different from treatment with IL-1 alone, 
ρ < 0.01 ; Student Τ test 
At least 10 joints of young mice were evaluated per experimental group and of each joint Э or 
more histological sections were measured using an automated image analysis system. In papain-
depleted cartilage, where no red stain was visible any more, this system still measured 50% of 
control values (see materials and methods). 
Table 4. Patellar cartilage proteoglycan content determined with the DMB 
method after triple intra-articular injections. Comparison with effects on 
proteoglycan synthesis. 
injected 
substance 
IL-1 
IL-1 + TGF-ßl 
TGF-ßl 
dav 1* dav 4 
content*(%) synthesis(% ƒ content(%) 
82 ±17 65 ± 16 87 ± 18 
94 ± 23 128 ± 15 102 ± 27 
115 ± 30 167 ± 35 128 ± 35 
synthesis(%) 
353 ± 49 
295 ± 50 
202 ± 36 
if See legends of table 1 for methods of proteoglycan synthesis measurement and data processing. 
* GAG content of each patella was determined using the DMB method. The GAG content of the 
treated patella was expressed as percentage ± SD of the GAG content of the contralateral control. 
& Days after the last of three intra-articular injections. 
Each value represents the mean ± SD of 5 patellae dissected from young mice. 
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DISCUSSION 
In the underlying study it was shown that TGF-ßl and the inflammatory 
mediator IL-1 acted synergistically in PMN attraction into the joint. In addition 
to this proinflammatory effect, TGF-ßl counteracted IL-1-induced inhibition of 
articular cartilage proteoglycan synthesis and stimulated restoration of the 
cartilage matrix after exposure to IL-1. 
This resulted in the apparent discrepancy of more inflammation with less 
cartilage damage. 
TGF-ß is known as a potent chemoattractant for PMN's and fibroblasts 
(14,15), and has been shown to induce transient inflammation and proliferation 
of synovial cells upon intra-articular injection (14,15,24). We found that TGF-
ßl synergized with IL-1 in PMN attraction, generating a severe synovitis similar 
to that seen during early experimental arthritis. However, in contrast to IL-1 
injected alone, the PMN's were not found in the joint space, but appeared to be 
trapped in the thickened synovium. Our data are in line with results of a recent 
study performed in a rabbit dermal inflammation model (30). In this dermal 
model PMN accumulation induced by IL-la and TGF-ß was found to be 205% 
greater than the additive sum of each response alone. 
In contrast to the synergism in cell attraction, IL-1 effects on articular 
cartilage proteoglycan synthesis were counteracted by TGF-ßl. Similar modula-
tion of IL-1 effects on chondrocyte proteoglycan metabolism by TGF-ß has been 
observed in vitro (19,22,25). The mechanism by which TGF-ß modulates effects 
of IL-1 on chondrocyte proteoglycan metabolism is still unknown. TGF-ß could 
interfere with IL-1 signalling by downregulation of IL-1 receptor expression 
(31,32), but there is doubt whether the reported decrease in receptor expression 
is sufficient, because only a low receptor occupancy is needed for effective IL-1 
signalling (33). TGF-ß could also antagonize IL-1 effects by increasing IL-1 
receptor antagonist production (34,35). Another possibility is that TGF-ß 
counteraction is not achieved by modulation of IL-1 signalling, but by stimula-
tion of proteoglycan synthesis via an independent mechanism. 
The inability of TGF-01 to counteract IL-1-induced suppression of 
proteoglycan synthesis in the medial tibia suggests that this area is prone to 
articular cartilage damage. This is consistent with the finding of enhanced 
vulnerability of the medial tibia to cartilage damage in murine osteoarthritis 
models (36) 
Our observation that TGF-ßl enhanced IL-1-induced synovitis and at the 
same time-point counteracted IL-1-induced suppression of cartilage proteoglycan 
synthesis could be important. These data suggest that during arthritis, inflamma-
tion and suppression of cartilage proteoglycan synthesis may be uncoupled, 
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dependent on the balance between local mediators. There is some evidence 
indicating that during arthritis PMN's do not affect articular cartilage (37), or 
that they even have a cartilage protecting role (38). The latter finding could be 
related to their production of IL-1 receptor antagonist (39,40), TGF-ßl (15),or 
other regulatory proteins. The localization of PMN's could also be of impor-
tance. Injection of TGF-ßl and IL-1 together causes massive inflammation that 
appears to be restricted to the synovium. In contrast, most of the cells attracted 
by IL-1 exudate into the joint space and will release their destructive mediators 
closer to the cartilage, allowing escape from inhibitors present in the synovial 
fluid (41). 
We measured patellar cartilage proteoglycan content to find out whether 
TGF-ßl counteraction of IL-1 effects was reflected in the level of cartilage 
proteoglycan depletion. In an earlier study (22) we found that at 24 hours after 
a single intra-articular injection, TGF-ßl had partly neutralized both IL-1-
induced suppression of proteoglycan synthesis and IL-1-induced stimulation of 
proteoglycan degradation. Surprisingly, no protection against proteoglycan 
depletion was found at one day after the last of three injections. In contrast, at 
the same time-point TGF-/81 injections had caused supra-normal proteoglycan 
levels. This could indicate that during inflammation caused by repeated IL-1 
exposure, other inflammatory mediators, besides IL-1, cause proteoglycan 
degradation. Interestingly, although TGF-ßl is not able to prevent IL-1-induced 
cartilage proteoglycan depletion, in the recovery phase TGF-ßl appeared to 
accelerate restoration of the cartilage matrix. This is consistent with in vitro data 
(22,42). 
In addition, we investigated whether age-related differences influence 
the interactions of IL-1 and TGF-/3. In old mice inflammatory signs after 
repeated IL-1/TGF-ßl injections were similar to those in young animals. But, 
while stimulation of proteoglycan synthesis by TGF-ßl was comparable with 
that seen in young mice, in old animals TGF-ßl could not counteract IL-1-
induced suppression of synthesis. However, as we described before (4), in old 
mice IL-1-induced suppression of proteoglycan synthesis is stronger and more 
prolonged, as compared to young animals. Due to a limited amount of material 
we were not able to do extensive IL-1/TGF-ßl dose-response studies. It can not 
be excluded that higher TGF-ßl doses could overcome IL-1 effects in old mice. 
So far we can only conclude that in old mice it is more difficult for TGF-ßl to 
counteract IL-1 than in young adult animals, which suggests that at an identical 
degree of inflammation, there may be more cartilage damage in old mice, than 
in young animals. 
Our finding that TGF-ßl increased both chondrocyte proteoglycan 
synthesis and cartilage proteoglycan content indicates that the newly formed 
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proteoglycans are normal, in the sense that they have the ability to reside in the 
cartilage matrix. The increase in proteoglycan content could also be related to 
increased hyaluronate production (43), or to decreased proteoglycan degrada-
tion. The latter explanation would be in line with the effect of TGF-ßl in vitro, 
where it prevents both basal and IL-1-stimulated release of proteoglycans in 
cartilage organ culture (25). In contrast to our findings, Elford et al. (44) found 
articular cartilage proteoglycan loss upon intraarticular injection of TGF-B2. 
This could be related to the use of a different species, the rabbit, and a different 
TGF-ß isoform, TGF-B2. Although the different TGF-ß isoforms have identical 
effects in a variety of systems, differences in their biological potencies have 
been noted as well (45-47). Also differences in the regulation of their expression 
by growth factors (48,49) and extracellular matrix (50), and differences in their 
expression patterns at the various stages of embryonic development (51,52) 
suggest that TGF-ß isoforms have distinct functions. Studies comparing the in 
vivo effects of TGF-ß isoforms on cartilage proteoglycan metabolism will be 
performed in our lab in the near future. 
Besides the cartilage protecting role of TGF-ßl, it could also play a 
negative part, because of its induction of osteophytes. Stimulation of bone 
formation by TGF-ß has been found in several systems, in vitro and in vivo 
(47,53,54). We found that this effect of TGF-ßl was not influenced by IL-1, 
which has also been reported to modulate bone metabolism (55,56). It is not 
known whether the TGF-ßl-induced osteophytes are deleterious or beneficial to 
the inflamed joint. They could decrease joint motility, but they could also 
compensate for inflammation-induced instability of the joint (57). Moreover, 
bone induction by another member of the TGF-ß superfamily, bone morpho-
genetic protein, has been shown (58,59) to be much less in primates compared 
to mice. 
From our results we can conclude that, in spite of its proinflammatory 
effects, intra-articularly injected TGF-ßl can protect against IL-1-induced 
suppression of proteoglycan synthesis in articular cartilage. In our experiments, 
TGF-/31 did not prevent IL-1-induced proteoglycan depletion, but it accelerated 
the subsequent replenishment of the cartilage extracellular matrix. 
ACKNOWLEDGEMENTS 
This study was supported by the Dutch League Against Rheumatism. We thank 
Dr AF Purchio (Oncogen, Seattle, WA) for the generous gift of human TGF-
ßl, and Dr IG Otterness (Pfizer Central Research, Groton, CT) for providing 
recombinant murine IL-la. 
114 
Chapter 7 
REFERENCES 
1. van de Loo AAJ, Arntz OJ, Ottemess IG, van den Berg WB: Protection against 
cartilage proteoglycan synthesis inhibition by antiintcrleukin 1 antibodies in experimental 
arthritis. J Rheumatol 19:348-356, 1992. 
2. Pettipher ER, Higgs GA, Henderson B: Interleukin 1 induces leukocyte infiltration and 
cartilage proteoglycan degradation in the synovial joint. Proc Natl Acad Sci USA 
83:8749-8753, 1986. 
3. van de Loo AAJ, van den Berg WB: Effects of murine recombinant interleukin 1 on 
synovial joints in mice: measurement of patellar cartilage metabolism and joint inflam­
mation. Ann Rheum Dis 49:238-245, 1990. 
4. van Beuningen HM, Arntz OJ, van den Berg WB: In vivo effects of interleukin-1 on 
articular cartilage: prolongation of proteoglycan metabolic disturbances in old mice. 
Arthritis Rheum 34:606-615, 1991. 
5. Hopkins SJ, Humphreys M, Jayson МГ : Cytokines in synovial fluid. I. The presence 
of biologically active and immunoreactive IL-1. Clin Exp Immunol 72:422-427, 1988. 
6. Rooney M, Symons JA, Duff GW: Interleukin 1 beta in synovial fluid is related to local 
disease activity in rheumatoid arthritis. Rheumatol Int 10:217-219, 1990. 
7. Fava R, Olsen Ν, Keski-Oja J, Moses Η, Pincus Τ: Active and latent forms of transfor­
ming growth factor В activity in synovial effusions. J Exp Med 169:291-296, 1989. 
8. Miossec P, Naviliat M, Dupuy d'Angeac A, Sany J, Banchereau J: Low levels of 
interleukin-4 and high levels of transforming growth factor β in rheumatoid synovitis. 
Arthritis Rheum 33:1180-1187, 1990. 
9. Brennen FM, Chantry D, Turner M, Foxwell B, Maini R, Feldmann M: Detection of 
transforming growth factor-beta in rheumatoid arthritis synovial tissue: lack of effect on 
spontaneous cytokine production in joint cell cultures. Clin exp Immunol 81:278-285, 
1990 
10. Wahl SM, Allen JB, Wong HL, Dougherty SF, Ellingsworth LR: Antagonistic and 
agonistic effects of transforming growth factor-B and IL-1 in rheumatoid synovium. J 
Immunol 145:2514-2519, 1990. 
11. Roberts AB, S po m MB: The transforming growth factors-B, in: Handbook of Ex­
perimental Pharmacology, Peptide Growth Factors and Their Receptors (Vol. 95/1). 
Edited by MB Sporn and AB Roberts, Heidelberg, Springer-Verlag, 1990, pp. 419-472. 
12. Roberts AB, Heine UI, Flanders КС, Sporn MB: TGF-fl: Major role in regulation of 
extracellular matrix. Ann NY Acad Sci. "Structure, Molecular Biology and Pathology of 
Collagen." 580:225-232, 1990. 
13. Wiseman DM, Polverini PJ, Kamp DW, Leibovich SJ: Transforming growth factor-beta 
(TGFB) is chemotactic for human monocytes and induces their expression of angiogenic 
activity. Biochem Biophys Res Commun 157:793-800, 1988. 
14. Allen JB, Manthey CL, Hand AR, Ohura K, Ellingsworth L, Wahl SM: Rapid onset 
synovial inflammation and hyperplasia induced by transforming growth factor B. J Exp 
Med 171:231-247, 1990. 
15. Fava RA, Olsen NJ, Postlethwaitc AE, Broadley KN, Davidson JM, Nanney LB, Lucas 
C, Townes AS: Transforming growth factor Bl (TGF-fl 1) induced neutrophil recruit­
ment to synovial tissues: Implications for TGF-8-driven synovial inflammation and 
hyperplasia. J Exp Med 173:1121-1132, 1991. 
1 1С 
Chapter 7 
16. Adams DH, Hathaway M, Shaw J, Bemett D, Elias E, Strain AJ: Transforming growth 
factor-ß induces human Τ lymphocyte migration in vitro. J Immunol 147:609-612, 1991. 
17. Kehrl JH: Transforming growth factor-/3: an important mediator of immunoregulation. 
Int J Cell Cloning 9:438-450, 1991. 
18. Lotz M, Kekow J, Carson DA: Transforming growth factor-β and cellular immune 
réponses in synovial fluids. J Immunol 144:4189-4194, 1990. 
19. ChandrasekharS, Harvey AK: Transforming growth factor-ß is a potent inhibitor of IL-
1 induced protease activity and cartilage proteoglycan degradation. Biochem Biophys 
Res Commun 157:1352-1359, 1988. 
20. Morales ΊΊ: Transforming growth factor-ß 1 stimulates synthesis of proteoglycan aggre-
gates in calf articular cartilage organ cultures. Arch Biochem Biophys 286:99-106, 
1991. 
21. Redini F, Daireaux M, Mauviel A, Galera Ρ, Loyau G, Pujol J-P: Characterization of 
proteoglycans synthesized by rabbit articular chondrocytes in response to transforming 
growth factor-ß (TGF-ß). Biochim Biophys Acta 1093:196-206, 1991. 
22. van Beuningen HM, van der Kraan PM, Amtz OJ, van den Berg WB: Protection from 
interleukin 1 induced destruction of articular cartilage by transforming growth factor fi: 
studies in anatomically intact cartilage in vitro and in vivo. Ann Rheum Dis 52:185-191, 
1993. 
23. Lafeber FPJG, van der Kraan PM, Huber-Bruning О, van den Berg WB, Bijlsma JWJ: 
Osteoarthritic human cartilage is more sensitive to transforming growth factor β than is 
normal cartilage. Br J Rheumatol 32:281-286, 1993. 
24. van Beuningen HM, van der Kraan PM, Amtz OJ, van den Berg WB: Transforming 
growth factor-ß 1 stimulates articular chondrocyte proteoglycan synthesis and induces 
osteophyte formation in the murine knee joint, submitted. 
25. Andrews HJ, Edwards ТА, Cawston ТЕ, Hazleman BL: Transforming growth factor-
beta causes partial inhibition of interleukin 1 stimulated cartilage degradation in vitro. 
Biochem Biophys Res Commun 162:144-150, 1989. 
26. van den Berg WB, Kruijsen MWM, van de Putte, van Beusekom HJ, van der Sluis-van 
der Pol M, Zwarts WA: Antigen-induced and zymosan-induced arthritis in mice: 
studies on in vivo cartilage proteoglycan synthesis and chondocyte death. Br J Exp 
Pathol 61:308-316, 1981. 
27. van den Berg WB, Kruijsen MWM, van de Putte LBA: The mouse patella assay: an 
easy method of quantitating articular cartilage chondrocyte function in vivo an in vitro. 
Rheumatol Int 1:165-169, 1982. 
28. de Vries BJ, van den Berg WB, Vitters E, van de Putte LBA: Quantitation of glycosa-
minoglycan metabolism in anatomically intact articular cartilage of the mouse patella: in 
vitro and in vivo studies with 3iS-sulfate, 'H-glucosamine, and 3H-acetate. Rheumatol 
Int 6:273-281, 1986. 
29. Famdale RW, Buttle DJ, Barrett AJ: Improved quantitation of sulfated glycosaminogly-
cans by use of dimethylmelhylene blue. Biochim Biophys Acta 883:173-177, 1986. 
30. Drake WT, Issekutz AC: Transforming growth factor-ß 1 enhances polymor-
phonuclear leucocyte accumulation in dermal inflammation and transendo-
thelial migration by a priming action. Immunology 78:197-204, 1993 
31. Harvey AK, Hrubey PS, ChandrasekharS: Transforming growth factor-ß inhibition of 
interleukin-1 activity involves down-regulation of interleukin-1 receptors on chondrocy-
tes. Exp Cell Res 195:376-385, 1991. 
116 
Chapter 7 
32. Rèdini F, Mauviel A, Pronost S, Loyau G, Pujol J-P: Transforming growth factor ß 
exerts opposite effects from interleukin-Iß on cultured rabbit articular chondrocytes 
through reduction of interleukin-1 receptor expression. Arthritis Rheum 36:44-50, 1993. 
33. Martel-Pelletier J, McCollum R, DiBattista J, Faure M-P, Chin JA, Fournier S, Sarfati 
M, Pelletier J-P: The interleukin-1 receptor in normal and osteoarthritic human articular 
chondrocytes. Arthritis Rheum 35:530-540, 1992. 
34. Turner M, Chantry D, Katsikis P, Berger A, Brennan FM, Feldmann M: Induction of 
the interleukin 1 receptor antagonist protein by transforming growth factor-fl. Eur J 
Immunol 21:1635-1639, 1991. 
35. Wahl SM, Costa GL, Corcoran M, Wahl LM, Berger AE: Transforming growth factor-
ß mediates IL-1-dependent induction of IL-1 receptor antagonist. J Immunol 150:3553-
3560, 1993. 
36. van der Kraan PM, Vitters EL, van Beuningen HM, van den Berg WB: Proteoglycan 
synthesis and osteophyte formation in 'metabolically' and 'mechanically' induced murine 
degenerative joint disease: an in-vivo autoradiographic study. Int J Exp Path 73:335-
350, 1992. 
37. McDonnell J, Hoemner LA, Lark MW, Harper C, Dey Τ, Lobner J, Eiermann G, 
Kazazis D, Singer II, Moore VL: Recombinant human interleukin-lfl-induced increase 
in levels of proteoglycans, stromelysin, and leukocytes in rabbit synovial fluid. Arthritis 
Rheum 35:799-805, 1992. 
38. Pettipher ER, Henderson B, Hardingham Τ, Ratcliffe A: Cartilage proteoglycan 
depletion in acute and chronic antigen-induced arthritis. Arthritis Rheum 32:601-607, 
1989. 
39. McColl SR, Paquin R, Ménard С, Beaulieu AD: Human neutrophils produce high levels 
of the interleukin 1 receptor antagonist in response to granulocyte/macrophage colony-
stimulating factor and tumor necrosis factor a. J Exp Med 176:593-598, 1992. 
40. Re F, Mengozzi M, Muzio M, DinareUo CA, Mantovani A, Colotta F: Expression of 
interleukin-1 receptor antagonist (IL-lra) by human circulating polymorphonuclear cells. 
Eur J Immunol 23:570-573, 1993. 
41 Schalkwijk J, van den Berg WB, van de Putte LB A, Joosten LAB: Elastase secreted by 
activated polymorphonuclear leukocytes causes chondrocyte damage and matrix degrada­
tion in intact articular cartilage: escape from inactivation by alpha-1-proteinase inhibitor. 
Br J Exp Pathol 68:81-88, 1987. 
42. Hardingham TE, Bayliss MT, Rayaan V, Noble DP: Effects of growth factors and 
cytokines on proteoglycan turnover in articular cartilage. Br J Rheumatol 31 (suppl 1):1-
6, 1992. 
43. Ogawa Y, Sawamura SJ, Ksander GA, Armstrong RM, Pratt BM, McPherson JM: 
Transforming growth factors-ßl and ß2 induce synthesis and accumulation of hyaluro-
nate and chondroitin sulfate in vivo. Growth Factors 3:53-62, 1990. 
44. Elford PR, Graeber M, Ohtsu H, Aeberhard M, Legendre B, Wishart WL, MacKenzie 
AR: Induction of swelling, synovial hyperplasia and cartilage proteoglycan loss upon 
intra-articular injection of transforming growth factor ß-2 in the rabbit. Cytokine 4:232-
238, 1992. 
45. Ohta M, Greenberger JS, Anklesaria P, Bassols A, Massagué J: Two forms of transfor-
ming growth factor-ß distinguished by multipotential haematopoietic progenitor cells. 
Nature 329:539-541, 1987. 
46. Roberts AB, Kondaiah P, Rosa F, Watanabe S, Good P, Danielpour D, Roche NS, 
117 
Chapter 7 
Rebbert ML, Dawid IB, Sporn MB: Mesoderm induction in Xenopus laevis distin­
guishes between the various TGF-fl isoforms. Growth Factors 3:277-286, 1990. 
47. Joyce ME, Roberts AB, Sporn MB, Bolander ME: Transforming growth factor-β and 
the initiation of chondrogenesis and osteogenesis in the rat femur. J Cell Biol 110:2195-
2207, 1990. 
48. Bascom CC, Wolfshohl JR, Coffey RJ, Madisen L, Webb NR, Purchio AR, Derynck 
R, Moses HL: Complex regulation of transforming growth factor /31, 02, and $3 
mRNA expression in mouse fibroblasts and keratinocytes by transforming growth factors 
/31 and /32. Mol Cell Biol 9:5508-5515, 1989. 
49. Villiger PM, Lotz M: Differential expression of TGFB isoforms by human articular 
chondrocytes in response to growth factors. J Cell Physiol 151:318-325, 1992. 
50. Streuli CH, Schmidhauser C, Kobrin M, Bissell MJ, Derynck R: Extracellular matrix 
regulates expression of the TGF-fll gene. J Cell Biol 120:253-260, 1993. 
51. Pelton RW, Saxena B, Jones M, Moses HL, Gold LI: Immunohistochemical localization 
of TGFfll, TGFB2, and TGFB3 in the mouse embryo: expression patterns suggest 
multiple roles during embryonic development. J Cell Biol 115:1091-1105, 1991. 
52. Roberts AB, Sporn MB: Differential expression of the TGF-fl isoforms in embryogene-
sis suggests specific roles in developing and adult tissues. Mol Reprod Devel 32:91-98, 
1992. 
53. Noda M, Caminiere JJ: In vivo stimulation of bone formation by transforming growth 
factor-fl. Endocrinology 124:2991-2994, 1989. 
54. Marcelli С, Yates AJ, Mundy GR: In vivo effects of human recombinant transforming 
growth factor β on bone turnover in normal mice. J Bone Min Res 5:1087-1096, 1990. 
55. Nguyen L, Dewhirst FE, Hauschka PV, Stashenko P: Interleukin-IB stimulates bone 
resorption and inhibits bone formation in vivo. Lymphokine Cytokine Res 10:15-21, 
1991. 
56. Mundy GR: Cytokines and local factors which affect osteoclast function. Int J Cell 
Cloning 10:215-222, 1992. 
57. Pottenger LA, Phillips FM, Draganich LF: The effect of marginal osteophytes on 
reduction of varus-valgus instability in osteoarthritic knees. Arthritis Rheum 33:853-
858, 1990. 
58. Miyamoto S, Takaoka K, Yoshikawa H, Hashimoto J: Trans-filter bone induction in 
monkeys by bone morphogenetic protein. 39th Annual Meeting of the Orthopaedic 
Research Society, San Francisco, California, page 99, 1993 (abstract). 
59. Aspenberg P, Wang E, Thomgren K-G: Bone morphogenetic protein induces bone in 
the squirrel monkey, but bone matrix does not. Acta Orthop Scand 63:619-622, 1992. 
11R 
Chapter 8 
SUMMARY AND FINAL REMARKS 
The proteoglycan aggregates in the extracellular matrix of articular cartilage 
determine in large part its unique properties. During arthritis cartilage proteo-
glycans are depleted as the result of both suppression of their synthesis and 
stimulation of their degradation by proteases. Most likely cytokines, released by 
inflammatory cells, synovial cells and chondrocytes are involved in this process. 
There is evidence that RA with onset at older age (^60 years) is more destruc-
tive. The aim of this study was to gain insight into this phenomenon. On the 
one hand this could be related to different progression of joint inflammation; on 
the other hand it could be related to enhanced vulnerability of cartilage in older 
joints. We have studied both aspects, with special emphasis on chronicity of 
arthritis and on interplay of cytokines and growth factors. 
We first confirmed the clinical observation of more destructive arthritis 
at older age in our animal model. In female C57B1/10 mice aged 18 months 
antigen-induced arthritis was found to be more chronic and destructive, compa-
red to young mice and 18 months old males. No differences in cellular and 
humoral antigen-specific immunity were found between these groups. Impaired 
clearance of the antigen from the joint was found at older age, in both male and 
female mice. Also sex hormones may be of importance, since experiments with 
gonadectomized and hormone supplemented mice showed that antigen-induced 
arthritis in old mice was enhanced by oestradiol and suppressed by androgens 
(unpublished observations). Possibly in old female mice increased chronicity of 
arthritis is caused by the combination of impaired antigen clearance and female 
sex hormones, (chapter 2). 
The cytokine interieukin-1 (IL-1) is considered to be an important 
inducer of cartilage destruction during arthritis. IL-1 causes suppression of 
patellar cartilage proteoglycan synthesis ("S-sulfate incorporation) and stimula-
tion of proteoglycan degradation ("S-sulfate release). We studied the effects of 
IL-1 on proteoglycan metabolism in intact murine patellar cartilage, in vitro and 
in vivo. No sex-related differences were found in these studies. Intra-articularly 
(i.a.) injected IL-1 induced stimulation of proteoglycan degradation that was 
slightly lower in old cartilage compared to young. However, suppression of 
proteoglycan synthesis after i.a. injection of IL-1 appeared to be more severe in 
old animals. The latter age-related difference was not seen if patellar cartilage 
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was incubated with IL-1 in vitro, suggesting that in vivo differences are caused 
by involvement of secondary mediators, including IL-1, IL-1 inhibitors, or other 
antagonists. Moreover, in old patellar cartilage IL-1-induced suppression of 
proteoglycan synthesis in vivo appeared to be more prolonged and, in agreement 
with this, restoration of articular cartilage proteoglycan content was retarded in 
old mice, (chapter 3). 
Prolonged suppression of proteoglycan synthesis in old articular car-
tilage was not exclusively found after in vivo exposure to IL-1, but appeared to 
be a more general feature, also seen after in vivo exposure to inflammatory 
metabolites like hydrogen peroxyde. This suggested that age-related changes in 
availability of and responses to the important anabolic factor for cartilage, insu-
lin-like growth factor-1 (IGF-1), could play a part in retarded restoration of 
matrix integrity found in old cartilage. To test this hypothesis plasma IGF-1 
levels of young and old mice were measured, and IGF-1 induced stimulation of 
in vitro proteoglycan synthesis was determined in young and old patellar 
cartilage. The data show that under normal circumstances supra-optimal levels 
of IGF-1 are present in blood (and presumably similar amounts have diffused 
into synovial fluid), of both young and old animals. Moreover, proteoglycan 
synthesis was at least equally stimulated in patellar cartilage of mice aged 18 
months as compared to 3 months. This makes it unlikely that mere changes in 
IGF-1 levels and in responses to IGF-1 are important determinants at old age. 
However, we were not able to obtain murine synovial fluids, and it can not be 
excluded that local changes in IGF-1 levels and levels of IGF-binding proteins 
in this compartment could induce a completely different IGF-1 supply in the ar-
thritic joint. Moreover, chondrocyte IGF-1 responsiveness was tested in non-ar-
thritic conditions, while it is known from earlier studies that IGF-1 respon-
siveness of chondrocytes may decrease dramatically during experimental arthri-
tis. Furthermore, the experiments of this chapter indicate that serum factors 
other than IGF-1 are important for recovery, either alone or in combination 
with IGF-1. Further analysis of changes in these factors with age is required, 
(chapter 4). 
Another important determinant in regulation of IL-1 effects is transfor-
ming growth factor-ß (TGF-ß). This mediator is present in high concentrations 
in synovial fluids of RA patients and has been reported to inhibit the cartilage 
damaging effects of IL-1 in vitro. We verified the reported in vitro effects in 
our culture system, using intact murine patellar cartilage, and extended these 
experiments to study IL-1/TGF-ß interactions under more physiologic cir-
cumstances, i.e. in presence of IGF-1. TGF-ß had no effect on basal proteo-
glycan degradation in vitro and partly inhibited IL-1 induced proteoglycan 
degradation. Proteoglycan synthesis was stimulated by TGF-ß both in presence 
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and in absence of IL-1, provided that patellae were cultured in the absence of 
physiologic concentrations of the anabolic factor IGF-1. In spite of the presence 
of IGF-1, however, TGF-ß stimulated ex vivo recovery from IL-1-induced sup-
pression of proteoglycan synthesis. This suggests that TGF-ß has a more 
specific role in restoration of chondrocyte proteoglycan synthesis, as compared 
to IGF-1, which factor stimulates control and IL-1 exposed cartilage equally. 
To investigate whether modulation of IL-1 effects by TGF-ß also occurs 
after in vivo administration we injected TGF-ß and IL-1 into normal murine 
knee joints. At 24 hours after a single intra-articular TGF-ß injection no effect 
on patellar cartilage proteoglycan synthesis was found. The same treatment 
induced slight proteoglycan degradation, probably induced by attracted inflam-
matory cells. In agreement with the in vitro results TGF-ß partly inhibited the 
IL-1 induced suppression of proteoglycan synthesis and the IL-1 induced stimu-
lation of proteoglycan degradation, (chapter 5). 
In chapter 6 and 7 the in vivo effects of TGF-ß were studied in more 
detail. Multiple injections were used to mimic prolonged exposure during ar-
thritis, and histology and cartilage metabolism were studied over a longer period 
of time. Moreover, the influence of age on TGF-ß effects was examined. The 
effects of injections of only TGF-ß on articular cartilage and other joint structu-
res were studied first. A single intra-articular TGF-ß injection caused transient 
influx of polymorphonuclear neutrophils (PMNs). However, after three TGF-ß 
injections (at alternate days) no PMNs were found, and the synovium was 
thickened and produced increased amounts of proteoglycans. Besides a strong 
increase of the amount of synovial fibroblasts, also many cells of the ma-
crophage/monocyte lineage were present in the synovium. While at 24 hours 
after TGF-ß injection no effects on proteoglycan synthesis were found, at later 
time-points both single and multiple injections induced strong and longlasting 
stimulation of articular cartilage proteoglycan synthesis and an increase of the 
proteoglycan content. Moreover, after triple TGF-ß injections impressive 
osteophytes developed at sites where osteophytes are observed in experimental 
arthritis and osteoarthritis models. This suggests a role for endogenous TGF-ß 
in osteophyte formation during joint pathology. The size and the localization of 
osteophytes were indentical in young and old mice. Also reactions of cartilage, 
synovium, and ligaments to TGF-ß were similar at both ages studied, (chapter 
6). 
In addition, the modulation of IL-1 effects by TGF-ß in vivo was 
studied more extensively. Multiple i.a. injections were performed, histology and 
articular cartilage metabolism were studied over a longer period of time and 
mice of different ages were used. TGF-ß appeared to aggravate IL-1 induced 
knee joint inflammation in a synergistic^ fashion. In comparison with IL-1 
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injection, the joint pathology induced by the combination of IL-1 and TGF-ß 
comes more close to that seen in experimental arthritis, including the charac-
teristic osteophytes and pronounced infiltrates. In spite of the proinflammatory 
effect of TGF-ß, however, it counteracted the deleterious effects of IL-1 on 
articular cartilage proteoglycan synthesis. This counteraction was reflected in 
accellerated restoration of the articular cartilage extracellular matrix after IL-1-
induced proteoglycan depletion. Protection against IL-1-induced suppression of 
proteoglycan synthesis by TGF-ß could not be demonstrated in old mice, sug-
gesting they are defective in this respect. Our findings indicate that the marked 
activation of endogenous TGF-ß found in the arthritic joint most likely is an 
attempt to minimalize cartilage destruction. Osteofyte formation and fibrosis 
may be merely side effects; possibly these processes even provide additional 
protection of articular cartilage integrity, by stabilizing the joint, (chapter 7). 
In conclusion, the above described studies demonstrate that the impact 
of the destructive cytokine IL-1 on articular cartilage had increased in old mice. 
Moreover, restoration of cartilage extracellular matrix at later times after IL-1 
injection appeared to be retarded at old age, but this could not be ascribed to 
deficient anabolic stimulation. Instead, suggestive evidence was found of age-
related defects in the control of IL-1 by natural inhibitors, like TGF-ß. In line 
with recent developments it would be of interest to include other regulators, e.g. 
IL-Ira, IL-4, and IL-10 in future studies. 
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SAMENVATTING 
De proteoglycan aggregaten in de extracellulaire matrix leveren een grote 
bijdrage aan de bijzondere eigenschappen van gewrichtskraakbeen. Tijdens een 
gewrichtsontsteking (artritis) neemt de concentratie van proteoglycanen in die 
matrix af, als gevolg van een toegenomen afbraak in combinatie met afgenomen 
synthese. Hoogstwaarschijnlijk zijn cytokines, uitgescheiden door ontstekingscel-
len, cellen uit het synovium, en kraakbeencellen (chondrocyten) betrokken bij 
dit proces. Het is aangetoond dat reumatoïde artritis (RA) die zich op hogere 
leeftijd (60 jaar en ouder) ontwikkelt, destructiever van aard is dan de vorm die 
zich in de jaren daarvóór openbaart. Het doel van deze studie was inzicht te 
verkrijgen in dit verschijnsel. De toename van destructie zou te maken kunnnen 
hebben met een ander beloop van de gewrichtsontsteking, maar ook met 
verhoogde gevoeligheid van kraakbeen in oudere gewrichten. We hebben beide 
aspecten bestudeerd, met speciale aandacht voor chroniciteit van de gewrichts-
ontsteking en voor het samenspel van cytokines en groeifactoren. 
Allereerst werd de klinische observatie van toenemende gewrichtsschade 
door arthritis die start op hogere leeftijd bevestigd in het diermodel dat we 
wilden gebruiken. In vrouwelijke C57B1/10 muizen van 18 maanden bleek 
antigeen-geïnduceerde arthritis chronischer en destructiever te zijn, vergeleken 
met jonge muizen van beide geslachten en met 18 maanden oude mannetjes. De 
immuniteit die deze groepen muizen ontwikkelden tegen het gebruikte antigeen 
was vergelijkbaar; zowel de cellulaire als de humorale antigeen-specifieke 
immuniteit. De verwijdering van het antigeen uit de ontstoken knie bleek 
vertraagd te zijn in oude muizen, zowel in mannetjes als in vrouwtjes. Ook 
geslachtshormonen zouden een rol kunnen spelen, want uit experimenten met 
gesteriliseerde en met geslachtshormonen behandelde dieren bleek dat antigeen-
geïnduceerde artritis in oude muizen wordt bevorderd door oestradiol en geremd 
door androgenen (niet gepubliceerde gegevens). Mogelijk wordt de toename in 
de chroniciteit van artritis in oude vrouwjes muizen veroorzaakt door de 
combinatie van vertraagde antigeen verwijdering op hogere leeftijd en de ontste-
king bevorderende werking van vrouwelijke geslachtshormonen, (hoofdstuk 2). 
Het cytokine interleukine-1 (IL-1) wordt beschouwd als een belangrijke 
veroorzaker van kraakbeenschade die ontstaat tijdens een gewrichtsontsteking. 
Het veroorzaakt remming van de proteoglycan synthese en stimulatie van de 
proteoglycan afbraak in gewrichtskraakbeen. Wij bestudeerden IL-1 effecten op 
het proteoglycan metabolisme v n het intacte kraakbeen v n de knieschijf v n 
de muis, in vitro (kraakbeenkweek) en in vivo (IL-1 injectie in de knie). We 
vonden hierbij geen sekse-afhankelijke verschillen. De door intra-articulair (i.a.) 
ingespoten IL-1 geïnduceerde proteoglycan afbraak bleek iets verminderd te 
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zijn in oude muizen, vergeleken met jonge dieren. De remming van proteo-
glycaan synthese na i.a. IL-1 injecties was echter ernstiger in kraakbeen van 
oude dieren. Dit laatste verschil trad echter niet op wanneer kraakbeen buiten 
het lichaam werd gekweekt in aanwezigheid van IL-1. Dit doet vermoeden dat 
de leeftijdsafhankelijke verschillen die optreden in vivo, veroorzaakt worden 
door secundair geproduceerde mediatoren, zoals IL-1 zelf, IL-1 remmers of 
andere antagonisten. Bovendien bleek dat de door i.a. geïnjecteerd IL-1 ver-
oorzaakte remming van de proteoglycaan synthese langer aanhield in oud kraak-
been, en dat, in overeenstemming hiermee, het herstel van het proteoglycaan 
gehalte van het gewrichtskraakbeen trager verliep in oude muizen, (hoofdstuk 
3). 
Een relatief langdurige remming van de proteoglycaan synthese in oud 
gewrichtskraakbeen werd niet alleen gevonden na in vivo blootstelling aan IL-1, 
maar bleek een meer algemeen verschijnsel te zijn, dat ook optrad na in vivo 
blootstelling aan bij ontsteking vrijkomende metabolieten, zoals waterstof 
peroxyde. Dit leidde tot het vermoeden dat leeftijdsafhankelijke veranderingen 
in beschikbaarheid van en reacties op de belangrijke anabole factor voor 
kraakbeen, insulin-like growth factor-1 (IGF-1), een rol zouden kunnen spelen 
in het vertraagde herstel van de extracellulaire matrix in kraakbeen van oude 
dieren. Om deze hypothese te testen werden de IGF-1 spiegels gemeten in 
plasma van jonge en oude muizen, en werd de door IGF-1 in vitro veroorzaakte 
stimulatie van de proteoglycaan synthese bepaald in oud en jong ge-
wrichtskraakbeen. Voor anabole stimulatie van normale knieschijfjes bleek meer 
dan voldoende IGF-1 aanwezig te zijn in bloed van zowel jonge als oude 
muizen. Waarschijnlijk worden via diffusie vergelijkbare spiegels bereikt in 
synoviale vochten. Bovendien bleek de proteoglycaan synthese in oud kraakbeen 
minstens zo sterk op IGF-1 te reageren als die in jong kraakbeen. Dit alles 
maakt het onwaarschijnlijk dat veranderingen in IGF-1 aanbod en in gevoelig-
heid van kraakbeen voor IGF-1, bepalende factoren zijn bij herstel van oud 
kraakbeen. Echter, omdat niet rechtstreeks in synoviale vochten uit de muize-
knie gemeten kon worden, kan niet worden uitgesloten dat lokale veranderingen 
in IGF-1 spiegels en in spiegels van IGF bindende eiwitten kunnen zorgen voor 
een volledig veranderd IGF-1 aanbod in het ontstoken gewricht. Bovendien 
werd de gevoeligheid van chondrocyten getest in knieschijfjes zonder ontsteking, 
terwijl eerdere studies hebben aangetoond dat tijdens experimentele arthritis de 
IGF-1 gevoeligheid van de chondrocyt sterk kan afnemen. De experimenten van 
dit hoofdstuk laten verder nog zien dat andere serum factoren dan IGF-1, alleen 
of in combinatie met IGF-1, belangrijk zijn voor herstel van protoglycaan 
synthese. Verdere analyse van veranderingen van deze factoren bij toenemende 
leeftijd is van groot belang, (hoofdstuk 4). 
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Een andere bepalende factor bij de regulering van de effecten van IL-1 
is de groeifactor transforming growth factor-ß (TGF-ß). Eerdere studies hebben 
aangetoond dat deze mediator in hoge concentraties aanwezig is in synoviale 
vochten van RA patiënten en dat de aantasting van de kraakbeen matrix door 
IL-1 in vitro door TGF-ß geremd wordt. Deze in vitro experimenten werden 
door ons in een uitgebreidere opzet herhaald in ons kweeksysteem met intact 
muizekraakbeen. Als aanvulling op eerdere studies werden IL-1/TGF-ß interac-
ties tevens onder meer fysiologische omstandigheden bestudeerd, d.w.ζ in 
aanwezigheid van IGF-1. TGF-ß bleek geen effect te hebben op basale proteo-
glycaan afbraak in vitro, maar verminderde gedeeltelijk de door IL-1 geïndu-
ceerde afbraak. Proteoglycaan synthese werd gestimuleerd door TGF-ß, zowel 
de basale, als de door IL-1 geremde synthese. Dit effect van TGF-ß op synthese 
werd niet gevonden in aanwezigheid van fysiologische concentraties van die 
andere anabole factor, IGF-1. Ex vivo herstel van door IL-1 geremde proteogly-
caan synthese werd echter bevorderd door TGF-ß, ondanks de aanwezigheid van 
IGF-1. Dit lijkt erop te wijzen, dat TGF-ß een specifiekere rol speelt bij herstel 
van chondrocyt proteoglycaan synthese dan IGF-1, dat normaal en met IL-1 
behandeld kraakbeen even sterk stimuleert. Om er achter te komen of modulatie 
van IL-1 effecten op muizekraakbeen door TGF-ß ook plaats zou vinden na in 
vivo toediening, werden TGF-ß en IL-1 in de knie ingespoten. In het tijdsbestek 
van 24 uur na TGF-ß injectie bleek de proteoglycaan synthese in gewrichts-
kraakbeen niet te veranderen. Wel ontstond er in de periode een geringe 
kraakbeenafbraak, waarschijnlijk veroorzaakt door de in het gewricht geïnfil-
treerde ontstekingscellen. In overeenstemming met de resultaten van in vitro 
experimenten remde TGF-ß gedeeltelijk de door IL-1 veroorzaakte remming van 
de proteoglycaan synthese en de door IL-1 geïnduceerde stimulatie van de 
proteoglycaan afbraak, (hoofdstuk 5). 
In de hoofdstukken 6 en 7 werden de in vivo effecten van TGF-ß uitge-
breider bestudeerd. Het kniegewricht werd nu meerdere malen ingespoten, 
waardoor de langdurige blootstelling aan mediatoren gedurende artritis enigszins 
werd nagebootst. Histologie en kraakbeen metabolisme werden nu gedurende 
langere tijd vervolgd. Bovendien werd nu de invloed van leeftijd op de TGF-ß 
effecten nagegaan. Eerst werden de effecten van i.a. TGF-ß injecties op 
gewrichtskraakbeen en andere gewrichtsstructuren in kaart gebracht. Na één 
TGF-ß injectie werd een kortdurende influx van voornamelijk polymor-
phonucleaire neutrofielen (PMNs) waargenomen. Na drie TGF-ß injecties (om 
de andere dag) waren PMNs afwezig, terwijl het synovium sterk geactiveerd 
(gestimuleerde proteoglycaan synthese) en verdikt was. Naast een sterke 
toename van het aantal fibroblasten in het synovium, werden daar ook veel 
monocyt-achtige cellen aangetroffen. Hoewel TGF-ß 24 uur na één i.a. injectie 
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nog geen effect had op de proteoglycaan synthese van gewrichtskraakbeen, werd 
op latere tijdstippen na zowel enkele als drievoudige injecties een sterke en 
langdurige stimulatie van de proteoglycaan synthese en een verhoging van de 
proteoglycaan inhoud van het kraakbeen gevonden. Ook de proteoglycaan 
synthese in de collaterale banden was verhoogd. Bovendien bleken na drie-
voudige TGF-ß injecties forse osteofyten te ontstaan op dezelfde plaatsen waar 
ook in experimentele artritis en osteoartrose modellen osteophyten worden 
gevonden. Dit duidt erop dat endogeen TGF-ß een rol zou kunnen spelen in 
osteofyt ontwikkeling gedurende gewrichtspathologie. De grootte en de lokali-
satie van de osteofyten waren identiek in jonge en oude muizen. Ook kraakbeen, 
synovium en ligamenten bleken op hogere leeftijd niet anders op TGF-ß te 
reageren dan bij jonge dieren, (hoofdstuk 6). 
Vervolgens werd de modulatie van IL-1 effecten door TGF-ß in vivo 
verder onderzocht m.b.v. meervoudige injecties, meerdere waarnemingen over 
een langere tijd en muizen van verschillende leeftijd. TGF-ß bleek de door IL-1 
veroorzaakte gewrichtsontsteking enorm te versterken; duidelijke trad een 
synergisme op bij de aantrekking van PMNs. Veel meer dan IL-1 injecties dat 
doen benadert de drievoudige co-injectie van IL-1 en TGF-ß de gewrichts-
pathologie die wordt gezien bij experimentele artritis, met de karakteristieke 
osteofyten en de in het oog springende infiltraten. Ondanks het ontstekingsbe-
vorderende effect van TGF-ß bleek het de schadelijke effecten van IL-1 op de 
proteoglycaan synthese en het proteoglycaan gehalte van gewrichtskraakbeen 
tegen te gaan. Dit beschermend effect van TGF-ß kon niet worden aangetoond 
in oude muizen, wat misschien betekent dat zij een defect vertonen in hun 
bescherming tegen IL-1. De opheffing door TGF-ß van de door IL-1 veroor-
zaakte remming van de chondrocyt proteoglycaan synthese werd weerspiegeld 
door een versneld herstel van de kraakbeenmatrix na door IL-1 veroorzaakt 
verlies van proteoglycanen. Onze bevindingen lijken er op te wijzen dat de 
opvallende activatie van endogeen TGF-ß in ontstoken gewrichten waarschijnlijk 
moet worden gezien als een poging om kraakbeendestructie binnen de perken te 
houden. Osteofyt vorming en fibrose zouden bijverschijnselen kunnen zijn; 
mogelijk bieden deze processen zelfs extra bescherming, doordat het gewricht 
erdoor wordt gestabiliseerd, (hoofdstuk 7). 
In de hier beschreven experimenten bleek de invloed van het destructie-
ve cytokine IL-1 op gewrichtskraakbeen te zijn toegenomen in oude muizen. 
Bovendien bleek het herstel van de extracellulaire matrix na het verdwijnen van 
IL-1 vertraagd te verlopen op hogere leeftijd, maar dit kon niet worden toege-
schreven aan ontoereikende anabole stimulatie. In plaats daarvan werden bij 
oude muizen aanwijzingen gevonden voor tekortschietende controle van IL-1 
effecten door de lokaal geproduceerde remmers, zoals TGF-ß. Recente ontwik-
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kelingen geven aanleiding om ook de kraakbeen beschermende werking van 
andere regulerende stoffen, zoals IL-1 receptor antagonist, IL-4 en IL-10 in 
toekomstige studies te betrekken. 
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